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An increasing number of annual joint replacement operations are performed. 
Prosthetic infection and aseptic loosening is very important and distinguishing 
between them allows prompt and accurate treatment but there is no consensus 
on how best to image these patients.  
 
I also reviewed the role of CT in prosthetic joint imaging with a spectrum of 
usual pathologic conditions and CT patterns. This showed that CT plays a 
significant role in detecting and demonstrating complications of joint prosthesis 
surgery but it may not be sufficient in itself. CT can be combined, in hybrid 
imaging, such as SPECT-CT and PET-CT.  
 
I assessed the magnitude of the problem with a retrospective study of painful 
prosthetic joints in UHCW from symptom onset to diagnosis. This demonstrated 
significant delays in diagnosis and the need for streamlined and reduced 
imaging tests with some patients undertaking multiple non-imaging and imaging 
tests.  
 
I performed a systematic review of the role of 
18
F-NaF showed that sodium 
fluoride positron emission tomography (
18
F-NaF-PET) is a promising tool with 
high sensitivity and specificity in the assessment of joint replacements after the 
ninth post-surgical month. A further study confirmed the practicality of 
performing dynamic 
18
F NaF PET-CT in detecting aseptic loosening of lower 






Beam hardening artefacts occur in CT and hybrid imaging of metallic prosthetic 
joints. A series of physics experiments to evaluate and correct beam hardening 
artefacts was performed to alleviate the problem.   Beam hardening artefacts 
from prostheses reduce image quality on 
18
F PET-CT.  The experiments 
included pre-filtering with Aluminium; dual-energy CT and mathematical 
algorithms with MATLAB
®
 filtered back projection. The results showed no 
significant difference in artefact reduction between the different methods. The 
artefact-reduction techniques introduce other secondary artefacts with 
subsequent image quality reduction.  
 
Analysis of data from the prospective dynamic 
18
F-NaF PET-CT trial showed 
inconsistent results due to data corruption and dynamic 
18
F-NaF data loss but 
quantitative methods with Time-Activity Curves and trend line assessment of 
99m
Tc-MDP 3-phase bone scans was more accurate. The trial problems were 
identified and suggestions were made for a larger study with opt-in methods for 
patient recruitment and more involved use of allied healthcare staff for patient 
recruitment.  
 







to assess periprosthetic membranes 
in vivo. Lymphoseek
® 
binds to the mannose receptor on the cell surface of 
macrophages and multinucleated giant cells which are likely to reflect wear 
particle aseptic loosening. Further in vitro periprosthetic membranes tests will 
also be performed using immunochemistry. This study has not yet been 
performed but it is hoped that a negative Tilmanocept scan would reassuringly 
make a diagnosis of wear particle induced aseptic loosening unlikely.  
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Chapter 1 Background and History of Joint Prostheses with 




Background: There is a steady increase in the use of prosthetic joint 
replacement medical devices to treat arthropathy with about 40,000 joint 
replacements of the knee and hip now occurring in the United Kingdom 
annually. Diagnosing the complications of joint prostheses often require imaging 
and an understanding of historic evolution of the different prosthetic types. This 
provides a historical vignette of pros and cons of the original and then 
subsequently developed joint prostheses as well as methods employed to 
investigate complications of treatment. Tomography was first suggested just 
over 100 years ago and Computed Axial Tomography (CT) was first developed 
almost 50 years ago. CT scans play an important imaging role before and after 
joint implant surgery as well as in hybrid imaging modalities such as SPECT-CT 
and PET-CT. 
Method: A review of English language publications that significantly impact on 
the knowledge of joint implant developers and the history joint prostheses. This 
was performed by accessing information on the history of joint prostheses and 
pathology carried out through PubMed, EMBASE, Cochrane and Google 
Scholar online databases at the same time also focusing on prosthetic materials 
and prosthesis patent holders. It chronicled the use of imaging techniques used 
in the assessment of joint prostheses as well as the advent of 
18
F-Fluoride PET 
and related PET-CT artefacts. In addition, a comprehensive review of literature 
to summarise the role of CT in imaging complications of prosthetic joint surgery 
as well as the role of CT before and after joint implant surgery; the development 
of metal artefact reduction techniques in CT for prosthetic joint imaging; the 
added value of CT in hybrid imaging modalities such as SPECT-CT and PET-
CT and lastly, a collated CT reporting checklist for CT prosthetic joint 




Results: Joint preservation surgery has been in use for almost 200 years. This 
chapter provides historical background of the use of joint prostheses and the 
use of imaging techniques in the assessment of joint prostheses infection and 
loosening, which are significant complications of joint replacement surgery. 
There is a wide variety of imaging techniques including 
18
F-Fluoride PET and 
PET-CT, which can produce varying types of confounding imaging artefacts. 
Further information is required on the potential role for and the rational use of 
18
F-NaF and PET-CT. CT has a role to play in diagnosing and distinguishing 
between septic and aseptic prosthetic joint loosening but metal artefact 
reduction techniques are often required. A table of useful reporting points and 
radiographic CT features for the radiologist to assess along with the significance 
of the radiographic features was issued.  
Conclusion: The more frequent use of prosthetic joint replacement medical 
devices to treat arthropathy and an aging population mean that there is likely to 
be a requirement for more resources to diagnose the complications of joint 
prostheses. There is a potential role for dynamic sequential multiphase 
18
F-NaF 
PET-CT but this requires further research to identify whether it can cost-
effectively and accurately detect periprosthetic infection and periprosthetic 
loosening. The combined use of very sensitive moderately specific dynamic 
18
F-
NaF PET-CT and a radionuclide predictive biomarker of macrophages in 
periprosthetic tissue are likely to increase the efficiency and accuracy of 
diagnosis. Furthermore, CT scans and the use of CT in hybrid imaging play an 
important role in imaging joint prostheses. The use of a reporting checklist can 










About 40,000 annual joint replacements of the knee and hip occur in the United 
Kingdom, using a wide variety of implants (1, 2). Prosthetic infection and 
loosening are significant complications of joint replacement surgery (3). 
Approximately 0.4 to 4% of these are complicated by deep infection but the true 
figure is probably less than 1% (2). Further complications of joint prostheses 
include aseptic loosening with an incidence of 2-18% and 2-3% respectively in 
the knees and hips (4) but infection has much more devastating consequences 
(5). The diagnosis of prosthetic infection and loosening is very important both to 
patient wellbeing and mobility as well as the health economy. Treatment of an 
infected prosthesis is well in excess of £30,000 (5) and prosthetic infection rates 
following surgical revision are considerably higher, with an occurrence rate of 
about 40% of patients (5).  
The incidence of infection after 2 years is relatively low but not out of the 
question, with a rate of less than 0.2% (2). Deep infection is usually preceded 
by (superficial) wound infection in up to a third of cases (2, 6). The presence of 
pain, fever, restricted joint movement, sinus formation and discharge are 
significant indicators of prosthetic joint infection; backed up with radiological 
evidence, haematological features and positive microbiological cultures from the 
prosthesis (2). Patients invariably have elevated serum inflammatory markers 
such as erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP). 
In fact, the presence of a normal CRP and ESR make deep infection unlikely. 
Leucocytosis, on the other hand, is more variable and tends to be raised when 
acutely infected (2, 7). The measurement of serum interleukin-6 (IL-6) is more 
accurate than CRP, ESR and the white cell count (7). Microbiologically, 
coagulase-negative Staphylococcus and Staphylococcus aureus are the 
commonest causes; two-thirds of cases tend to be single organism related and 
the other third are multi-organism related. 
In modern medicine, the use of prostheses in joint replacement now forms an 
important part of the management of patients with arthropathy to alleviate pain 
and to improve mobility, whilst maintaining stability and preserving joints (8). 
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Early surgical attempts to treat joint disease involved joint excisions and 
amputations, which were sometimes performed liberally (9, 10). One of the 
earliest recorded surgical attempts at treating severe joint disease whilst 
preserving the joint was made by Anthony White
 
in Westminster Hospital, 
London. Although he was credited with the first excision arthroplasty in 1821, 
White did not publish or report this new surgical procedure. Excision 
arthroplasty improved patient pain and maintained mobility, but it also resulted 
in poor stability (9). Thereafter in 1826, the first osteotomy on a hip was 
performed in Philadelphia by John Rhea Barton (9). Some of the other early 
attempts at joint surgery also involved total hip arthroplasty techniques to relieve 
patient suffering due to joint pain and immobility. Similarly, there were further 
surgical attempts to remove arthritis spur calcium deposits and irregular 
cartilage in order to make the joint surfaces more smooth (11). 
One of the most common indications for early joint replacements was in the 
management of tuberculous arthritis (12). There are reports of John Murray 
Carnochan, a New York surgeon making the first attempts to use artificial 
material to replace joint surfaces by using wood to replace the hip joint in 1840 
(11, 13). This was followed by the use of ivory about half a century later by 
Professor Themistocles Gluck (12). He pioneered joint replacements and 
performed the first human total joint replacement despite suffering severe 
criticism from both his peers and superiors he replaced a knee joint in Berlin 
using a hinged ivory prosthesis in 1890. Thereafter, Gluck developed models for 
replacements of the shoulder, elbow, and wrist (12). In March 1892, Dr Jules-
Emiles Pean in Paris closely followed this by performing a prosthetic shoulder 
joint replacement using platinum and rubber which was cemented with plaster 
and pumice (14), but the joint replacement only lasted 2 years due to infection 
(15). Gluck is known to have contributed significantly to Pean’s work and Gluck 
also designed prostheses for several other joints making use of elephant ivory 
(14, 16). In 1914, F. Koenig made a subsequent attempt at shoulder prosthesis 
implantation, also using ivory (15). Then the use of glass moulds was reported 
soon afterwards by Marius Smith-Petersen operating in Massachusetts General 
Hospital, Boston, but operating with glass had to be abandoned because some 
of the glass moulds broke (17). In New York, further progress was made using 
20 
 
modern era monoblock designs for prostheses which were successfully applied 
to shoulder replacements by Charles Neer (15, 16).  
The first modern era shoulder replacement using anatomically-shaped 





 had been developed in 1932 by Albert W. Merrick 
for the Austenal Laboratories
®
 (19) and the Austenal Laboratories
®
 later 
patented it on May 15 1934. Vitallium
®
 was initially used as a cast for metal 
dentures and consists of an inert alloy with more than 50 per cent cobalt, 10 – 
40 per cent of chromium, and was later developed for gas turbine blades in 
1941 (20-22). This new alloy was quite revolutionary due to its inert, light, 
strong, biocompatible and corrosion-resistant properties; and is still being used 
today (19). While the newly patented Vitallium
®
 proved to be a great success, 
the hip resurfacing technique was not adequate as a consequence of poor 
implant design, inadequate instrumentation, crude surgical techniques and the 
use of inappropriate materials, rather than inherent difficulty with the surgical 
procedure itself (23). Acrylic material was used in Paris in 1947 in the first 
attempt at prosthetic knee replacement with a hinged knee endoprosthesis by 
French brothers, Jean and Robert Judet (24-26). Thereafter, the first successful 
knee replacement was performed by Moore, using metal in 1950 (25).  
One of the pioneers of modern-day total hip replacement was Professor Sir 
John Charnley, a British orthopaedic surgeon from Lancashire, England (27). 
Charnley developed the low‐frictional torque arthroplasty which used dentist's 
methacrylate cement for a Moore femoral prosthesis. He developed it at 
Wrightington Hospital in Lancashire from 1958 to the early 1960s (27-31). Later 
on, due to the failure of approximately 1 out of every 10 prosthesis in a 10 year 
period (32), the first hip joint resurfacing was embarked upon in 1951 by Sir 
John using Teflon/Teflon bearings, but the Teflon was not robust enough and 
succumbed to early damage of the prosthetic material (33). Hip resurfacing 
entails surgical excision of diseased femoral head and  acetabular surfaces and 
then shaping the surfaces as well as replacing the joint surfaces with materials 
such as metal or acrylic (33). 
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The rising number of hip and knee prostheses implanted yearly in most western 
countries, including the United Kingdom (1, 2) is due to a combination of 
population growth, worsening obesity (34), a growing number of knee injuries as 
well as expanding indications for joint replacements (35). Most contemporary 
hip and knee replacements occur due to advanced osteoarthritis (36), with an 
increasing number occurring following femoral fractures (36) due to newer 
surgical approaches. On the other hand, improved medical therapy of 
inflammatory arthropathy means that number of knee and hip joint replacements 
due to rheumatoid arthritis are on the wane (36). 
Prosthetic infection and loosening are well recognised and significant 
complications of joint replacement surgery (3). It is believed that 1 out of every 
10 prostheses will fail within 10 years of surgery and that 2 out of every 10 
prostheses which necessitates re-revision will fail in 5 years (32). Thus, the 
diagnosis of prosthetic infection and loosening is very important both to patient 
well-being and mobility as well as the health economy. Generally speaking, the 
cure rate of infection is quite similar in both hip and knee prostheses and the 
mean time from surgery to diagnosis is just under 14 months but majority of 
patients present after 3 months (2). The management of these cases could be 
conservative or surgical. Antibiotics, joint lavage and debridement may be 
applied acutely whilst one or two-stage revisions for prosthetic infections are 
more helpful in chronic cases; amputation is a last resort (2).  
Deep prosthetic infections can be classified according to the Coventry 
classification which was later modified by Fitzgerald into acute cases which 
occur within 2 weeks of surgery; delayed phase (occurring 12 weeks to 2 years 
following joint surgery) and presumed haematogenous cases which are usually 
those cases which occur after 2 years (2, 37). Prosthetic infections could arise 
from contamination during the surgical operation or afterwards by the spread of 
blood borne pathogens (2).  
Due to the anticipated increase in numbers of both hip and knee arthroplasty 
surgery (38), there is likely to be an increased need for assessing complicated 
joint prostheses more efficiently. Therefore, research into this area is required 
and further advancements in the use of imaging to diagnose and distinguish 
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loosening from infected joint prostheses will contribute to knowledge in this field. 
Furthermore, I have chosen to investigate patients presenting with painful joint 
prostheses because pain is one of the first clinical indications of complications 
(39). 
 
1.1.3 Imaging Techniques 
There is no consensus on imaging algorithms for the diagnosis of loosening and 
infection (32). The usual current imaging investigations used in prosthetic joints 
include serial radiographs, ultrasound, Magnetic Resonance Imaging (MRI), 
Computed Tomography (CT), contrast arthrography and conventional Nuclear 
Medicine studies (40, 41). In the majority of cases, plain films are adequate for 
the assessment of prostheses. The sensitivity, specificity and accuracy for the 
plain radiographs are approximately 43%, 86% and 64%, respectively (42, 43). 
The use of plain radiographs for diagnosing loosening in un-cemented 
arthroplasties also has the disadvantage of poorer sensitivity due to the lack of 
a cement-bone interface between which loosening lucencies may been 
visualized (44). Indications for ultrasound include assessment of soft-tissue 
collections, guiding joint aspiration and capsular biopsy (41). Ultrasound can be 
particularly useful in the hips and may guide drainage but has no role to play in 
diagnosing loosening with accuracy (45).  
Radioisotope investigations yield functional detail and are generally highly 
sensitive but they relatively less specific for diagnosing infection and loosening 
(40, 41) whilst lacking a great deal of anatomical detail (46). Metal-related 
artefacts in computed tomography and magnetic resonance imaging scans can 
significantly degrade image quality and diagnostic yield (41, 46). Despite CT 
and MRI metal-related artefacts, they do have a role in diagnosing 
periprosthetic collections, although the significant artefacts in the region of the 
prosthesis can render them uninterpretable. The use of artefact-reduction in CT 
and MRI could potentially result in an increased usage of CT and MRI in the 
imaging of prosthetic joints. 
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Newer techniques using PET-CT (Positron Emission Tomography-Computed 





2-deoxyglucose) PET-CT in prosthetic imaging was initially hailed as promising 
(3, 39), 
18
F-FDG uptake in prosthetic joint infection has yielded limited results 
(47). The sensitivity, specificity, and accuracy of the combined use of 
radiolabelled leukocyte with bone marrow imaging outperforms 
18
F-FDG in 
diagnosing infected hips and knee prostheses (48) as illustrated in a recent 
meta-analysis of the use of 
18
F-FDG-PET in detecting prosthetic hip or knee 
joint infection in which 11 studies involving 635 prostheses yielded a pooled 
sensitivity and specificity of FDG-PET for the detection of prosthetic hip or knee 
joint infection ranging from 68.0-90.8% and 79.7-91.4%, respectively (49). 
However, PET-CT research into joint prosthetic imaging using 
18
F-NaF (Sodium 
Fluoride) has also shown promising results (41). 
Contrast arthrography is a more invasive test and requires test operators to be 
more practically skilled than in other routinely used imaging techniques as a 
result this is not a routinely used examination for prosthetic joint assessment.  
A meta-analysis of more than 30 wide ranging English-language medical papers 
published over almost 30 years between 1975 and 2004 (50) compared the use 
of several radiological techniques in the diagnosis of aseptic loosening of hip 
prostheses using plain radiography, subtraction arthrography, nuclear 
arthrography and bone scintigraphy. Although the study demonstrated no 
statistical difference in the diagnostic accuracy amongst the different 
radiological techniques, plain radiographs and bone scans were proven to be 
beneficial for femoral components due to their ease of use, low cost, 
noninvasiveness, as well as relative low radiation dose to the patient (32). 
Nuclear arthrography is performed using intra-articular injection of a 
radionuclide such as non-soluble 
111
Indium labelled sulphur colloid, in 
combination with radiographic contrast. Some authors advocate 20mls of low-
osmolar contrast media with 300 strength combined with 1ml of 10MBq 
111
In 
labelled sulphur colloid (51). This may be performed in combination with a 
technetium labelled MDP (Methylene Diphosphonate) bone scan for correlation. 
Some of the problems with this technique are that it is an invasive and skilled 
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procedure requiring intra-articular injection. In addition, despite being non-
soluble, some of the indium could get absorbed systemically and the presence 
of 
111
indium in the urinary bladder is an important indicator of systemic 
absorption (52). 
Differentiating prosthetic joint infection from aseptic mechanical loosening can 
be difficult even with a thorough clinical assessment and a battery of imaging 
and non-imaging diagnostic tests (46, 53). Some authors advocate the use of 
radionuclide imaging as the mainstay and modality of choice in the investigation 
of suspected prosthetic joint infection (46). The use of a combination of 
radiolabelled leukocyte and bone marrow scans can improve the accuracy of 
bone scans with a combined accuracy of about 90% in diagnosing prosthetic 
joint infection (46, 54). There are several important limitations in the use of in 
vitro labelled leucocytes (46). The in-vitro labelling process is quite demanding 
in terms of staff man-hours and radiopharmacy space and is therefore not 
always available. Furthermore, it involves the lengthy handling of human blood 
and blood products with its inherent risks (55).  
The combination of labelled white cell scans with complementary radionuclide 
imaging using bone marrow or bone scans is often required in bone infection. 
This not only makes interpretation difficult but also adds to healthcare cost as 
well as patient inconvenience (55). Recently discontinued radionuclide infection 
agents include murine monoclonal anti-granulocyte antibodies, such as 
Fanolesomab (NeutroSpec
®
) (56) and radionuclide labelled antibiotics have 
been investigated for a potential role in prosthetic joint imaging (46). Other 
radionuclide infection imaging agents in current use include radiolabelled 
antibiotics and 
18
F-FDG PET (55). In a meta-analysis of monoclonal antibody 
fragment imaging in 13 studies involving 522 joint prostheses; there was an 
estimated sensitivity and specificity of 83% and 80%, respectively (49). 
Analyses uncovered no significant statistical differences between the various 
subgroups of monoclonal antibody fragments. For weighted analysis, there was 





) is one of the more common murine monoclonal antibody 
fragments of the IgG1 class (58). LeukoScan
®
  is a 50 kDa fragment antigen 
binding (Fab′) that binds to the NCA-90 antigen on the surface of human white 
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cells (58). There are varying clinical reports as to whether human anti-mouse 
antibody (HAMA) is a contraindication to LeukoScan
®
 usage since the antibody 





has 100% sensitivity and negative predictive value but a poor specificity of only 
20%. To improve test accuracy and positive predictive value would require 
combining the 
99m
Tc-sulesomab scan with a 
99m
Tc- bone scan or a 
99m
Tc-
nanocolloid bone marrow scan (54) but murine monoclonal anti-granulocyte 
antibodies have been discontinued (56). 
A large number of aseptically loosened prostheses result from 
inflammatory/immune reactions (60) which involve histiocytes, giant cells, 
lymphocytes and plasma cells (61). The cells secrete pro-inflammatory 
cytokines and proteolytic enzymes with resultant osteolysis and loosening (61). 
Loose joint prostheses have a periprosthetic pseudomembrane (61) which is 
composed of histiocytes (95% of samples), giant cells (80% of samples), 
lymphocytes, plasma cells (25% of samples) and neutrophils (less than 10% of 
samples). The presence of a significant number of neutrophils in samples is 
what distinguishes periprosthetic infection from aseptic loosening (58, 61). 
White cells in general are present in both inflammation and infection, and 




F-FDG-PET is incapable of 
differentiating aseptic loosening from the infected joint prosthesis (55).  
 
1.1.4 The Advent of 
18
F Fluoride PET 
Fluorine is the ninth element in the periodic table; it is a monovalent halide that 
often exists in nature as an inorganic anion bound to other cations.  There are 






F alone, being the solitary stable 
isotope (62, 63). 
18
F is an artificial radionuclide which was first produced in 1936 
(62, 63).  
18
F may be produced within nuclear reactors by using fast neutron 
bombardment of lithium‐6 enriched solid lithium carbonate targets  (62). This 
method is inefficient and produces impure fluorine. The use of cyclotrons in the 
production of 
18





F. The promising role of Fluoride in nuclear medicine was first 
discovered by Anbar et al in 1959; they explored the role of 
monofluorosulphonates, difluorophosphates and fluoroborates as competitors 
for  iodine uptake in the thyroid gland in a similar fashion to perchlorate ions 
(64). In addition, Anbar suggested a role for 
18
F in brain imaging. The value of 
fluoride in bone imaging was first recognised by Monte Blau and team in 1962 
(65, 66). 
18
F decays to 
18
O (oxygen-18) with a half-life of 109.7 minutes for 97% 
by the emission of positrons which leads to the production of 0.51MeV 
annihilation photons (62, 63). The remaining 3% of 
18
F decay is by electron 
capture (62, 63). 
18
F is usually administered in its salt form as 
18
F-NaF and may 
be taken either orally or intravenously. Oral intake is less reliable due to the 
possible reaction with gastric contents which may result in the formation of 
insoluble compounds, but oral intake is more conducive when microbiological 
purity is less than acceptable. Consuming as much water as possible and 
emptying the urinary bladder reduces the radiation dose as well as decrease 
urine–related artefact. 




cations in bone occurs via the mechanism of ion exchange 
with the hydroxyl anions on the surface of hydroxyapatite crystals (67); these 
crystals are small-sized and thus present large surface areas for ion exchange 
in bone molecules which are in equilibrium with plasma (66). The rate limiting 
steps in the ion exchange process is blood flow and most 
18
F-NaF is retained in 







concentration levels rapidly fall to 20% of peak levels within 30 minutes; 10% of 
peak levels within 60 minutes and approximately 1% by 5 hours (66, 68). 
Fluoride is excreted via the kidneys; it is filtered through glomerular capillaries, 
but approximately one quarter of the filtered fluoride is reabsorbed through the 
nephron tubules (68, 69) and there is a reasonably direct correlation between 
glomerular filtration rate (GFR) and 
18
F clearance as well as chloride clearance 




NaF is rapidly cleared from the body with 
rapid achievement of high bone: soft tissue ratios (66), the most favourable 






F-FDG PET versus Other Nuclear Medicine Techniques 
 
The 2 PET tracers that are generally used to assess bone disease are 
18
F-
Sodium Fluoride and 
18
F-FDG (70). Although the use of 
18
F-FDG PET-CT in 
prosthetic imaging was initially hailed as promising (3, 39), 
18
F-FDG usage in 
joint prosthesis infection has yielded limited results (47) and the sensitivity, 
specificity, and accuracy of the combined use of radiolabelled leukocyte/marrow 
imaging outperforms 
18
F-FDG in detecting joint prosthetic infection in both hips 
and knees (48). In a blinded study of 35 patients, 
18
F-FDG PET did not perform 
any better than three-phase bone scintigraphy in patients with prosthetic joint 
replacement infections, and conventional radiography was more sensitive but 
less specific than 
18
F-FDG PET (71). 
18
F-NaF PET-CT is slightly more specific 
than 
18
F-FDG PET-CT in the assessment of hip prostheses (72). PET scanners 
have become obsolete equipment and since 2000 PET-CT scanners have 
replaced dedicated PET scanners (73). 
 
1.1.6 PET-CT Artefacts 
The high density related to metallic components of prostheses result in artefacts 
in both PET and PET-CT images (74). These occur when attenuation artefacts 
in PET are corrected with the use of transmission scans, which are generated 
with CT or germanium-68 (
68
Ge). These attenuation corrected artefacts mimic 
periprosthetic increased metabolic activity, which are said to be more evident 
when there is patient motion between the emission and transmission scans. The 
employment of attenuation-weighted iterative reconstruction may reduce these 
artefacts (74). It is well recognised that these artefacts may result in false 
positive interpretation in patients with suspected infection. Marked increased 
activity in the attenuation-corrected images requires confirmation with the non-
attenuation-corrected images and the follow up of this artefactual increased 
uptake for over a year usually confirms no change in the periprosthetic intensity 




1.1.7 The Future 
PET-CT combines 2 sensitive data sets yielding both anatomical and functional 
information. The rapid accumulation of 
18
F-Fluoride ion within the skeleton 
makes it the ideal isotope for the demonstration of prosthetic infection and 
sequential imaging of prostheses with 
18
F-NaF shows great promise (76). 
Further advantages of this technique include a shorter scanning time and 
resultant increased patient throughput which may further offset the relatively 




Tc-HDP (hydroxydiphosphonate) dynamic 
bone scans (77). 
18
F-NaF Dynamic (sequential multiphase) images with Time-
Activity-Curves may yield more diagnostic information (78) and therefore more 
accurately diagnose loosening of joint prostheses; diagnose infection of joint 
prostheses; and distinguish loosening from infection of joint prostheses. We will 
investigate whether sequential multiphase 
18
F-NaF PET-CT, as a single imaging 
investigation, is a more cost-effective and accurate method of detecting of 
periprosthetic infection/loosening.  




) may reliably 
demonstrate the accumulation of macrophages around joint prostheses and 
therefore identify the presence of periprosthetic loosening versus infection of 
joint prostheses using both quantitative and visual analysis. 
 
 
1.1.8 The Need for More Research 
Prosthetic joint replacements are becoming increasingly more common (79) and 
there are several outstanding wide-ranging reviews of prosthetic joint 
complications (80). There are several reviews of arguments for and against 
different imaging investigations for symptomatic joint prostheses, each of which 
to some extent reflects the authors’ personal clinical and research bias as well 
as expertise (43, 46, 81, 82). There are unresolved conflicts and gaps in 
research of failed prosthesis imaging that still require exploration. In addition, 
there are new developments that are required due to improvements in the state 
of knowledge in metal artefact reduction, positron imaging, 
18
F-NaF supply and 
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radionuclide imaging of mannose receptors (CD206) located on the surface of 
macrophages. Due to the speed of basic science and clinical research in this 
field, a strictly comprehensive review is perhaps impossible, but this thesis will 
attempt to present a brief review of the attributes of different imaging tests 
available for investigating the complications of joint prostheses. 
This review would cover historical and current state of imaging modalities in 
prosthetic joint imaging; the history and role of 
18
F-NaF PET as well as CT and 
multimodality imaging while reviewing methods for overcoming artefacts from 
metallic prostheses. The motivation for this research is the lengthy time and 
non-standardized test algorithms for investigating patients with painful joint 
prostheses. The specific principles covered include physics of PET and CT as 




There is an increasing use of prosthetic joint replacement medical devices to 
treat arthropathy as well as a continuing increase in aging population which 
means that there is likely to be a requirement for more resources to diagnose 
the complications of joint prostheses. The combined use of very sensitive 
moderately specific dynamic 
18
F-NaF PET-CT and a radionuclide predictive 
biomarker of macrophages in periprosthetic tissue are likely to increase the 






1.2 Role of CT in Prosthetic Joint Imaging; Pathologic Spectrum 




The history of tomography dates back to 1914 when it was first suggested by 
polish radiologist Karol Mayer. Various authors subsequently developed the 
initial idea further and individually built their own equipment as well as published 
additional work in the area (83). Alongside further developments in electronics, 
the Computed Axial Tomography (CT) scanner was first developed and 
commercialized in 1972 by Sir Godfrey Hounsfield, an engineer at Electric and 
Musical Industries (EMI), the same company that sold The Beatles' records (83, 
84). Hounsfield and Dr Jamie Ambrose, a consultant radiologist in Atkinson 
Morley’s Hospital, Middlesex presented a paper ‘‘Computerised Axial 
Tomography (A new means of demonstrating some of the soft tissue structures 
of the brain without the use of contrast media)’’ in April 1972 at the 32nd 
Congress of the British Institute of Radiology (85) and the following month 
Hounsfield and Dr James Bull presented the first clinical images at a neurology 
postgraduate course at the Albert Einstein College of Medicine, New York (85). 
Since then, successive generations of CT scanners have been developed with 
significantly improved image quality and reduced scanning times. 
With the relative recent growth of hybrid imaging, the role of computer 
tomography technique (CT) is being reassessed for the provision of anatomic 
information, due to poor structural detail in conventional radionuclide images 
performed for possible prosthetic joint instability, component loosening and mal-
positioning (43). 
CT has advantages over Magnetic Resonance Imaging (MRI) due to quicker 
scan times, superior views of the acetabular roof, better images of heterotopic 
bone, cement and metallosis (86). CT is superior to ultrasound because it is 
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less operator-dependent and has superior bony detail. CT and ultrasound may 
guide percutaneous joint infections, biopsies and aspirations (87).  
CT scans have an important role before and after joint implant surgery (88). 
Computed Tomography data is used in computer-aided custom-made 
prostheses for prototyping to produce precise pelvic models used to design and 
manufacture joint prostheses (88, 89). 
 
 
1.2.2 CT in Preoperative Planning and Intra-Operative Planning  
 
Preoperative surgical planning is not routinely performed but some authors 
suggest that CT scans of the pelvis may have an important role to play in the 
assessment of ideal acetabular implant positioning in order to ensure total hip 
arthroplasty implant stability, i.e., to gauge whether more than 70% of the bone-
implant interface would be covered and also that the acetabular implant is 
placed as close to the anatomical rotation centre as possible (90).  
Prior to revision, computed tomography-based or imageless navigation systems 
can improve the accuracy of component positioning (91, 92). The final 
orthogonal alignment results from CT are much closer within acceptable number 
of degrees of the predicted surgical plans, but problems may arise in the talus in 
ankle replacements due to the differing preference regarding the extent of gutter 
debridement amongst surgeons  (93). CT scans are used as the basis for 
commercially available robotic surgical systems which can be adapted to assist 
preoperative planning and intraoperative placement of knee prostheses (94), 
resulting in improved prosthetic component alignment and improved bone-
implant fit, reduced implant loosening particularly in non-cemented prostheses 
(94). However, disadvantages include the requirement for fiducial markers, 
increased operating times and higher treatment costs (94).  
The role of Magnetic Resonance Imaging (MRI) in patient specific cutting guides 
is small and although MRI can lead to reduced operating times and also 
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improve the consistency of prosthetic joint alignment it does lead to significantly 
increased overall medical costs (95). 
 
1.2.3 Postoperative Planning  
 
CT-based systems can be used in accuracy assessments of post-operative 
patient-specific instrumentation systems for joint replacements (96, 97). There 
are several types of orthopaedic devices that can be implanted in several joints 
– most commonly in order of occurrence knee, hip, ankle, shoulder and elbow 
followed by wrist and then carpal and tarsal joints (98). However, current trends 
and industry projections suggest that it is more likely that an increase in the 
number of upper extremity arthroplasty will exceed the steady increasing 
requirements for hip and knee arthroplasties (99). This section of the chapter 
concentrates on the role of CT in the 2 most common joint replacements that 
currently occur.  
 
 
1.2.4 CT in Post-Operative Imaging of the Hip 
 
The indicators of hip replacement infection on CT are a volume of periprosthetic 
fluid of more than 1 ml and prosthetic acetabular malpositioning (100). 
Component malpositioning also can result from aseptic loosening, instability, 
polyethylene wear as well as joint instability and dislocation (101). Further 
confirmatory evidence of prosthetic sepsis can be provided by positive bacterial 
culture from joint fluid aspirate obtained under CT guidance all resulting in 70% 
sensitivity, 100% specificity and 100% positive predictive value (100).  
The American academy of orthopaedic surgeons advocates that there is no 
compelling evidence for the use of CT as a diagnostic test for periprosthetic joint 
infection, stating that there is an unclear balance between benefits and potential 
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harm (102).  The American academy of orthopaedic surgeons also advocate a 
central role for blood tests (ESR and CRP), as well as joint aspiration (including 
frozen section aspiration) (102), and also state that nuclear imaging has a 
limited role in the diagnosis of periprosthetic joint infection (102), despite the 
fact that it is well recognised that nuclear medicine studies have high negative 
predictive values (103) and also that combined nuclear medicine studies have 
high positive predictive values (103).  
Loosening at the bone/cement interface or prosthesis/bone interface is 
demonstrated on radiographs as a progressive increase in radiolucency on 
serial radiographs (104), often of up to 2 mm at the interface or a change in 
position on serial imaging. Loosening may also occur at the prosthesis/cement 
interface (105). CT is able to demonstrate more subtle bony change including 
erosion and periosteal reaction (106). Postoperative findings must always be 
interpreted in conjunction with clinical symptoms and previous imaging (105), 
because CT artefacts are known to occur more commonly around the 
acetabulum. In addition, artefactual radiolucency at the metal-cement interface 
may also occur secondary to the Mach effect (107) and radiolucencies around 
revised prostheses are generally wider (105). Other radiographic signs of 
loosening include the development of bony sclerosis in the region of the distal 
tip of the prosthesis, cement fracture, prosthesis fracture, prosthesis movement 
as well as prosthetic rotation (105). Prosthetic micro-abrasive wear of 
polyethylene or polymethylmethacrylate (PMMA) cement can result in particle 
deposition in periprosthetic tissues, which incites a multinucleate giant cell 
granulomatous inflammatory response, resulting in periprosthetic osteolysis and 
a form of endosteal scalloping on plain radiographs and CT, known as particle 
inclusion disease (105, 108-110). Metal wear results in periarticular metallic 
fragments (105).  
Particle inclusion disease, also known as histiocytic response results in focal 
osteolysis and was first recognised by John Charnley. It was initially thought to 
be secondary to cement (105), but is now known to be induced by deposited 
foreign bodies (metallic, PMMA cement, as well as polyethylene fragments) 
following implant wear 1 to 5 years post-surgery (105). Polyethylene inclusion 
disease is now most common because of reduced use of cemented implants 
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(105). On radiographs, inclusion disease may be distinguished from loosening 
by focal endosteal scalloping as opposed to linear radiolucency which occurs in 
loosening and infection (105). Periarticular soft tissue density and fluid may also 
occur in particle inclusion disease (105). Inclusions and fractures are elegantly 
demonstrated on cross-sectional imaging. The bony defects produced by 
particle inclusion disease result in an increased fracture risk and therefore 
requires close follow up with radiographs or CT (105). 
Low-grade infection can be difficult to distinguish from aseptic loosening on 
imaging alone. High-grade infection results in joint effusion, osteolysis and 
sclerosis (105) as well as other signs of infection on the plain radiograph 
consistent with osteomyelitis (105). On plain radiographs, infection may also be 
difficult to distinguish from the endosteal scalloping of particle inclusion disease 
(105). CT defines bony changes in better detail as well as assesses adjacent 
soft tissue change much more clearly when compared with radiographs. 
 
 
1.2.5 CT in Post-Operative Imaging of the Knee 
 
The hip and knee are the most replaced joints in the human body (111, 112). 
Age-related degenerative change commonly affects the knee (111), whilst 
rheumatoid arthritis and osteoarthritis are the 2 commonest indications for knee 
arthroplasty (111). Depending on disease severity, the type of joint replacement 
undertaken may be total or limited to a single compartment (111). Commonly 
employed knee prostheses consist of cobalt-chromium alloys for both the 
condylar and tibial components with an ultrahigh molecular weight polyethylene 
(UHMWPE) layer on the tibial component (111, 112). Other employed metals 
have involved the use of binary titanium and zirconium alloys (111, 112) with 
improved biocompatibility and reduced reaction (113). Total knee prostheses 
are either of the unconstrained or semi-constrained category and their 
implantation requires sacrifice of the anterior (together with or without the 
posterior) cruciate ligaments (111). The patella may also be resurfaced to 
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reduce post-surgical anterior knee pain and the requirement for revision (114). 
Total knee replacement is one of the most successful joint replacement 
procedures in orthopaedic surgery (101, 115). Total knee replacements last 
longer than unicompartmental replacements; with survival rates of greater than 
90% after 15 years (101) and total knee replacements generally last from 10 to 
15 year with all being well, or 20 years at the most (111).  
Adequate total knee replacements require fitted condylar and tibial components, 
employing 5 to 8 degrees of valgus alignment with normal tension maintained 
between the surrounding soft tissue structures (111). The failure of prostheses 
often result from a combination of factors including infection, aseptic loosening, 
implant wear, unsuitable mechanical load, fatigue failure at implant: bone 
interfaces due to repeated remodelling in response to altered mechanical loads, 
excessive implant motion resulting in resorption, and possibly hydrodynamic 
pressure (116). Albeit rare, some of the most common symptoms experienced 
after knee surgery include pain, instability and reduced range of movement 
(111). Imaging is required to exclude post-surgical complications and other 
unrelated conditions (111). For this to happen, an understanding of surgical 
techniques and surgical dates is important (111). Immediate post-surgical 
radiographs are required to assess the alignment of implant components. 
Haemorrhage and infection tend to occur more commonly in the subacute 
stage. Radiographs are also able to demonstrate effusions and intra-articular 
haemorrhage (111), but CT also has a role to play (111). 
Technical artefacts arising from metal prostheses may be overcome to a degree 
by using pre-scanning techniques to perform the CT scan in a specific manner 
(117). The degree of artefact produced depends on the amount and type of 
metal present in the prosthesis, with titanium producing less artefact than cobalt 
(82). Titanium is the one of the most ideal alloy components for prostheses due 
to its suitable biocompatible composition which limits unfavourable tissue 
reactions, corrosion resistance and resistance to chemical breakdown in vivo 
(113). Titanium also possesses high levels of strength, low elasticity levels and 
produces relatively less debris (113). 
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CT scans provide detailed structural information which can also enhance the 
surgical planning stage (117). CT scans provide a means to measure the 
relationship between direct post-operative stem anteversion and rotational 
stability, because gradually worsening retroversion of a cemented stem on CT is 
a good indicator of prosthetic loosening and impending failure (118). Thus, an 
anteversion angle of less than 10° is detrimental to the future prospects of 
cemented hip prosthetic stems (118).  
Prosthetic joint loosening is a clinical-radiologic diagnosis, but endosteal 
resorption of cortical bone in the mid-femur on CT is an indicator of primary 




1.2.6 CT in Diagnosing and Distinguishing Between Septic and Aseptic 
Loosening in Hip Prostheses 
 
The diagnosis of post-surgical hip complications may require multiple imaging 
tests (105), but plain film radiography remains the basis of post-surgical 
musculoskeletal radiology and it generally forms the initial evaluation of 
symptomatic post-surgical joint prostheses (82). In addition to plain radiographs, 
multi-slice CT may be used for additional assessment of joint prostheses in the 
detection of infected prostheses (106, 120). Oedema and haematoma in the 
immediate post-surgical period can mimic soft tissue infection (120), but CT is 
able to illustrate soft tissue infective changes such as abscesses following the 
administration of intravenous contrast and CT can guide percutaneous abscess 
drainage and other intervention procedures such as arthrography and synovial 
biopsy (120). Additionally, CT can detect bony changes of infection such as 
cortical and trabecular erosion; periosteal reaction, sequestration, fistulae, 
cortical tracts, sinus tracts and soft tissue defects (120). CT can also detect 
aseptic complications such as periprosthetic fractures, aseptic loosening, 
osteolysis, heterotopic bone formation, trochanteric bursitis as well as osteolysis 
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from foreign body granulomatosis (82). Care should be taken because 
osteolysis may confused with pre-existing cysts or geodes as well as spot-welds 
with stress-shielding (121). In an epidemiological study of the 60,355 total knee 
arthroplasty revision procedures performed in the United States during a 15 
month period between October 2005 and December 2006 (122), the most 
common identified causes of failed prostheses were infection in 25.2% and 
aseptic mechanical implant loosening in 16.1% of the failed prostheses. Other 
causes of prosthetic failure included dislocation, implant fracture, periprosthetic 
fracture, periprosthetic osteolysis, bearing surface wear; and other mechanical 
complications of prosthetic joint implants (122). The presence of post-operative 
surgical site infection, synchronous malignancy, prior revision arthroplasty, 
nosocomial infection as well as operating room time of greater than 3 hours are 
some of the most significant prognostic factors which can predict prosthetic joint 
infection (103). The success of total knee replacements also depends on the 
preoperative condition of the patient, the design and materials of the 
components and the surgical technique used (101). 
Artefacts from metallic prostheses can result in unreadable CT images. More 
artefacts are visualized in larger metallic implants as well as cobalt chrome 
prostheses (as opposed to titanium) (82, 123). Several methods can be 
employed to reduce the detrimental effect of beam hardening artefact and to 
also improve image resolution. These include pre-image acquisition techniques 
such as optimal patient positioning; increasing the peak kilo-voltage (KVp) and 
tube current; and the use of overlapping slices, increasing slice thickness (82, 
123, 124). Post-processing image reconstruction techniques including the use 
of multi-planar reformats; including the use of soft tissue windows for bulky 






2.7 Proposed CT Reporting Checklist 
 
A systematic approach to radiographic evaluation of prosthetic joints using a 
checklist of important reporting points would help direct the radiologist to 
specific significant features when assessing prosthetic joints (90). In order to 
emphasise the role of CT in the diagnosing periprosthetic complications, this 
proposed CT reporting checklist (Table 1) provides an important tool for the 









points                    
Radiographic features to assess for and significance                    
Prior 
radiographic 
and CT findings 
Is the implant positioned properly and intact? Is the 
prosthesis position stable with good component fixation? Is 
the host bone abnormal and is there any adverse soft tissue 
feature such as muscle atrophy? Comparison with baseline 
radiographs helps detect complications. 
Periprosthetic 
bone         
Assess for periprosthetic fractures, as well as the presence, 
character and quantity of periprosthetic osteolysis. Also 
estimate the total amount of the prosthetic component such 
as acetabular cup that is fixed to bone. This also helps for 




Assess component positioning/alignment, for polyethylene 
wear and component fractures. Examine for excessive 
version which can lead to subluxation and dislocation.  
Periprosthetic 
fluid collections 
Look for periprosthetic bursae, periarticular and deep 
collections with sinus tracks to the skin. CT arthrography may 
also demonstrate communication with the joint. 
Ossified 
masses 
Identify and localize ossified masses. Define the extent of the 
ossified mass and assess whether the mass bridges the joint. 
Periprosthetic 
soft tissue 





Ischial tuberosity line, ilioischial line,  
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1.2.8 Hybrid Imaging 
 
CT scans and radionuclide imaging can form part of a multi-modality algorithm 
(126). Hence, integrated functional and anatomical imaging with SPECT-CT and 
PET-CT scans may be employed to diagnose prosthetic joint septic and aseptic 
loosening. SPECT-CT images can be performed following the injection of 
99m
Tc-
labeled bone isotopes (127) and PET-CT images may be obtained using 
18
F 
labelled radiopharmaceuticals such as 
18





F-fluorine labelled Fluorodeoxyglucose (
18
F-FDG) (128), but 
18
F-NaF is 
more accurate than 
18
F-FDG in the assessment of joint prostheses (129). 
Bone SPECT-CT with 
99m
Tc-labelled phosphonates demonstrate increased 
periarticular bone turnover in the subchondral region, which corresponds with 
osteophytes, meniscal injury and osteochondral lesions on CT and bone 
SPECT-CT is able to accurately assess early osteoarthropathy (130). SPECT-
CT animal experimental studies with radioactive ligands of a folic acid analogue 
has demonstrated synovial activated macrophages accumulation in cartilage 





 SPECT-CT imaging (128). In addition, Tilmanocept
®
 







 to demonstrate CD206 receptor on activated macrophages and 
multinucleated giant cells due to wear particles in aseptic loosening and 
periprosthetic pseudotumours (128). 
 
1.2.9 Reducing Metallic Artefact 
 
The high proton density (Z) composition of embedded metallic prostheses result 
in artefacts that create a contradiction between the true attenuation coefficients 
in the reconstructed image of the metallic object and the measured CT 
Hounsfield Units (131). These metal streak artefacts result from a varying 
combination of beam hardening, scatter, photon starvation, partial volume 
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averaging and aliasing (131). The degree of artefact produced is dependent on 
the type and quantity of metal.  
Metallic artefacts can be reduced before the image acquisition using pre-scan 
methods. Further artefact reduction can be accomplished using concurrent as 
well as post-scan techniques. 
Pre-scan and concurrent techniques include patient positioning, increasing peak 
voltage KVp and tube current (mAs), overlapping slices which results in 
increasing the effective mAs. The most ideal position for imaging would be one 
with the least diameter of metal for the x-ray beams to traverse (105).  
Metal artefact reduction (MAR) algorithms have employed interpolation 
methods, iterative projection modification and filtered back projection methods 
(131). Commercial post-processing software packages such as the orthopaedic 
metal artefact reduction (O-MAR) algorithm from Philips
®
 (131), monochromatic 
gemstone spectral imaging (GSI) from GE
®
 which employs dual-energy CT, and 
gemstone spectral imaging (GSI) monochromatic imaging metal artefact 
reduction (MAR) algorithm also from GE
®
 (132). MARs should be used with 
caution, because it underestimates metal implant length and unintentionally 
introduces more artefacts (132). Both the metal artefact reduction algorithms 
induced other secondary artefacts and also result in an increased radiation dose 
(125, 132). With the MARs technique, a filtered back-projection image is created 
when the initial CT image is reconstructed and back-projected to generate CT 
images (125). If the uncorrected and raw images are dissimilar, other 
reconstructions are produced and fewer artefacts are produced with a higher 
number of reconstructions (125). Dual-energy techniques involve scanning the 
same body part at two different energy levels (125). Dual-energy CT scanners 
produce virtual monochromatic spectral (VMS) images which display what the 
prosthesis would have looked like if the image had been produced by a single 
photon energy x-ray beam (133). 
Several methods have been combined with some success; image-based 
weighted superposition of images obtained from different metal artefact 
reduction methods such as linear interpolation of re-projected metal traces and 
multi-dimensional adaptive filtering of the raw data result in reduced corrupted 
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CT values and fewer secondary artefacts (134) and the quality of images 
produced is usually better than that produced from one single MAR method 
(134).  
The use of multi-planar reformats can improve visualisation of periprosthetic 
pathology (105). Furthermore, improved visualisation of  bony/metal interfaces 
can be achieved by reviewing images with soft tissue algorithms and 
alternatively applying bony algorithms for periprosthetic soft tissue (105).  
 
1.2.10 Summary of the Role of Computed Axial Tomography (CT) in Prosthetic 
Joint Imaging 
 
In this latter section of the chapter, the literature relating to the role of Computed 
Axial Tomography (CT) in prosthetic joint imaging and the detection of 
complications of prosthetic joint surgery was reviewed. CT has an important role 
to play before and after surgery as well as in the production of prototypes to be 
used in the design and manufacture of joint prostheses. CT is often combined, 
in hybrid imaging, with other modalities such as SPECT-CT and PET-CT. 
Although beam hardening artefact has the potential to reduce the diagnostic 
yield from CT there are several pre-scan, scan and post-scan artefact reduction 
methods. Further commercial and in-house artefact reduction methods can also 






1.2.11 Summary  
 
x There is a steady increase in use of prosthetic joint replacement to treat 
arthropathy. 
x The demand for resources to diagnose complications of joint prostheses 
is likely to rise.  
x Efficiency and accuracy of diagnosis may be achieved by combining 
dynamic 
18
F-NaF PET-CT and a radionuclide biomarker of macrophages. 








Chapter 2   Painful Joint Prostheses; a Retrospective Study of the 
Use of Dynamic Bone Scans (and Other Imaging Modalities) – From 




Background: A significant number of patients with joint prostheses may go on to 
experience pain at the site of arthroplasty at some point after surgery. It is 
useful to understand the profile of patients and symptoms with painful joint 
prostheses; including the use of imaging investigations and the time interval 
from symptom onset to diagnosis. It is not entirely clear whether an increased 
number of imaging investigations can prolong the length of time from symptom 
onset to diagnosis. 
Method: This was a retrospective study of 27 adults who had bone scans for 
painful knee and hip prostheses over a 3 month period at the University Hospital 
Coventry & Warwickshire nuclear medicine department between January and 
March 2007. The study was performed retrospectively using data collected from 
the hospital’s radiology information system records of all bone scans that were 
performed over the specified period and the final diagnosis was confirmed using 
microbiology, clinical follow up, surgical findings or other radiological data.  
Results: Nineteen female and eight male patients were identified with an age 
range from 28 to 86 years and an average age of 64 years. The time range of 
symptom onset to diagnosis was 2 months to 121 months. All but one patient 
had plain radiographs and only one patient had an MRI scan of the painful joint. 
Almost twice as many knees were investigated over the time period and the 
most common symptom in these set of patients was pain. Dynamic bone scans 
were performed from 2 to 120 months post-joint replacement. The overall 




Conclusion: The length of time from symptom onset to diagnosis for patients 
with painful joint prostheses dynamic isotope bone scans ranged from 2 months 
to 121 months with an average of 42.9 months delay in diagnosing painful joint 
prostheses. Factors including the use of multiple non-imaging tests including the 
use of anatomical imaging modalities as well as functional imaging modalities 
may have contributed to the delays in reaching a diagnosis. A streamlined 
reduced number of imaging tests and fused functional anatomical imaging may 




The diagnosis of post-surgical hip and knee joint replacement complications 
often require various imaging tests (135). False positives bone scans commonly 
persist for several months after joint replacement surgery. The aim of our 
retrospective study was to identify and demonstrate the delay in diagnosing the 
cause of painful joint prostheses. Joint prosthetic failure occurs in less than 1 in 
10 patients during the lifetime of the joint prostheses, mostly due to aseptic 
loosening and less commonly due to infection (5). Prosthetic joint infections 
result in higher morbidity, prolonged hospitalisation and significantly higher 
treatment costs (5) due to additional surgery and antibiotic therapy with possible 
recurrent infirmity (5). Infection rates following surgical revision are significantly 
higher than after primary replacement. Furthermore, infection rates following 
primary joint replacement are more common in the elbow and knee than in hip 
and shoulders (5). Coagulase-negative staphylococci is the responsible microbe 
in a third of cases (5). Aseptic loosening is usually due to metallic and non-
metallic particulate deposition leading to macrophage phagocytosis and 
osteolysis (5). Current research into new imaging modalities or isotopes for 
painful prosthetic joint imaging is limited. There is a debate over what the 
optimal imaging or imaging pathway for prosthetic joint replacements and a lack 
of consistency of what imaging modality is utilised in the United Kingdom. It is 
also important for the advancement of treatment of painful joint prostheses to 
diagnose complications in a quicker and more streamlined manner (136).  
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2.3 Research Question 
 
In patients with painful joint prostheses that are investigated with dynamic 




The objectives of this retrospective review were 1: To measure the proportion of 
patients undergoing nuclear medicine bone scan investigations who have a final 
diagnosis of infected prostheses and 2: To describe the time interval between 
onset of symptoms, imaging tests and final diagnosis.  
 
2.5 Materials and Methods 
 
A 3 month study of all dynamic bone scans performed for painful joint 
prostheses over a 3 month period at University Hospital Coventry & 
Warwickshire nuclear medicine department between January and March 2007. 
The choice of 3 months was based on the estimated number of scans 
performed each week and also because the aim was to provide a retrospective 
snapshot of clinical practice as opposed to a lengthy retrospective study.  
All patients with painful joint prostheses referred to the university hospital 
nuclear medicine department over a 3-month period between January 2007 and 
March 2007 were included (n = 27). The study was performed retrospectively 
using data collected from the hospital’s radiology information system records of 
all bone scans that were performed over the specified period. Twenty seven 
patients met the criteria and the final diagnosis was confirmed microbiologically. 
Where there was no confirmatory microbiological result, results from clinical 
follow up as well as surgical and radiological data were used.  
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The final diagnosis of the painful joint was confirmed with surgery, or 
microbiologically or, in the absence of these, clinical follow up as well as 
surgical findings were used. Where available, other radiological investigations 
were used. We also assessed patient demographics, reported symptoms, the 
type and number of imaging tests as well as the time it took to make a 
diagnosis.  
The microbiological definition of prosthetic joint infection include the 
preoperative aspiration as well as the intraoperative isolation of similar 
microorganisms which are indistinguishable from three or more independent 
specimens, taken as part of a standard set of 5 or 6 periprosthetic intraoperative 
tissue samples or the explanted prostheses (137, 138). Clinical features of a 
sinus tract that communicates with the prosthesis or persistent wound drainage 
over a joint is also considered evidence of prosthetic joint infection (138).  
Radiological evidence of prosthetic joint infection includes positive findings from 
plain radiographs, bone scans, white cell scans, magnetic resonance imaging 
(MRI), computed tomography (CT), and ultrasound scans (138, 139). 
Surgically, the presence of acute inflammation as seen on histopathologic 
examination of the periprosthetic tissue at the time of surgical debridement or 





The retrospective study identified 27 adults who had bone scans for painful 
knee and hip prostheses over a 3 month period. Nineteen female and eight 
male patients were identified. Their ages ranged from 28 to 86 years, with an 
average age of 64 years (Figures 1 and 2). The time range of symptom onset to 
diagnosis was 2 months to 121 months (Figure 3). All but one patient had plain 
radiographs and only one patient had an MRI scan of the painful joint (Table 2) 
and almost twice as many knees were investigated over the time period (Table 
3). All the patients had their inflammatory blood markers measured. The 
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diagnosis and treatment of painful joint prostheses can be challenging and time 
consuming, resulting in multiple unhelpful investigations and therefore delayed 
treatment. The most common symptom in these set of patients was pain (table 
4). Dynamic bone scans were performed from 2 to 120 months post-joint 
replacement (Figure 4). Twenty-six out of twenty-seven patients had a final 
diagnosis. The mean time from scan to diagnosis was 9.5 months. The overall 
average length of time from symptom onset to diagnosis in this group was 42.9 
months (Table 5) and only 7% of these patients had infected prostheses; this 
contrasts with the much shorter duration of about 1 month to 6 months of 
symptoms and time to diagnosis in cases with virulent coagulase-negative 
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Figure 3. Frequency histogram of symptom onset to diagnosis 
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Table 4. Presenting symptoms of patients 
 
Presenting symptoms Numbers 
Pain 27 
Swelling 9 














Delayed diagnosis of painful joint prostheses can be defined as the time of 
symptom onset to the time of diagnosis or more than 25 days in hip arthroplasty 
and more than 42 days after knee arthroplasty (142). The group studied 
included both men and women across a wide age range (28-86 years). Pain 
and swelling were the most common presenting complaints and these 
corresponded with symptoms most frequently quoted in the literature (103, 143).  
The median number of months from initial prosthetic surgery to the onset of 
symptoms was 15.5 months (interquartile range of 2 to 39 months). The median 
number of months from symptom onset to the bone was 11 months 
(interquartile range of 2 to 22 months).  
The median number of months from the time of the bone scan to the final 
diagnosis was 7.5 months (interquartile range of 4 to 14 months). Diagnostic 
delays occurred in the majority of patients (Table 5) in this retrospective study. 
Studies have shown that patients having to wait for multiple out-patient 
investigations (144) as well as the duplication of investigations (144) especially 
when significant non-standardised variations occur in the diagnostic work-up 
can lead to diagnostic delays (145). There is an excess of females which may 
partly be explained by the higher propensity of rheumatoid arthritis in females as 
well a reflection of the longer survival of females (146). Additionally, there is a 
strong association in general between old age and obesity as independent 
factors with diagnostic delays (147) and this combined with the fact that post-
surgical function is worse in older female patients who undergo hip and knee 
joint replacements (148) may contribute to a high number of diagnostic delays in 

































1 Left UKR 12 11 14 (C,R) Loose 




3 Right TKR 0 18 11 (C,R,S) 
Neuroma 
4 Right hip 
hemi-
arthroplasty 





5 Right TKR 8 13 16 (C,R) Patellar 
arthropathy 
6 Left TKR 2 12 4 (C,R,S,M) 
Unstable, 
loose 




























9 Left TKR 65 5 12 (C,R,S,M) No 
diagnosis 
10 Right TKR 24 22 6 (C,R,M) 
Infection 
11 Left TKR 0 36 10 (C,R,S,M) 
Loose 
12 Right TKR 4 2 5 (C,R) 
Neuroma 
13 Right TKR 21 5 23 (C,R,S,M) 
Referred pain  
14 Right TKR 23 11 6 (C,R,S,M) 
Loose  



































19 Right UKR 6 22 5 (C,R,S,M) 
Loosening 
20 Right hip 
resurfacing 
0 30 6 (C,R,S,M) 
Pseudotumou
r 
21 Left THR 0 25 N/A (C,R) No 
diagnosis 
22 Right hip 
resurfacing 
15 1 3 (C,R) Aseptic 
loosening 
23 Left TKR 0 37 26 (C,R,S,M) 
?Aseptic 
loosening 
24 Left TKR N/A N/A 20 (C,R,S,M) 
?aseptic 
loosening 
25 Right THR 39 1 30 (C,R) 
Trochanteric 
bursitis 
26 Left THR 24 50 4 (C,R) Loose 
acetabular 
cup 




Note. Key: C = Clinical, S = Surgical, R = Radiological, M = microbiological, RA 
= Rheumatoid Arthritis, THR = total hip replacement, TKR = total knee 
replacement, UKR = unicompartmental knee replacement 
 
The early diagnosis of septic periprosthetic loosening is vital for successful 
therapy (149) as less invasive treatment may only be feasible in patients with a 
less than a 3 week duration of infection (149). Furthermore, a delayed diagnosis 
can result in reduced joint function, worsening morbidity and the requirement for 
more complicated or repeated surgery (150, 151), but selected patients may 
benefit from less aggressive surgery (151). 
Although causality for the lengthy diagnostic period for painful joint prostheses 
has not been identified in this study, possible contributory factors include 
multiple imaging and non-imaging tests, often at different hospital sites and 
interspersed with multiple clinic appointments under different doctors. 
Furthermore, disagreements in image interpretation even between expert 
readers can lead to additional diagnostic difficulty (152). Surprisingly, there is no 
data regarding medicolegal cases for delayed diagnosis of painful joint 
prostheses. However, recent reviews confirm that leg-length discrepancy is the 
commonest reason given for patient discontent and medicolegal action in hip 
arthroplasty (153) and that the use of patient-specific instrumentation increases 
the exposure to malpractice suits (154). 
No single diagnostic test for painful joint prostheses achieves all the ideal 
qualities of high levels of accuracy, safety, ready availability, cost-effectiveness 
as well as widespread acceptance (152). Imaging investigations therefore often 
rely on algorithms or a combination of tests. Multiple investigations may result in 
additional healthcare costs and consequently delayed diagnoses (155). Patients 
that initially present with vague medical symptoms may result in misdiagnoses, 
delayed diagnoses and repeated hospital visits may occur (156). A positive test 
does not necessarily satisfy criteria of a gold standard test as false-positive and 
false negative results are possible. However, many clinicians still assume that 
positive tests with positive clinical features of infection constitute a positive gold 
standard, and also that patients with no clinical evidence of infection and 
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negative test results constitute the negative gold standard (157). It is well 
understood that when single tests or investigations yield non-specific results 
which are singly insufficient to confirm a diagnosis, clinicians frequently to resort 
to the use of a panel of investigations, often combining several clinical, 
radiological and pathology investigations to reach a final diagnosis (158). The 
combination of positive test results from either of more than one diagnostic 
study caries more clinical weight than a single test by improving test sensitivity 
but this may also result in a modest reduction in test specificity (159). In 
addition, the combination of data from anatomical and functional data sources 
can yield significantly higher sensitivity and specificity than scanning performed 
with either technique (160). However, there are disadvantages to the routine 
use of multiple investigations which can result in increased cost of patient care 
as well as increasing patient’s radiation exposure. For example, radiation doses 
from a CT scan of the pelvis and knee with give a dose of 6 mSv and 1 mSv 
respectively, while the dose from a knee radiograph is 0.001 mSv (161). Our 
retrospective study has shown a significant time lag between symptom onset 
and diagnosis of up to three and a half years.  
Developing a single imaging test that combines high end functional and 
anatomical data, such as in 
18
F-NaF PET-CT may provide accurate diagnostic 
information. Challenges with the use of 
18
F-NaF PET include the scarce 
availability of PET-CT scanners and PET-CT experts; relative high cost and 
scarcity of 
18
F-NaF isotope; short half-life of 
18
F; artefacts from prostheses on 
CT and PET. Some of these challenges will be addressed and solutions 
proposed over the coming chapters. In complicated joint prostheses, there is a 
direct relationship between delayed diagnosis and patient morbidity. Delayed 
diagnosis often results in a reduction in the preservation of joint function, worse 
outcomes and also leads to increased healthcare costs (162) because there is a 
limited time for successful implant treatment with retention following prosthetic 
joint infections (163).  
Critical analysis of this retrospective study indicates that although researchers 
generally prefer prospective studies over retrospective studies, the follow-up 
period with retrospective studies which goes forward in time can make 
retrospective studies epidemiologically similar to prospective studies (164). 
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Notwithstanding that the diagnosis of the cause of the painful prosthetic joint 
was clearly defined as the research end point, further flaws originated from the 
retrospective design and the absence of a control group. The lack of a control 
group made it difficult to identify potential confounding factors resulting in bias. 
In addition, the short study period of 3 months resulted in a small and limited 
sample size which could potentially undermine the value of the results, 
decrease statistical power and potentially lead to Type II error skewing. 
However, the findings from this spot check demonstrated what has always been 
suspected and to prolong the study would not have demonstrated any further 
benefit in spite of wasting time and resources. Further limitations of the study 
include selection bias because only symptomatic joint prostheses referred for 
isotope bone scans were included in the study. Lastly, reduced statistical power 
of the study was caused by the limited number of gold standard microbiological 
tests. Positively, the retrospective data collection in this study and reliance on 
clinical notes, laboratory reports as well as radiology reports was an 
inexpensive and a quick method of testing the hypothesis with already existing 
data. The study did not introduce observer variability and no technical difficulty 
was encountered. Newly identified knowledge suggests a possible association 
between referrals for dynamic isotope bone scans and diagnostic delays of up 
to 121 months in patients with painful joint prostheses. This is important with the 
current rising trend in usage of multimodality imaging in nuclear medicine and 
there is a role for further research in this field. 
 
2.8 Conclusion  
 
In patients with painful joint prostheses that are investigated with dynamic 
isotope bone scans the length of time from symptom onset to diagnosis ranges 
from 2 months to 121 months with an average of 42.9 months. This small series 
demonstrates that delays do exist in diagnosing painful joint prostheses. Factors 
including the use of multiple non-imaging tests including the use of anatomical 
imaging modalities as well as functional imaging modalities contributed to the 
delays in reaching a diagnosis, further adding to diagnostic delay. The 
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retrospective study indicated that a streamlined reduced number of imaging 
tests may contribute to an improvement in the speed of diagnosing painful joint 
prostheses. Fused functional anatomical imaging may also solve or reduce the 
need for repeated hospital visits for multiple imaging tests in the investigation of 
painful joint prostheses. The diagnostic delays do not imply causation as a 
result of the number of investigations ordered. 
 
 
2.9 Summary  
 
x There are diagnostic delays in diagnosing painful joint prostheses.  
x Multiple non-imaging tests are usually combined with anatomical imaging 
modalities as well as functional imaging modalities to reach a diagnosis 
x Fused functional anatomical imaging may form part of the solution to the 






Chapter 3   The Role of 
18
F-NaF PET in Diagnosing and 
Distinguishing Between Aseptic Loosening and Septic and Aseptic 





Background: Joint replacement surgery is an important and commonly used 
intervention for severe arthritis. Implant failure is a cause of morbidity for 
patients who have undergone joint arthroplasty. Determining the cause for 
failure is fundamental to the further management of such patients. Amongst the 
most important causes for failure include infection and aseptic loosening. 
Differentiating between these two conditions is problematic using clinical and 
biochemical tests. Novel radiological techniques such as SPECT-CT and PET-
CT have been increasingly used to differentiate between these two problems. 
Method: A systematic review of MEDLINE, EMBASE (University of Warwick 
Encore) and Cochrane library database was undertaken to identify diagnostic 
studies of sodium fluoride (
18
F-NaF) Positron Emission Tomography (PET) in 
joint prostheses to diagnose loosening and/or infection.   
Results: The review identified 3 prospective studies (Figure 5) that met the 
inclusion criteria. The selected studies consist of a total number of 94 patients 
(these included 110 joints). There were 96 hips and 14 knees, of which 35 were 
asymptomatic and 65 joints were symptomatic. Only one study differentiated 
aseptic loosening from infection. A weighted average of sensitivity and 
specificity of the different studies was determined. The sensitivity of 
18
F-NaF 
PET in identifying prosthetic infections was found to be 97.04%; The weighted 
specificity, positive predictive value (PPV), negative predictive value (NPV) and 
accuracy were 88.11%, 84.68%, 98.82% and 87.33% respectively. 
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Conclusion: Sodium fluoride positron emission tomography 
18
F-NaF PET is a 
promising tool with high sensitivity and specificity in the assessment of joint 
replacements, but it possibly will be of limited use before the ninth post-surgical 
month. However, this can be overcome by routinely imaging ‘at risk’ prostheses 
at three month intervals for the detection of abnormal rates of decline in 
periprosthetic 
18
F-NaF uptake. The CT component in 
18
F-NaF PET-CT may add 
further diagnostic value. 
 
3.2 Background  
 
There is an increasing trend to apply hybrid imaging in the investigation of 
painful joint prostheses, often employing SPECT-CT, which combines the high 
resolution of CT and the functional sensitivity of Single Photon Emission 
Tomography (SPECT) (165). Attempts have been made to employ PET-CT to 
identify aseptic loosening and infection with 
18
F-Fluorodeoxyglucose (FDG) and 
Sodium Fluoride 
18
F-NaF (71, 166). Sodium fluoride metabolism uptake in bone 
is reliant on the rate of blood flow, which is the rate-limiting step and most of the 
sodium fluoride delivered is retained by bone after a single pass of blood (68). 
The 1
st
 pass rate varies among different bone components (68), i.e., the degree 
18
F-NaF uptake in bone marrow is negligible when compared with the bony 
cortex levels (68). The second factor that affects 
18
F-NaF tracer bony uptake is 
the rate of bone turnover (167). 
18
F-NaF bone uptake is dependent on the 
exchange of fluoride ions with hydroxyl ions in hydroxyapatite crystal to form 
fluorapatite (167). 
18
F-NaF is freely diffusible across membranes and one hour 
after injection, only 10% of 
18
F-NaF remains in plasma.
18
F-NaF is rapidly 
cleared from plasma and excreted by the renal system following glomerular 
filtration and tubular secretion (68, 168).  
The aim of this study is to perform a systematic review of the literature to 
evaluate the capacity of sodium fluoride (
18
F-NaF) positron emission 
tomography (PET) in distinguishing between septic and aseptic failure in hip 
and knee replacements. This is intended as a scoping exercise and literature 
review of the role of PET-CT in joint prostheses imaging and should also 
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demonstrate the evidence for PET-CT in distinguishing between these two 
causes of failure.  
 
3.3 Methodology 
3.3.1 Study Design 
A systematic review of the literature was undertaken according to the methods 
described in the Cochrane Handbook for Systematic Review of Interventions. 
The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) guidelines were adopted for all literature to date at the time of 
reporting (2015) but a small number of studies returned.  
3.3.2 Research Question 
What is the evidence for use of sodium fluoride PET in differentiating between 
septic and aseptic failure of hip and knee replacements. 
3.3.3 Inclusion Criteria 
Prospective studies in humans that reported data on sodium fluoride in joint 
prosthesis imaging to diagnose loosening and/or infection.  
3.3.4 Exclusion Criteria 
Studies were excluded where other isotopes other than sodium fluoride were 
used. Studies were limited to English language and filters for human studies 
and clinical trials were applied. 
3.3.5 Search Strategy 
Studies were identified using MeSH terms and keywords in MEDLINE, 
EMBASE, Cochrane and Dynamed. 133 studies were excluded at title and 
abstract, 1 was excluded at full paper review. No paper was added after review 
of the references. 
PubMed MESH search terms -(((((((((infection) OR sepsis) OR loosening) OR 
aseptic loosening) OR osteolysis)) AND ((((prosthesis) OR joint replacement) 
OR knee replacement) OR hip replacement)) AND ((((((sodium fluoride) OR 
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fluoride) OR fluorine) OR NaF) NOT FDG) NOT fluorodeoxyglucose))) NOT 
dental. See table 3 for full search builder. 
Two independent authors checked all data used in the analysis. When 
disagreements arose, these were resolved by consensus. Initially, the title and 
abstracts were reviewed. Potentially relevant papers were then reviewed in their 
entirety. The references cited by each potentially relevant paper were 
scrutinized in order to locate additional potentially relevant papers.  
 
3.3.6 Statistics 
The summative weighted sensitivities and specificities were calculated from the 
data extracted. 
 
3.4 Results  
Following the extraction of data (Figure 5), 3 studies were selected which 
satisfied the required characteristics. Data was extracted from each study and is 
summarised in Table 6. The review identified 3 prospective studies (169-171) 
that met our search criteria. A flow diagram of systematic review methodology 
resulted in a final 3 prospective studies (Figure 5) which satisfied the required 
characteristics and which were selected. The selected studies consist of a total 
number of 94 patients with 110 joint replacements (Table 6). There were 96 hips 
and 14 knees, of which 35 were asymptomatic and 65 joints were symptomatic. 
Only one study differentiated aseptic loosening from infection (169). Minimum 
time from surgery varied from 3 months to just over 12 months. Twenty two 
patients were followed up surgically while the remaining patients were followed 
up clinically for periods varying from 6 months to 12 months. A weighted 
average of sensitivity and specificity of the different studies was determined 
(Table 7). The sensitivity of 
18
F-NaF-PET in identifying prosthetic joint infections 
was found to be 97.04%; this was calculated from the weighted average 
sensitivity from the 3 different studies. The weighted specificity, PPV, NPV and 
accuracy were 88.11%, 84.68%, 98.82% and 87.33% respectively. Of the 3 





Figure 5. Flow diagram of systematic review methodology examining evidence 
for use of Sodium Fluoride PET in differentiating between septic and aseptic 
failure of hip and knee replacements 
 





Google Scholar (97) 
Did not meet criteria or duplicate record (n=135) 
Records screened (n=138) 




Google scholar (n=0) 
Studies for inclusion in review  
Hips (n=2) 
Knees (n=1) 
Full text articles excluded (n=135) 
Review article (n=23) 
Other modality or disease, (n=52) 
Case report (n=7)  
Not Applicable or in another language and no translation available, (n=53) 
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Table 6. Summary of included studies of Sodium Fluoride PET in differentiating 
between septic and aseptic failure of hip and knee replacements 
 
 
Authors Kobayashi N et al Sterner et al Creutzig H 
 
Year 2011 2007 1976 
 
Patients 49 14 31 
 
Gender (M/F) N/A 9/6 N/A 
 
Hip joints 65 0 31 
 
Knee joints 0 14 0 
 
Symptomatic joints 38 14 13 
 
Control group Yes No Yes 
 
Asymptomatic 27 0 18 
 
Minimal time from 
surgery 





12 months 6 months 12 months 
 
 














Table 7. Results from the included studies examining evidence for use of 
Sodium Fluoride PET in differentiating between septic and aseptic failure of hip 
and knee replacements 
 
 
Authors Kobayashi N et al Sterner et al Creutzig H 
 
Patient (joints) 49 (65) 14 (14) 31 (31) 
 
TP 36 5 13 
 
TN 23 5 14 
 
FP 6 4 4 
 
FN 2 0 0 
 
Sensitivity, %  95 100 100 
 
Specificity, % 88 56 78 
 
PPV, % 95 56 76 
 
NPV, % 98 100 100 
 
 















The value of fluoride in bone imaging was first recognised by Monte Blau and 
team in 1962 (65, 66). Hans Creutzig in Hannover, then in West Germany, was 
the first to demonstrate the importance of 
18
F-NaF PET in joint prosthetic 
infection in 1976 with 31 THR (171). He also mapped the comparable normal 




F-NaF uptake in the post-
surgical period from 3 to 12 months using uptake ratio in both symptomatic and 
asymptomatic prostheses. NaF uptake levels are said to be similar to levels of 
HEDP (170). The ratios were found to decline rapidly (Figures 6 & 7) and reach 
a nadir at 6-9 months following surgery with more rapid decline demonstrated in 
the femoral component (171). Interestingly, departures from this normal pattern 
of decline preceded the development of symptoms in patients with bone and 
soft tissue infections (171). In this study, the distinction between aseptic 
loosening and infection was unclear (171). Images were acquired 3 hours after 
the injection of 148 MBq of 
18
F-sodium fluoride. Relatively poor quality images 
from using coincidence imaging and a 5"-rectilinear scanner may have 
accounted for inability to distinguish soft tissue infection from bone infection 
(171). The 3 hour uptake period would also have been detrimental, because 
early high target-to-background ratios in result in peak bone uptake levels 
around 45–60 minutes after radioisotope injection (68). At 60 minutes after 
radioisotope injection, only 10% of 
18
F-Fluoride remains in plasma due to 
negligible plasma protein binding, rapid blood and renal clearance, and high 













Figure 6. Graphical representation of HEDP bone scan uptake ratio over the 
cup plotted against the number of months after joint replacement surgery in 
patients without complications.  
 
Note: This has been adapted from Creutzig H. Bone imaging after total 
replacement arthroplasty of the hip joint. A follow-up with different 
radiopharmaceuticals from Eur J Nucl Med. 1976 Aug 12;1 (3):178 with kind 











Figure 7. Graphical representation of HEDP bone scan uptake ratio over the 
thigh plotted against the number of months after joint replacement surgery in 
patients without complications.  
 
Note: This has been adapted from Creutzig H. Bone imaging after total 
replacement arthroplasty of the hip joint. A follow-up with different 
radiopharmaceuticals from Eur J Nucl Med. 1976 Aug 12;1 (3):178 with kind 
permission from Springer Science + Business Media B.V.  
 
 
Thomas Sterner performed the only prospective study with the use of 
18
F-NaF in 
imaging knee prostheses, but no attempt was made to differentiate aseptic 
loosening from infection (170). 14 symptomatic knee prostheses were examined 
and no control group was employed. Of these 14 patients, 6 underwent surgery 
for confirmation of the imaging findings and the other 8 were followed up 
clinically for 6 months. The relatively low specificity in this study may have 
arisen from several factors including the fact that this the study included only 
knees, the sample size was relatively small and finally that even intermediate 
levels of periprosthetic uptake were regarded as positive for aseptic loosening 
or infection (170). Sterner et al also regarded the scan as abnormal if (a) there 
was relatively more uptake in the prosthesis/bone interface than in 
normal/bone/soft tissue or contralateral asymptomatic prostheses, (b) the 
increased uptake included half the bone/metal interface in the femoral 
component; or (c) if the tibial stem in the tibial component was involved. 
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Furthermore, they discovered that the use of semi-quantitative analysis with 
standardized uptake values (SUVs) yielded no added value (170). Image quality 
in this study was bound to be better because the authors employed an ECAT-
Exact HR+ (Siemens Medical Systems) PET scanner 1 minute and 60 minutes 
after the injection of 350MBq of 
18
F-Fluoride (170). 
In 2011, Naomi Kobayashi et al published a prospective study of 
18
F-NaF PET 
in 65 hip prostheses; to date, this has been the only prospective trial which 
differentiated aseptic loosening from sepsis (169). Images were acquired 40 
minutes after injection of 185 MBq of 
18
F-Fluoride using a SET 2400W device 
(Shimadzu, Kyoto, Japan). She was able to distinguish between normal, aseptic 
loosening and infected prostheses. The first method involved measuring the 
degree of 
18
F-Fluoride uptake in periprosthetic tissues (SUVmax). Average 
values for the normal, aseptic and septic loosening prostheses were estimated 
to be 4.9 + 2.5, 8.1 + 2.9, and 10.5 + 3.4, respectively (169). When a threshold 
SUVmax of 6.9 is applied for diagnosis of infection, the test had a sensitivity and 
specificity of 81% and 80% respectively (169). Furthermore, when a threshold 
SUVmax of 4.9 is applied for aseptic loosening, the test yields a sensitivity and 
specificity of 95% and 82% respectively (169). PET images were also analysed 
for the pattern and distribution of 
18
F-Fluoride PET uptake and categorised into 
3 types. Type 1 uptake showed no significant 
18
F-Fluoride uptake; Type 2 
uptake shows mild localized uptake on the cup side or stem. Type 3 pattern of 
uptake demonstrates significant uptake which extends through more than half of 
the bone-implant interface (169). 96% of Type 1 uptake cases were normal, 
80% of Type 2 pattern were due to aseptic loosening and 95% of Type 3 pattern 
cases were due to infection (169). The final diagnosis of infection was obtained 
by a combination of microbiologic culture, histopathology and polymerase chain 
reaction (PCR) analysis of bacterial DNA with 2 different primer and probe sets, 
one specific for the detection of methicillin-resistant staphylococcus and another 
for broad-range detection by universal PCR that targets a part of 16S rDNA 
gene, with increased sensitivity (169, 172). Many polymerase chain reactions 
that detect the universal 16S rRNA bacterial gene have problems with false- 
positive results due to necrotic bacteria detected by polymerase chain reactions 
(173). The clinical importance of positive results in the absence of other clinico-
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pathologic and radiological features of infection is of uncertain significance, but 
specificity can be improved by combining a universal polymerase chain reaction 
with subsequent bacterial sequencing (173).  
Critical analysis of this systematic review which collated, assessed and 
synthesised evidence from 3 previous experiments in order to demonstrate the 
role of 
18
F-NaF PET in diagnosing and distinguishing between septic and 
aseptic loosening in hip and knee prostheses shows that the study did not 
combine numerical data from the 3 separate studies. Furthermore, the studies 
did not meet the criteria for randomized controlled trials which have higher 
levels of evidence. Therefore, the study does not meet the criteria for a meta-
analysis. The main limitations of this study include the heterogeneity of the 
systematic review which included studies from 2 continents over a period lasting 
more than 35 years. The study is also limited by the small number of 3 papers 
which reduces the statistical significance of its findings. The small number of 
studies which resulted from using the PRISMA guidelines may inadvertently 
increase the likelihood of reporting bias and evidence selection bias. The study 
was also susceptible to biases arising in all the included primary studies. The 
first and second papers had 2 blinded observers hence reducing intra-observer 
variability. However, the third paper made was not read by dual blinded 
observers hence introducing intra-observer variability. Newly identified 
knowledge suggests that sodium fluoride positron emission tomography (
18
F-
NaF-PET) is a promising tool in diagnosing and distinguishing between septic 
and aseptic loosening in joint prostheses; with a high sensitivity and specificity 
after the ninth post-surgical month. In addition, routine 
18
F-NaF-PET imaging of 






Our small series demonstrates that Sodium fluoride positron emission 
tomography (
18
F-NaF-PET) is a promising tool in diagnosing and distinguishing 
between septic and aseptic loosening in joint prostheses. It demonstrates high 
sensitivity and specificity in the assessment of joint replacements after the ninth 
post-surgical month. Routine imaging of ‘at risk’ prostheses at 3 month intervals 
for the detection of abnormal rates of decline in periprosthetic 
18
F-NaF uptake 
may overcome this problem. The CT component in 
18
F-NaF PET-CT also adds 
diagnostic value. 
 
3.8 Summary  
 
x Sodium fluoride positron emission tomography 18F-NaF PET has a 
promising role in the assessment of joint replacements after the ninth 
post-surgical month.  
x The sensitivity and specificity of 18F-NaF PET in the assessment of joint 
replacements is low in immediate post-surgical period. 




Chapter 4   The Promising Role of Dynamic 
18
F-NaF PET-CT in 
Diagnosing Symptomatic Joint Prostheses (78) 
  
4.1 Abstract  
 
Background: There is an increasing number of lower limb arthroplasties and 
multiple imaging modalities are often used in the investigation of painful joint 
prostheses. Research into decreasing the time and cost of investigations is 
required and the purpose of this study was to test the feasibility of dynamic 
18
F-
NaF PET-CT in order to establish proof of principle as a case study for the use 
of in the assessment of knee and hip prostheses.  
Method: Approval was granted by the research ethics committee and informed 
consent was obtained. A patient with bilateral knee prostheses (1 
symptomatic/painful and 1 asymptomatic) was scanned with dynamic 
18
F-NaF 
PET-CT. In addition, knee aspirate was obtained from the asymptomatic knee 
and serum C-reactive protein and erythrocyte sediment rate levels as well as a 
peripheral white cell count were obtained and then a 12 month clinical follow up. 
The images were interpreted as normal, aseptic loosening or sepsis as defined 
by the hypothetical graphical pattern of tracer uptake produced at the bone–
prosthesis interface. A final diagnosis was made by a combination of joint 
aspiration microbiology and clinical follow-up for 1 year in addition to C-reactive 
protein and erythrocyte sediment rate levels as well as peripheral white cell 
count. 
18
F-NaF PET results also were compared with 3-phase dynamic bone 
scan results and plain radiographs.  
Results: The dynamic 
18
F-NaF PET-CT scan revealed no significant uptake in 
the asymptomatic right knee and increased uptake in the symptomatic left knee 
with an aseptic loosening pattern. The degree of uptake in the symptomatic joint 
exceeded background levels and also exceeded levels of uptake in the 




asymptomatic and symptomatic joints matched the pattern of uptake in our 
hypothesis based on the understood pattern of uptake in dynamic bone scans. 
The imaging aseptic pattern corresponded with the absence of infection in blood 
tests as well as microbiological cultures and the histopathological examination 
of the periprosthetic membrane.  
Conclusion:
  
Diagnostic quality dynamic 
18
F-NaF PET-CT images with graphical 
data from symptomatic joint prostheses can be acquired and archived 
successfully. 
18
F-NaF PET-CT can detect aseptic loosening of lower limb 
prostheses and dynamic 
18
F-NaF PET-CT may be more useful than 3 phase 
bone scans in the assessment of painful hip and knee prostheses but more 
research is required.  
 
4.2 Introduction  
The feasibility of dynamic 
18
F-NaF PET-CT was assessed as an imaging tool for 
investigating symptomatic joint prostheses in a single case study. This is an 
important area of research in order to reduce time and cost of investigations by 
reducing the number of imaging tests (128). In addition, the importance of this is 
highlighted by the fact that there is an increasing number of lower limb 
arthroplasties (174).  
 
4.3 Aim  
The aim was to test the hypothesis that dynamic 
18
F-NaF PET-CT is feasible and that 
dynamic 
18
F-NaF PET-CT may be used to diagnose symptomatic joint prostheses by 
employing the graphical uptake pattern of 
18
F-NaF in the periprosthetic region (Figure 
8).  This is intended as a scoping exercise and literature review of the role of 
18
F-










F-NaF PET-CT a feasible test and can diagnostic quality dynamic 
18
F-NaF PET-CT images with graphical data be acquired and archived 
successfully from symptomatic joint prostheses? 
 
4.5 Materials and Methods  
 
Our patient was a 72 year old female with a painful left knee total knee 
replacement studied with dynamic 
18
F-NaF PET-CT. She had undergone 
routine clinical and laboratory studies for the evaluation of painful prostheses, in 
addition to the dynamic 
18
F-NaF PET-CT scan. The 
18
F-NaF PET-CT scan was 
obtained more than 12 months after joint replacement surgery. The interval 
between arthroplasty and PET-CT was 8 years. The patient gave written 
informed consent for the study.  
Dynamic 
18
F-NaF PET-CT images were acquired using a GE Discovery ST with 
16 slice CT (GE Healthcare
®
) volume imaging protocol (ViP) (175). The patient 
fasted for at least 6 hours before receiving the injection. CT images of the joints 
were acquired, followed by dynamic PET image acquisition in list mode from the 
time of injection till 30 to 40 minutes after bolus intravenous administration of 
250 MBq 
18
F-NaF (175). The images were reconstructed using ordered-subset 
expectation maximization, and images were corrected for attenuation.  
Image Interpretation – two experienced radiologists read the studies 
independently, and in the case of discrepancies, a consensus was reached 
following discussion. When an area of increased uptake was detected in the 
bone–prosthesis interface for either hip or knee arthroplasty compared with 
adjacent bone and soft tissue, the region of interest was assessed using time-
activity curves with simple standardized uptake value (SUV) analysis and 
background subtraction (176).  
Graphical interpretation was performed using our hypothesis to decide if there is 




were analysed visually for malalignment by ruling out gross malpositioning of 
the prosthetic components and also assessing for periprosthetic fluid collections 





Figure 8. Time-Activity-Curve of sequential multiphase 18F-NaF PET-CT scan 
of joint prostheses  
 
Note: Sequential multiphase 
18
F-NaF PET-CT Time-Activity-Curve in the 
dynamic Imaging of joint prostheses with expected appearances in dynamic
18
F-
NaF PET-CT for infection (blue), loosening (red) and normal (yellow)  
Prostheses. The hypothetical graphical pattern images are based on the 
pharmacokinetics 
18
F-NaF uptake in the body and at the bone–prosthesis 
interface (figure 8) (66, 67). 
 
Follow-up - The final diagnosis was made by joint aspiration and clinical follow-
up for 1 year. The arthroplasty would have been considered infected if 
aspiration cultures grew organisms, if infection was clinically obvious, if 
microbiological samples demonstrated infection with sensitivity of 72% (177), or 
elevated synovial neutrophils with sensitivities between 84 and 95% (177). 
Arthroplasties would be considered aseptic if the preceding investigations were 
negative and this was backed by normal C-reactive protein and erythrocyte 




arthroplasty does not require surgical exploration during the follow-up period it 






F-NaF PET-CT scan revealed no significant uptake in the 
asymptomatic right knee and increased uptake in the symptomatic left knee with 
aseptic loosening pattern (Figure 8). The degree of uptake in the symptomatic 
joint exceeded background levels and also levels of uptake in the asymptomatic 
knee. The pattern of uptake and curve slope in both the asymptomatic and 
symptomatic joints matched the pattern of uptake in our hypothesis based on 
the understood pattern of uptake in dynamic bone scans (Figure 8) (178). 
However, the difference in the size and also the dissimilar type of prosthesis is 
a confounding factor, i.e., larger symptomatic left total knee prosthesis and a 
smaller right asymptomatic unicompartmental prosthesis (Figures 9 and 10).  
The corresponding 3-phase bone scan (Figures 11 and 12) revealed delayed 
phase marked uptake in left femoral and tibial components in the symptomatic 
left knee only favouring aseptic loosening. The NaF PET-CT graphs showed a 
steeper slope and higher plateau of uptake in the symptomatic loose knee 
prosthesis, when compared with asymptomatic knee prostheses (Figure 13) as 
well as in the symptomatic loose knee prosthesis, when compared with left knee 
soft tissue background (Figure 14). The CT component revealed no gross 
malpositioning or abscess. The peripheral blood erythrocyte sedimentation rate 
(ESR) was 26 mm/hour (reference range 0-35); C-reactive protein (CRP) was 5 
mg/L (reference range <11); total peripheral white blood cell count was 8.26 x 
10
9
 g/L (reference range 4-11); peripheral neutrophilic count was 4.85 x 10
9 
g/L 
(reference range 2-7). The left knee aspirate and periprosthetic membrane were 
















Figure 10. Symptomatic left knee radiograph of total knee prosthesis (the 






Figure 11. Left total knee replacement on arterial and venous phase bone scan 
images 
 
Note: The blue arrows in the images shows minimally increased uptake in the 







Figure 12. Left total knee replacement on delayed phase bone scan images  
 
Note: The blue arrows in the delayed phase bone scan images shows marked 








Figure 13. Time-Activity-Curves NaF PET-CT scan (SUVmax vs Minutes)  
 
Note: This graph shows a gradual increase in the SUVmax levels in the 
symptomatic left knee (pink curve) which plateaus at 25 minutes versus no 











Figure 14. Time-Activity -Curves NaF PET-CT scan (SUVmax vs Minutes) 
 
Note: This graph in a patient with confirmed aseptic loosening shows a gradual 
increase in the SUVmax levels in the symptomatic left knee (pink curve) which 
plateaus at 25 minutes versus soft tissue background (blue arrows) in the left 







The results from this patient who had a symptomatic left TKR and an 
asymptomatic right UKR demonstrate normal CRP, ESR, WCC as well as the 
knee aspirate and periprosthetic microbiology. The final diagnosis of the 
symptomatic left TKR was aseptic loosening and this was determined by 
imaging and long-term clinical follow up. The interval between surgery and 
18
F-
NaF PET-CT was more than 1 year. Further research is required to confirm this 
proof of concept for uptake of 
18
F-NaF in painful prosthesis as well as clearly 
define the appearance of infection using this promising technique. One of the 
major advantages of 
18
F-NaF PET-CT over conventional nuclear medicine 
techniques is the simplicity of the approach and the timely availability of results 





F-NaF PET-CT has been used extensively for the detection of bone 
metastases. However, 
18
F-NaF uptake is not specific for bone malignancy and 
increased bone uptake may occur with any other condition resulting in 





F-NaF accumulation has been reported in fractures and a 
variety of metabolic bone disease such as renal osteodystrophy, Paget’s 
disease and fibrous dysplasia (179) as well as infection or inflammation (180). 
This study demonstrates that the use of dynamic 
18
F-NaF for diagnosing the 
presence or absence of prosthetic loosening is feasible and that there is a 
relatively higher degree of 
18
F-NaF uptake in symptomatic joints when 
compared with asymptomatic joints. Studies also show that there is a relatively 
higher degree of 
18
F-NaF uptake in infection when compared with aseptic 
loosening (169). Larger trials are required, especially to prove the role of this 
novel technique for the detection of periprosthetic infection because pre-surgical 
accurate diagnosis or elimination of periprosthetic infection significantly allows 
clinical teams to accurately plan management (174). Current assessment 
methods often require the combination of clinical signs, laboratory findings and 




from post-operative change and infection with an acceptable sensitivity and 
specificity (182). Although the plain radiograph gives important information 
regarding joint stability, malrotation and malalignment as well as the type of 
prosthesis (183);  the role of plain radiographs in the diagnosis of infection 
associated with prostheses is limited because of nonspecific findings common 
to both septic and aseptic loosening (174).  
Joint aspiration or biopsy is a valuable preoperative diagnostic tool for the 
detection of sepsis, with a sensitivity and specificity ranging from 50% to 93% 
and from 82% to 97%, respectively (174), but this degree of accuracy remains 
too low to exclude sepsis with certainty (174) and prior antibiotic administration 
may further reduce sensitivity (174). Nuclear medicine imaging has a valuable 
role to play in assessing joint prostheses for infection. The 3-phase radionuclide 
bone scan is the most common nuclear medicine investigation for the 
assessment of prosthetic joint sepsis (55). However, the presence of 
orthopaedic hardware reduces the sensitivity of bone scans (182). Two other 
limitations are the lengthy examination time and the cost of the examinations 
(174). Sequential radionuclide bone and gallium scans were the first combined 
studies used to diagnose osseous infection (182) and have been applied to 
painful lower limb prostheses since the 1970s (174), but are less favoured due 
to reported low sensitivity of 38% at the lower end of the spectrum in literature 
(174) or overall accuracy of 65 to 80% at the more optimistic end (182). 
111
In-
labeled white blood cell scanning combined with 
99m
Tc-sulphur colloid bone 
marrow imaging has a sensitivity, specificity, and accuracy of 86%– 100%, 
89%–94%, and 89%–96%, respectively (174). Disadvantages of Indium-labelled 
leukocyte imaging include the demanding man-hours required for in vitro 
labelling with resultant increasing opportunities for iatrogenic errors (174) and 
also the requirement for delayed imaging at 24 hours post-injection (174).  
Occasionally, there is a requirement for additional bone marrow imaging, 
resulting in relatively higher radiation exposure. Attempts have been made with 
limited success to replace 
111
Indium-labelled white cell imaging with 
99m
Technetium-labelled murine monoclonal anti-granulocyte antibody 
fragments. 
99m 
Tc-–labelled murine monoclonal antibody of the immunoglobulin 




human polymorphonuclear leukocytes (53, 184) and do not require in vitro 
labelling process. Antibody fragment imaging has a high negative predictive 
value (185), but murine antibodies have a reduced plasma half-life of few hours 
when compared with human IgG half-life of 3 weeks (186). In addition, the 
murine IgG invokes a HAMA response that results in faster removal of the 
mouse IgG, and may rarely, also result in anaphylactic hypersensitivity 
response (186). The decreased circulating half-life requires increasing 
administered doses (which can then lead to increasing risk of HAMA, or a 
reduced effectiveness of the study (186). Since the completion of this study 
monoclonal antibodies have been permanently discontinued by 
Immunomedics™ GmbH and the European Union (187). 
Early attempts to justify the use of 
18
F-FDG PET as a single, cost-effective 
method of diagnosing periprosthetic infection (71, 174) have since been proven 
to be incorrect due to false positive nonspecific periprosthetic uptake (188). The 
cost of 
18
F-NaF PET-CT is substantially lower than the combined costs of 
sequential studies comprising 2 to 3 commonly performed radionuclide scans 
(mainly 
111
In-labeled white blood cell scans, bone scans and bone marrow 
scans) (166, 174). Furthermore, tomographic images with PET provide better 
spatial resolution than planar conventional nuclear medicine modalities (174), 
significantly improving test accuracy (166, 174). Dynamic 18F-NaF PET-CT can 
be completed within an hour, compared with 4 hours to 2 days for other nuclear 
medicine methods (174). 
Critical analysis of the feasibility study which was designed to establish proof of 
principle for the use of dynamic 
18
F-NaF PET-CT in the assessment of knee 
prostheses revealed limitations. Generally, the results from small first-stage 
sample feasibility studies are limited and usually highly variable. Feasibility 
study results can if relied upon can diminish the quality of subsequent clinical 
trial design (189). Furthermore, the very limited data and small size meant that 
very little statistical information could be deduced from the results of this study 
and no meaningful clinical end point was presented. However, the feasibility 
study helped guide the subsequent trial protocol design and implementation by 
identifying more practicable and economic methodology. Considering the small 




played a role in the feasibility study outcome. Lastly, the images were not 
reviewed by non-blinded observers and hence potentially introducing possible 





F-NaF PET-CT of knee prostheses is feasible and diagnostic quality dynamic 
18
F-NaF PET-CT images with graphical data from symptomatic knee prostheses 
can be acquired and archived successfully. This preliminary data demonstrates 
early proof of the principle that dynamic 
18
F-NaF PET-CT can detect aseptic 
loosening of lower limb prostheses. The CT component provides anatomical 
correlation. Dynamic 
18
F-NaF PET-CT may be more useful than 3 phase bone 
scans in the assessment of painful hip and knee prostheses. Routine clinical 
use should not be initiated until the accuracy of dynamic 
18
F-NaF PET-CT is 
fully validated. Future research trials with larger patient populations are required 
to establish a role for dynamic 
18
F-NaF PET-CT for detecting aseptic loosening 
and septic loosening. New knowledge identified that dynamic 
18
F-NaF PET-CT 
can detect aseptic loosening of lower limb prostheses and that future research 







x Dynamic 18F-NaF PET-CT can detect aseptic loosening of lower limb 
prostheses.  
x CT component provides anatomical correlation.  
x Dynamic 18F-NaF PET-CT may be more useful than 3 phase bone scans 
in the assessment of painful hip and knee prostheses. 
x Future research trials with larger patient populations are required to 
establish a role for dynamic 
18
F-NaF PET-CT for detecting aseptic 




Chapter 5   Evaluating and Correcting Beam Hardening Artefact 
from Prostheses on Dynamic 
18
F-NaF PET-CT – Using Pre-Filtering 
with Aluminium; Dual-Energy CT and Mathematical Algorithm with 
MATLAB
®
 Filtered Back Projection  
 
5.1.1 Abstract 
Background: Metallic joint prostheses result in beam hardening artefacts which 
add undesired background activity to the images, degrade image quality and 
reduce the diagnostic yield in periprosthetic region. Beam hardening artefact 
also has the undesired effect of introducing increased activity levels on the 
emission images. There are different proprietary methods of correcting artefacts 
in periprosthetic tissues. Artefact reduction techniques often introduce 
secondary artefacts and reduce image quality around the prosthetic-bone 
interface. 
 
Methods: All scans have been carried out on the same GE Healthcare
®
 
Discovery 710 PET-CT system PET-CT scanner under controlled conditions to 
evaluate and compare different methods of correcting which result from metallic 
joint prostheses in 
18
F-NaF PET-CT. Three techniques of correcting beam 
hardening artefacts were assessed - pre-filtering with Aluminium using an 
18
F- 
PET-CT phantom; dual-energy CT using an 
18
F- PET-CT phantom and post-
scan image manipulation employing MATLAB
®
 mathematical algorithm and 
filtered back projection on images that were acquired from 6 patients. The 
phantom based experiment was performed 4 times using pre-filtering with 
Aluminium and dual-energy CT simultaneously. The hip prosthesis phantom 
consisted of a cylindrical Perspex
®
 phantom containing a metallic femoral 
component surrounded by low levels of 
18
F activity which was scanned with or 
without an additional Aluminium dome filtering at either 120 KVp or 140 KVp 
peak Kilovoltage energies. 15 CT density maps of CT periprosthetic lucency 
using the French colour look-up table (CLUT) were assessed to distinguish 





Results: No significant difference was identified between the use of 120 KVp, 
140 KVp with or without aluminium. The post-scan image manipulation with 
MATLAB
®
 reduced beam hardening artefacts in some of the images but the 
manipulated images introduced secondary artefacts and resulted in reduction in 
image quality and some loss of anatomic detail around the prosthetic-bone 
interface. The CT density maps of CT periprosthetic lucency did not distinguish 
accurately between symptomatic and asymptomatic joint prostheses, nor was it 
able to distinguish aseptic loosening from septic loosening. 
 
Conclusion: Beam hardening artefacts from prostheses contribute to poor 
image quality on 
18
F PET-CT. Pre-filtering with Aluminium; dual-energy CT and 
mathematical algorithms with MATLAB
®
 filtered back projection reduce beam 
hardening artefact but with no significant difference. There is also no significant 
difference in beam hardening artefact reduction between pre-filtering with 
Aluminium; dual-energy CT and mathematical algorithms with MATLAB
®
 filtered 
back projection. Artefact-reduction techniques should be used with caution 
because they introduce other secondary artefacts with subsequent image 
quality reduction.  
 
5.1.2 Problem Statement 
Beam hardening artefacts from prostheses interfere with CT and 
18
F PET image 
quality.  
Would the use of pre-filtering with Aluminium improve image quality?  
Would the use dual-energy CT improve image quality?  
Would the use of mathematical algorithms with MATLAB
®
 filtered back 





Pre-filtering with Aluminium, dual-energy CT and MATLAB
®
 filtered back 
projection can improve image quality. 
 
5.1.4 Aim 
To measure image quality of a metallic prosthesis phantom without any 
additional processing/material; (a) pre-filtering with Aluminium (b) with the use 
dual-energy CT and (c) with the use of MATLAB
®
 filtered back projection. 
 
5.1.5 Apparatus and Materials 
Titanium alloy femoral component of hip prosthesis (Figure 15), Cylindrical 
Perspex
®
 phantom (Figures 15 and 16), Aluminium dome (Figure 16), 5 litre 







 Discovery 710 PET-CT system PET-CT scanner, GE 
Healthcare Xeleris
®
 version 4 workstation and MATLAB
®
 software (The 






        
Figure 15. Perspex® phantom containing femoral prosthesis  
Note: This photograph shows the 15 cm long and 20 cm diameter cylindrical 
Perspex
®
 phantom which contains a fixed central femoral component of hip 
prosthesis composed of metallic alloys of titanium. The Perspex was filled with 









Figure 16. Sagittal and axial CT images of Perspex® phantom containing 
femoral prosthesis 
 
Note: These are sagittal and axial CT images of the cylindrical Perspex
®
 
phantom containing a fixed central femoral component of hip prosthesis and 
surrounded by
18
F-FDG. The cylindrical Perspex
®
 phantom is encased by a 





The experiments were performed under controlled conditions to evaluate and 
compare different methods of correcting which result from metallic joint 
prostheses in 
18
F-NaF PET-CT.  
Beam hardening artefacts from a hip prosthesis phantom surrounded by low 
levels of 
18
F activity were compared with and without an additional pre-scan pre-
filtering with Aluminium dome to assess for improvements in the beam 
hardening artefact. Further beam hardening artefacts from the hip prosthesis 
phantom were compared at different energies to assess for improvements in the 
beam hardening artefact. Lastly, the post-scan technique of periprosthetic beam 
hardening artefact improvement or worsening was assessed using images from 
6 patients that had undergone 
18
F-NaF PET-CT scans of joint prostheses. Post-
scan image manipulation was performed using open source in-house 
mathematical algorithm employing MATLAB
®
 for filtered back projection in order 
to assess for change. 
5.1.7 Variables 
x Independent variables – presence or absence of Aluminium filter; dual-energy 
120 KVp and 140 KVp; use or non-use of MATLAB
®
 filtered back projection 
x Dependent variables - beam hardening artefact on PET-CT 
x Confounding variables-18F-FDG dose (MBq), room temperature (degrees 
Celsius) 
x Controlled variable – hip prosthesis, scan time (minutes) 
 
5.1.8 Expected Results  
Pre-filtering with Aluminium, use of mathematical algorithms and dual-energy 
CT would improve image quality but may introduce secondary artefacts. Image 





5.1.9 Treatment of Results (Linking of Expected Results to Hypothesis) 
If pre-filtering with Aluminium, MATLAB
®
 and dual-energy CT improve image 
quality, and then the hypothesis is correct. If image quality is most improved 
using the dual energy CT method, then the second part of the expected results 
is correct. 
 
5.1.10 Physics Principles (Connect Methodology to Problem Statement) 
Metallic prostheses have high proton densities (Zahl), thus resulting in beam 
hardening artefact and false positive PET uptake. Correction with pre-
acquisition, scanning as well as post-processing methods can alleviate some of 
these issues. 
 
5.1.11 Sources of Error/Assumptions/Limitations 
 
There are other inherent factors including the atomic number which affect image 
quality. The location of radioactivity at different points in relation to the 
prosthesis may be more open to interpretation. Further limitations of this study 
include the small number of case as well as the fact that the phantom 
experiments were only performed once for each category. Furthermore, only six 
post-scan software manipulations were performed. The study was also 
susceptible to biases arising two non-blinded observers. Additional limitations in 
the application of these techniques occurred due to secondary artefacts as well 







5.2.1 Methodology; Pre-Filtering with Aluminium and Dual-Energy CT  
 
Pre-filtering with Aluminium has visible effect on beam hardening artefact on CT 
and PET using 
18
F as well as improves the quality and diagnostic quality of 
PET-CT images with prostheses. 
All scans have been carried out on the same GE Healthcare
®
 Discovery 710 
PET-CT system PET-CT scanner and with the help of Mr Samuel Colclough, 
clinical scientist Dr James Cullis, consultant Clinical scientist, both from 
University Hospital Coventry & Warwickshire. 
A cylindrical Perspex
®
 phantom, 18 cm long and 20 cm in diameter containing a 
fixed central femoral component of hip prosthesis composed of metallic alloys of 
titanium (figures 15 and 16). The central prosthesis is surrounded by a 5 litre 





F- FDG). The cylindrical Perspex
®
 phantom was filled with the solution and 
then sealed.  
The phantom was placed at the centre of the imaging field of view and its axis 
was perpendicular to the long axis of the patient couch. Imaging was performed 
with a GE Healthcare
®
 Discovery 710 PET-CT system PET-CT scanner (GE 
Healthcare, Waukesha WI) with a gantry bore diameter of 70 cm and a spatial 
resolution of approximately 4.5 mm (190). Computed Tomographic images of 
the phantom were obtained and positron emission tomographic reconstructions 
were obtained with the same stipulated number of minutes for each bed 
position. Tomographic reconstructions were performed with a 3D ordered 
subset expectation maximization (OSEM) method (VUE Point) and attenuation 
correction was performed with the low dose CT images. Further decay 
corrections were made for injected radioactivity by the PET scanner. 
The PET-CT scans were performed four times using 2 different peak 
Kilovoltage energies (both with and without aluminium), i.e., 120 KVp with 
aluminium, 140 KVp with aluminium, 120 KVp without aluminium and 140 KVp 
without aluminium (Tables 8 and 9). Regions of interest (ROIs) in each of the 







Table 8. Pre-filtering with Aluminium and dual-energy CT 
 
 












































Table 9.  Pre-filtering with Aluminium and dual-energy CT 
 
 














Not significant at 
p<0.5 
 
140 KVp with  
aluminium 
 
0.83 0.84 Not significant at 
p<0.5 
 
120 KVp without 
aluminium 
 
0.99 0.80 Not significant at 
p<0.5 
 
140 KVp without 
aluminium 
 




Note: Because the p-value is greater than 0.05; the null hypothesis is not 
rejected and it cannot be concluded that a significant difference exists between 








5.3.1 Post-Imaging Manipulation 
 
Post-imaging manipulation with in-house mathematical beam hardening 
correction (BHC) algorithms with MATLAB
®
 has visible effect on beam 
hardening artefact on CT and PET using 
18
F and can improve the quality and 




Interpretation of CT into hybrid imaging using SPECT-CT and PET-CT images 
in the assessment of post-surgical complications of joint replacement surgery is 
impeded by the presence of beam hardening artefacts caused by metal 




The purpose of this project was to design a simple post-imaging process that 
would reduce beam hardening artefact on the CT component to allow for more 




Metal-related artefact result from several mechanisms including beam 
hardening, scatter, Poisson noise, motion and edge effects (191).  
The statistical error of low photon counts in CT images from low dose (mA) 
results in Poisson noise and appears as randomly distributed hypodense and 
hyperdense lines on the CT image, usually in the direction of most attenuation 




algorithms which may be applied following image acquisition. One of the newer 
methods uses Metal Deletion Technique (MDT) (US 8233586B1) which is a 
patented iterative technique which reduces artefacts from all these mechanisms 





Six patients with ten prostheses in total were imaged using a GE Healthcare
®
 
Discovery 710 PET-CT system PET-CT scanner (GE Healthcare, Waukesha 
WI) with a gantry bore diameter of 70 cm and a spatial resolution of 
approximately 4.5 mm (190). All the imaged prostheses were located in one or 
both knee joints of the patients that were imaged. 
18
F-NaF PET-CT - Dynamic 
images were acquired using a GE Discovery ST with 16 slice CT (GE 
Healthcare
®
) volume imaging protocol (ViP) (78, 175). The patients fasted for at 
least 6 hours before receiving the injection. CT images of the joints were 
acquired, followed by dynamic PET image acquisition in list mode from the time 
of injection till 30 to 40 minutes after bolus intravenous administration of 250 
MBq 
18
F-NaF (175). The images were reconstructed using ordered-subset 
expectation maximization, and images were corrected for attenuation (78). All 
analyses of the CT images were performed with the help of Mr Matthew 
Galloway, clinical scientist from University Hospital Coventry & Warwickshire. 
MATLAB
®
 (The Mathworks, Natick, Massachusetts) with parallel-beam 
algorithm was used to open the DICOM image stacks from the local hard disk. 
One of the first steps would be to use Hounsfield units of 3,000 and above to 
identify metal objects in each image. 
Then identify projections affected by metal and then forward project the 2D 
distribution of metal images from multi-angular projections to obtain a metal 
sinogram and also forward project the whole image to obtain a whole image 




represents the tube angle and the vertical axis represents the detector number 
(191). 
Identify the metal sinogram on the whole image sinogram and then correct the 
image by replacing it with a realistic Hounsfield unit by calculating the mean 
Hounsfield unit on either side of the metallic prosthesis. 
Then delete the metal pixels by using forward back projection to iteratively 
replace metal images (2) with dedicated built-in plugins. These images which do 
not have any metal in them are reconstructed with forward back projection using 
MATLAB
®
 "iradon.m" routine (193, 194) thus creating images without the metal 
included. The metal from the original image is the re-inserted back into the back 
projected images to recreate the mathematically reprocessed image. The 
MATLAB
®
 iradon function performs filtered back projection by "smearing back" 
pixel grid images of each acquired image projection using a low pass filter. This 
process is reiterated for each projection and then the contribution from each 
projection is added up (195). 
The CT images from 15 patients with hip or knee prostheses that had been 
scanned as part of a separate experiment were assessed for periprosthetic 
lucency by the sole radiologist in this study using OsiriX
®
 Pixmeo SARL 
Switzerland which used to be an open source software (OSS) with practical 
features for the analysis, interpretation and post-processing of radiological 
images (196) as a fast, simple and intuitive DICOM viewer program that runs on 
an Apple Macintosh operating system (macOS) version 10.11.6 (197). Images 
were presented with the French colour look-up table (CLUT) due to its superior 
contrast: background ratio and the degree of periprosthetic lucency in the 
images were assessed visually. Inter-observer variability and reliability cannot 
be tested due to there being a sole observer in this study. In order to ensuring 
reliability the method was assessed using normal bone cortex: air, normal bone 
cortex: marrow and normal bone cortex: soft tissue interface. The CT images 
are subject to beam hardening artefact from the prostheses and images were 







Although the post-scan image manipulation with MATLAB
®
 resulted in reduced 
beam hardening artefact in some of the images the manipulated images 
introduced secondary artefacts and resulted in reduction in image quality and 
some loss of anatomic detail around the prosthetic-bone interface (Figures 17 
and 18).  
The 15 CT density maps of CT periprosthetic lucency using the French CLUT 
did not distinguish accurately between symptomatic and asymptomatic joint 
prostheses, nor was it able to distinguish aseptic loosening from septic 







Table 10.  Periprosthetic lucency or reduced density using CT density maps 































































9 9 5 Right Bilateral 
THR with 
loose right  












































Note: CLUT = Colour Look-Up Table; CLUT 1-10 with 1 being the least 
radiolucent and 10 the most radiolucent (1= white, 2, pink, 3=purple, 4=blue, 
5=turquoise, 6= olive green, 7= light green, 8 = light brown, 9 = dark brown, 10 






Figure 17. Post-scan image manipulation with MATLAB® resulting in image 
deterioration  
Note: Symptomatic left total knee replacement in patient with bilateral knee 
replacements and symptomatic left total knee replacement diagnosed with 
Instability (not loose and not septic). The OsiriX
®
 density map images (left) and 
CT images (right) show beam hardening artefact but the post-scan image 
manipulation with MATLAB
®
 show a reduction in image quality and loss of 

















 density map images (left) and CT images (right) in patient with 
synovitis in symptomatic right total knee replacement and asymptomatic left 
knee replacement. The OsiriX
®
 density map images (left) and CT images (right) 
show beam hardening artefact but the post-scan image manipulation with 
MATLAB
®
 show a reduction in image quality and loss of anatomic detail around 










Figure 19. Patient 3 with symptomatic left total knee replacement  
 
Note: This patient has bilateral knee replacements and a symptomatic left total 
knee replacement. OsiriX
®
 density map images (left) and CT images (right). 
Patient with symptomatic left total knee replacement diagnosed with Instability 
(not loose and not septic) as well as asymptomatic right knee replacement. 
There is relative increased lucency or reduced density in the symptomatic left 









 density map images (left) and CT images (right) in a patient with 
synovitis in a symptomatic right total knee replacement and an asymptomatic 
left knee replacement. There is relative increased lucency or reduced density in 
the symptomatic right over asymptomatic left prosthesis (blue arrows). 












 density map images (left) and CT images (right) in a patient with 
aseptic loosening in symptomatic left total knee replacement and asymptomatic 
right knee replacement. No relative increased lucency or reduced density in the 
symptomatic left knee over asymptomatic right knee (blue arrows). The 
symptomatic left total knee with aseptic loosening replacement shows increased 
periprosthetic uptake on NaF PET-CT (left) and late phase isotope bone scan 











 density map images (left) and CT images (right) in a patient with 
synovitis in a symptomatic right total knee replacement and an asymptomatic 
left knee replacement. There was no relative increased lucency or reduced 




The type of mathematical algorithm applied for image post-processing can have 
profound results on image noise, image contrast and image signal-to-noise ratio 
(SNR), leading to a resultant enhanced or diminished ability to detect any 
differences in density (198). Evaluation of all 10 prostheses revealed image and 
periprosthetic uptake distortion on the reconstructed images due to aliasing 
artefacts, edge enhancement and Poisson artefacts (Figures 23 and 24). The 
use of mathematical algorithms improve image resulted in image distortion and 
reduced accuracy with no improvement in the quality and diagnostic quality of 
CT images with joint prostheses. 
The use of this technique resulted in drawbacks including ray aliasing artefacts 
which appeared on the images as cross-hatched distortion lines on the 
reconstructed tomographic images emanating from the centre and produced 
after applying the filtered-back projection algorithm (199). Aliasing distortions in 
this case resulted from either using an undersampling of projection data,  
because an inadequate number projections were recorded or both (199) and 






Figure 23. Poisson artefact appearing secondarily on the filtered-back 
projection images 
 
NOTE: This image demonstrates Poisson secondary artefact on similar images 
(blue arrow) through the knees in the reconstructed tomographic images on the 





Figure 24. Ray aliasing artefact appearing secondarily on the filtered-back 
projection images  
 
Note: image demonstrating ray aliasing artefacts on similar images through the 
knees in the reconstructed tomographic images on the right (blue arrow) after 






Edge enhancement results from the suboptimal implementation of filtered back 
projection at the borders of a limited field of view resulting in a sinogram outside 
the field of view set to zero (191) producing a sharp bright rim at the image 
edge, which is intensified by filtered back projection (191). 
Poisson artefacts results from photon counting errors (192) due to low photon 
counts and resemble dark and bright lines that are projected in the direction of 
greatest attenuation or highest number of Hounsfield units (191). Poisson 




Beam hardening artefacts from prostheses contribute to poor image quality on 
18
F PET-CT. Pre-filtering with Aluminium; dual-energy CT and mathematical 
algorithms with MATLAB
®
 filtered back projection reduce beam hardening 
artefact but with no significant difference. The artefact-reduction techniques 
should be used with caution because they introduce other secondary artefacts 
with subsequent image quality reduction. Positively, this demonstrated and 
documented some secondary artefacts. In addition, this makes a case for 
potential radiation dose reduction to the patient because imaging with 140 KVp 
did not produce any significant difference over imaging with 120 KVp. New 
knowledge identified that there is no significant difference in beam hardening 
artefact reduction between pre-filtering with Aluminium; dual-energy CT and 
mathematical algorithms with MATLAB
®
 filtered back projection. Further 
research in to metal artefact reduction is ongoing in both commercial and 
academic settings due to image degradation from metal. Research into 










x Beam hardening artefacts from prostheses reduce image quality on 18F 
PET-CT.  
x Beam hardening artefact can be reduced with Pre-filtering with 
Aluminium; dual-energy CT and mathematical algorithms with MATLAB
®
 
filtered back projection.  
x There is no significant difference in artefact reduction between the 
different methods.  
x The artefact-reduction techniques introduce other secondary artefacts 
with subsequent image quality reduction. 
x Beam-hardening artefact evaluation and reduction in dynamic 18F PET-





Chapter 6   Dynamic 
18
F-NaF PET-CT and 3-Phase Bone Scan 




Background: Imaging investigations for painful joint prostheses frequently 
involve serial radiographs or multiple cross-sectional studies. Hybrid imaging 
using PET and CT may obviate the requirement for multiple imaging tests. This 
study aimed to prospectively evaluate the usefulness of 
18
F- NaF PET-CT using 
a sequential multiphase technique in comparison to bone scan in the diagnosis 
of periprosthetic joint loosening and infection. 
Methods: This pilot prospective study included 15 patients with 25 prostheses 
with symptoms of painful joint prostheses. Sequential 
18
F-NaF PET-CT and 
conventional 3-phase bone scans with planar images was performed in all 
patients. The final diagnosis was made by microbiological, biochemical and 
surgical findings as well as clinical follow up. The PET-CT and bone scan 
images were also assessed with GE ADW 4.6 and Xeleris
®
 version 4 
workstations as well as using MATLAB
®
 open source software. The R
2
 bone 
scan trendline pattern was calculated from 3-phase bone scans with a final 
diagnosis of aseptic or septic prosthesis and lastly CT periprosthetic lucency 
was assessed with the use of French colour look-up table (CLUT) density maps 
on OsiriX
®
 version 10.0.2 running on an Apple Macintosh operating system 
(macOS) version 10.11.6. 
Results: Out of the 15 patients and 25 prostheses that were scanned, 15 were 
symptomatic and 10 were asymptomatic. Of the 15 symptomatic prostheses – 1 
patient died, 2 patients had results from clinical follow up and 12 patients had 
results from surgical follow up. Out of the 12 patients that underwent surgery 3 
were infected and 9 were loose or other. 3-phase bone scans were 100 % 
sensitive for sepsis and inflammation but had a 42% false positive rate for 
sepsis/inflammation. In addition, the 3-phase bone scans were 58 % sensitive 




due to data corruption and image data storage difficulties. In addition, there 
were inconsistent results from the dynamic 
18
F-NaF PET-CT and 
18
F-NaF 
SUVmax levels. Results revealed poor correlation between the 
18
F-NaF uptake 
patterns, dynamic NaF pattern and the bone scan uptake pattern with the final 
diagnoses. However, there was statistical correlation between the final 
diagnosis and the R
2 
bone scan trendline pattern with an optimal cut-off point of 
0.2 above which the likelihood of a septic joint was higher. CT periprosthetic 




F-NaF PET-CT is feasible but has not been proven to be 
an accurate or ideal test to investigate periprosthetic infection or loosening. R2 
values from 
99m
Tc-MDP dynamic bone scans greater than 0.2 favour 
periprosthetic septic loosening or inflammation. Combining dynamic bone scan 
R2 values with CT periprosthetic lucency from SPECT-CT may improve test 




1. To validate a new imaging method of diagnosing loosening of joint 
prosthesis. 
2. To validate a new imaging method of diagnosing infection of joint prosthesis.  
3. To validate a new imaging method of distinguishing loosening from infection 
of joint prosthesis.  
4. To see whether 
18
F-NaF PET- CT is more cost-effective and accurate in the 
detection of infection/loosening.  
Hypothesis:  Sequential multiphase 
18
F-Fluoride PET-CT as a single imaging 
investigation can identify the presence of loosening and infection of joint 




Research Questions:  Is sequential multiphase 
18
F-Fluoride PET-CT as a single 
imaging tool able to reliably diagnose loosening of joint prostheses? 
Is sequential multiphase 
18
F-Fluoride PET-CT as a single imaging tool able to 
reliably diagnose periprosthetic infection in joint prostheses? 
Is sequential multiphase 
18
F-Fluoride PET-CT more accurate and cost-effective 
in the detection of infection/loosening? 
 
6.3 Materials and Methods 
 
This was a pilot study using a prospective uncontrolled case series (longitudinal 
observational study) of patients with symptomatic knee and hip joint prostheses 
awaiting surgical revision.  
The patients were selected based on clinical presentations of painful knee or 
hip arthroplasties and were recruited from the implant revision waiting list over a 
2 year period. The initial goal had been to scan 50 prostheses as proof of 
concept in order to ensure adequate numbers of hips and knees with both 
septic and aseptic loosening as well as other possible diagnosis. Ultimately, 15 
patients with 25 prostheses were scanned.  
All patients had conventional isotope bone scans and multiphasic 
18
F-NaF PET-
CT scans; and serum inflammatory markers. All patients were followed up 
clinically and some had post-surgical microbiological and histological evaluation 
of the joint prostheses. The trial algorithm that was followed is schematically 
represented as a flow diagram of the progress through the phases of 












Symptomatic hip or knee prostheses likely to undergo 
surgical treatment 
1 HDP bone scan (if not already performed) 
1 18F-NaF PET-CT scan 
Microbiological follow-up 







Analysis of PET-CT data: Visual scoring was performed as described by 
Kobayashi et al (169), with 3 types of PET-CT image findings defined according 
to the 
18
F-NaF pattern of uptake with sub-groupings, based on the localization 
of the 
18
F-NaF pattern of uptake, was divided as follows: (Type 1) no localized 
uptake; (Type 2) minor localized uptake; and (Type 3) more extensive diffuse 
periprosthetic uptake that extends over one half of the bone-implant interface 
(169). 
Automated computerised analysis was performed using the Advantage 
Workstations (versions ADW 4.6 and ADW 4.3) software as well as Xeleris
®
 
version 4 both developed by the GE Healthcare. Bone scan images were 
analysed with Xeleris
®
 version 4 and Insignia
®
 InSight PACS version 8.2. CT 
density maps were obtained using OsiriX
® 
software version 10.0.2. Two 
versions of the ADW 4.6 and ADW 4.3 were used due to a change in hospital 
equipment and also different functionalities on the newer version ADW 4.6. 
Images were also assessed with Xeleris
®
 version 4 and MATLAB
®
 open source 
software programmes developed by the Nuclear Medicine department 
University hospital Coventry & Warwickshire and statistics information was 
provided by the Statistics department, University of Warwick.  
 
Statistical analysis: Statistical analyses of the relationship between the uptake 
type classification, intensity of activity and the final diagnosis was performed 
using the extended Fisher exact test. The differences between the maximum 
standardized uptake values (SUVmax) for each diagnosis was analysed by 1-
way analysis of variance followed by a Fisher protected least significant 
difference (PLSD) test. Graphical curves of the SUVmax values were plotted for 
the diagnosis of infection and loosening generated using GE Healthcare 
Advantage Workstation 4.6 software. P values of less than 0.05 were 




Inclusion Criteria:  
1. Symptomatic hip or knee prostheses awaiting surgical revision.  
2. No previous major surgical procedure on the joint in 12 months  
3. All patients of childbearing potential had to be screened for pregnancy. 
4. Written informed consent.  
 
Exclusion Criteria:  
1. Other concurrent uncontrolled medical conditions  
2. Pregnant or lactating (due to potential harmful radiation dose to the foetus) 
3. General status that does not allow the investigations.  
4. Any condition that compromised the patient’s ability to give informed consent 
such as severe medical and psychiatric illnesses. 
5. Prosthetic Joint replacement performed within the last 12 months.  
 
Patients recruited from University Hospital Coventry and Warwickshire joint 






6.4.1 Results  
 
In total, 15 patients and 25 prostheses were scanned. These consistent of 9 
hips ad 16 knees (Table 11).  
 
Table 11. Imaged prostheses 
 
 





1 Left KR 1 
2 Right KR 1 
3 Left KR 2 
4 Right KR 2 
5 Left KR 2 
6 Right KR 2 
7 Left KR 2 
8 Right KR 2 
9 Right HR 2 
10 Right KR 1 
11 Left KR 1 
12 Right HR 2 
13 Right HR 1 
14 Right HR 2 
15 Right HR 2 
 





Due to data corruption and storage difficulties, 5 static 
18
F-NaF PET images and 
10 dynamic graphs from 
18
F-NaF PET imaging were unavailable for analysis 
(Table 12). All the successfully archived bone scans, CT images, dynamic NaF 
graphs and static NaF uptake images are detailed in (Tables 12 and 13).  
 





CT scan Dynamic NaF 
graph 
Static NaF uptake 
25 joints (15 
symptomatic 
joints) 
25 joints (15 
symptomatic 
joints) 













Table 13. List of patients and their successfully archived images 
 
Note :(+) successfully archived, (-) unsuccessfully archived 
 




1 1 + + + + 
2 1 + + - + 
3 2 + + - + 
4 2 + + + + 
5 2 + + - + 
6 2 + + - + 
7 2 + + + + 
8 2 + + - + 
9 2 + + + + 
10 1 + + - - 
11 1 + + - - 
12 2 + + + + 
13 1 + + - - 
14 2 + + - - 




Of the 25 prostheses scanned, 15 joints were symptomatic and 10 joints were 
asymptomatic. Of the 15 patients that were scanned – 1 patient was lost to 
follow up due to death; 1 patient was diagnosed with results from clinical follow 
up and the remaining 13 patients were diagnosed following surgical revision. 
The commonest organisms cultured were Proteus Vulgaris, Pseudomonas 
Aeruginosa, and Staphylococcus Aureus by enrichment from cross-
contamination (Table 14). All other relevant laboratory results are shown in 
Table 14. Out of the 13 patients that underwent surgery, 3 patients were 
inflamed or infected and 10 patents were loose or other (Table 14). The 3-
phase bone scans were correlated with clinical and surgical findings as well as 
the type of successfully archived dynamic 
18
F-NaF image (Table 15). 5 static 
18
F-NaF PET-CT images and 6 
18
F-NaF graphs were successfully archived but 
there were 4 incomplete sets of 
18





















































































1 17 10 7.82 4.55 Neg. Neg. Not septic No infection 
2 13 <3 7.8 5.24 NS NS Not septic No surgery 




4 22 3 7.06 4.57 Neg. Neg. Negative 
Loose, 
Synovitis 
5 24 9 9.97 6.13 Neg. Neg. Loose Loose 
6 38 7 11.6 8.4 Neg. Neg. Loose 
Synovitis, 
No infection 




8 57 26 7.24 5.15 Neg. PV, PA Infected Infected 




















































































10 7 3 7.09 4.64 
SA 
(e) Neg. Loose Loose 
11 7 6 7.3 4.1 Neg. Deceased Loose Deceased 
12 8 <3 5.29 3.48 Neg. Neg. Loose Loose 
13 95 8 7.12 4.41 Neg. Neg. loose Loose 
14 58 53 2.55 1.29 Neg. Neg. 
Not 
infected Not infected 










Note: Neg. = Negative, NS = No sample, PV = Proteus Vulgaris, PA = 






























2 Not septic No surgery Static Late-phase 
positive  
-100 





positive left  
47.8 





5 Loose Loose Static Late-phase 
positive  
35 













8 Infected Infected Static 3-phase 
positive  
51.8 
9 Loose Loose Graph Late-phase 
positive  
49 
10 Loose Loose Incomplete 3-phase 
positive  
54 





































15 Loose Broken 
femoral 
stem 




Note: P/B = Periprosthetic: Bone ratio. 
 
Only 1 patient of the 3 patients with inflamed or infected joints was infected with 
Proteus Vulgaris and Pseudomonas Aeruginosa (Table14). The other 2 patients 
demonstrated non-infected inflammatory arthropathies. There was a single case 
of Staphylococcus Aureus contaminant in an aseptic joint that was grown by 
enrichment only. 3-phase bone scans were 100 % sensitive for sepsis and 
inflammation but had a 42% false positive rate for sepsis/inflammation (Tables 
15 and 16). The 3-phase bone scan uptake patterns were correlated with final 
diagnosis of aseptic loosening or septic prostheses (Table 16) to reveal 58 % 
sensitivity for aseptic loosening (Tables 15 and 16). All 3 patients with synovitis 
or septic loosening exhibited higher periprosthetic/background percentage 
ratios above 40 but there were 6 false positive cases of high 





6.4.4 Analysis of Bone Scan Periprosthetic Uptake Pattern  
 
The bone scan periprosthetic uptake images were correctly interpreted as 
positive for aseptic loosening in 7 of 12 patients (Table 16) and correctly 
interpreted as positive for infection/inflammation in 3 of 3 patients and 5 patients 
were incorrectly identified as septic (Table 16).  The bone scan uptake pattern 
was assessed by applying the final prosthetic joint diagnosis using two-tailed 
Fisher’s exact test, p = 0.2 (Table 16), indicating that null hypothesis can be 
accepted and the results show no significant effect of the final prosthetic joint 
diagnosis on the bone scan pattern, i.e., independence between final prosthetic 
joint diagnosis and the bone scan pattern (Table 16).  
 





















6.4.5 Analysis of Bone Scan R
2
 Trend Line 
The R
2
 trend line was calculated using a linear equation (Equation 1) which was 
plotted on a 25 cm chart representing the relationship between periprosthetic 
uptake (y) versus time (x) from a dynamic bone scan of a symptomatic joint. 
The regression line is used to visually depict the relationship between the 
independent (x) and dependent (y) variables of time and uptake respectively in 
the graph and is graphically represented as:  
 
Equation 1. Bone scan trend line equation 
 
y = mx + b  
or  
y = slope(x) + (y-intercept) 
m is the slope and  
b is the y-intercept where the curve crosses the y-axis.  
 
The coefficient of correlation “R” is the degree of relationship between the 2 
variables - x and y whilst the coefficient of determination is the square of 
coefficient of correlation R
2
. To create the bone scan trendline, use a 25 cm 
chart of dynamic bone scan periprosthetic uptake plotted against time. 
Calculate y which is the intercept. Then calculate the slope m. Thereafter, 
calculate R and R
2
 from the graph. The graph also demonstrates a linear 
regression line or trendline From the trendline, calculate to see if m is greater 
than 0.5 or if R² > 0.2 as the higher values are more likely to be infected or 
inflamed as seen on boxplot chart (Figure 26). The diagnosis of prosthetic joint 
loosening or infection was confirmed in 15 of 15 joints using the R
2
 bone scan 
trendline cut off of 0.2. The R
2
 trendline therefore had 100% sensitivity for 
sepsis and inflammation as well as 100% sensitivity for aseptic loosening. 




diagnosis and the R
2 
bone scan trend line pattern as shown in Table 17 and 
Figure 26.  
 









>0.2 0* 3* 
<0.2 12* 0* 
 
  




Figure 26. Box and whisker plot of 3-phase bone scan R2 trend line pattern 
 
Note: The box and whisker plot of 3-phase bone scan R
2
 trend line pattern with 


















bone scan trendline pattern was calculated in 3-phase bone scans with 
a final diagnosis of aseptic or septic prosthesis. It was determined that an R
2 
bone scan trendline of 0.2 was the optimal cut-off point above which the 
likelihood of a septic joint was higher  using the two-tailed Fisher’s exact test p 
value = .0022 (Table 17). The null hypothesis can therefore be rejected and the 
results that the final prosthetic joint diagnosis has a significant effect of on the 
R
2 
bone scan trendline pattern, i.e., dependence between final prosthetic joint 
diagnosis and the R
2 
bone scan trendline pattern which is considered to be very 
statistically significant (Table 17). The optimal cut-off point of 0.2 is also shown 
on the box and whisker plot of the 3-phase bone scan R
2
 trend line pattern 
(Figure 26). The R
2 
trendline pattern was correctly interpreted as positive for 
aseptic loosening in 12 of 12 patients (Table 17) and correctly interpreted as 
positive for infection/inflammation in 3 of 3 patients. There was no false positive 
or false negative case in both the aseptic loosening and infection/inflammation 
group (Table 17).  The patient with an infected prosthesis was indistinguishable 
from inflammatory synovitis on the bone scan trendline images (Table 18). 
Figures 27 to 41 demonstrate the relevant 3-phase bone scan R
2
 trend line 
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Figure 27. Bone Scan TAC & trend line 
 
Note: Patient 1 with symptomatic unilateral left TKR (red) showing bone scan 
TAC & trend lines for both the symptomatic left knee (red) and the 
asymptomatic normal knee (blue). 
 
 
y = 0.2396x + 91.24 
R² = 0.06095 
y = 0.1855x + 96.312 



















Figure 28. Bone scan TAC & trend line 
 
Note: Patient 2 with symptomatic unilateral right TKR (blue) showing bone scan 
TAC & trend lines for both the symptomatic right knee (blue) and the 






y = 0.1311x + 82.19 
R² = 0.03932 
y = 0.0418x + 94.116 



















Figure 29. Bone scan TAC & trend line 
 
Note: Patient 3 with bilateral TKR. This shows symptomatic left TKR (red) and 






y = 0.0744x + 99.155 
R² = 0.00485 
y = 0.3604x + 93.045 
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Figure 30. Bone scan TAC & trend line 
 
Note: Patient 4 with bilateral TKR. This shows symptomatic right TKR (blue) 







y = 0.5932x + 118.49 
R² = 0.30232 
y = 0.4653x + 82.655 
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Figure 31. Bone scan TAC & trend line 
 
Note: Patient 5 with bilateral TKR. This shows symptomatic left TKR (red) and 






y = 0.0782x + 90.607 
R² = 0.00604 
y = 0.4455x + 72.522 
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Figure 32. Bone scan TAC & trend line 
 
Note: Patient 6 with bilateral TKR. This shows symptomatic right TKR (blue) 








y = 0.6622x + 124.8 
R² = 0.20751 
y = 0.2419x + 65.685 
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Figure 33. Bone scan TAC & trend line 
 
Note: Patient 7 with bilateral TKR. This shows symptomatic left TKR (red) and 






y = 0.1774x + 71.469 
R² = 0.07755 
y = 0.3996x + 116.02 







0 50 100 150 200 250










Figure 34. Bone scan TAC & trend line 
 
Note: Patient 8 with bilateral TKR. This shows symptomatic right TKR (blue) 




y = 0.6141x + 124.84 
R² = 0.20486 
y = -0.1283x + 87.816 
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Figure 35. Bone scan TAC & trend line 
 
Note: Patient 9 with bilateral THR. This shows symptomatic right THR (blue) 




y = 0.1358x + 68.818 
R² = 0.10591 
y = -0.0187x + 83.871 
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Figure 36. Bone scan TAC & trend line 
 
Note: Patient 10 with symptomatic unilateral right TKR. This shows symptomatic 







y = 0.3397x + 114.04 
R² = 0.10029 
y = 0.0219x + 86.271 
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Figure 37. Bone scan TAC & trend line 
 
Note: Patient 11 with symptomatic unilateral left TKR. This shows symptomatic 







y = 0.0196x + 68.29 
R² = 0.00079 
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Figure 38. Bone scan TAC & trend line 
 
Note: Patient 12 with bilateral THR. This shows symptomatic right THR (blue) 







y = -0.137x + 115.82 
R² = 0.02378 
y = -0.1762x + 114.33 
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Figure 39. Bone scan TAC & trend line 
 
Note: Patient 13 with bilateral THR. This shows symptomatic right THR (blue) 








y = -0.0365x + 88.842 
R² = 0.00358 
y = -0.1536x + 94.883 
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Figure 40. Bone scan TAC & trend line  
 
Note: Patient 14 with bilateral THR. This shows symptomatic right THR (blue) 







y = -0.1272x + 81.202 
R² = 0.02895 y = -0.2474x + 80.359 












0 50 100 150 200
Joint 
Uptake 










Figure 41. Bone scan TAC & trend line 
 
Note: Patient 15 with bilateral THR. This shows symptomatic right THR (blue) 






y = -0.1169x + 74.874 
R² = 0.03233 
y = -0.1196x + 70.386 
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6.4.2 Analysis of NaF Periprosthetic Uptake Pattern 
  
The NaF periprosthetic uptake images were correctly interpreted as positive for 
aseptic in 5 of 5 patients (Table 19) and correctly interpreted as positive for 
infection/inflammation in 3 of 3 patients. 2 patients were incorrectly identified as 
septic (Table 19). 
The NaF uptake pattern was assessed by applying the final prosthetic joint 
diagnosis using two-tailed Fisher’s exact test, p = .1667 (Table 19), indicating 
that null hypothesis can be accepted and the results show no significant effect 
of the final prosthetic joint diagnosis on the NaF uptake pattern, i.e., 
independence between final prosthetic joint diagnosis and the NaF uptake 
pattern (Table 19). 
The NaF PET-CT static images were correctly interpreted as positive for aseptic 
loosening in 5 of 5 patients (Table 19) and incorrectly interpreted as positive for 
infection in 2 of 5 patients (Figure 42).  
 
 







Type 1 0* 0* 
Type 2 5* 0* 
Type 3 2* 3* 







Figure 42. Plain radiograph, NaF PET-CT, CT density map and bone scan 
 
Note: Patient 4’s plain radiograph of the right knee with TKR shows 
periprosthetic radiolucency. The NaF PET-CT of the knees shows periprosthetic 
activity (green arrows). The CT density map of the right TKR shows 
periprosthetic radiolucency (red arrows). The arterial phase bone scan, blood 
pool phase and delayed phase bone scan show 3-phase increased uptake   




6.4.3 Analysis of NaF Dynamic Time-Activity Curve 
 
The dynamic NaF periprosthetic uptake images (Figures 43 and 44) were 
correctly interpreted as positive for aseptic loosening in 3 of 4 patients (Table 
20) and the only infection/inflammation was incorrectly interpreted as negative 
for infection/inflammation in 1 of 1 patient. 1 patient was incorrectly identified as 
septic (Table 20). The dynamic NaF uptake pattern was assessed by applying 
the final prosthetic joint diagnosis using two-tailed Fisher’s exact test, p = 1 
(Table 20), indicating that null hypothesis can be accepted and the results show 
no significant effect of the final prosthetic joint diagnosis on the dynamic NaF 
uptake, i.e., independence between final prosthetic joint diagnosis and the 
dynamic NaF uptake pattern (Table 20). 
 
 

























Figure 43. Dynamic NaF graphs  
 
Patient 1 with a symptomatic left knee replacement (purple and red) which 
shows only relatively mildly increased uptake on the left when compared with 
the normal right knee (blue). The uptake curve demonstrates a gradual fall post-
peak which matches with that of a non-septic or aseptically loose prosthesis 





Figure 44. Dynamic NaF graphs 
 
Patient 12 with symptomatic right hip showing confirmed aseptic loosening (red) 
and asymptomatic left hip (green). Symptomatic right hip with relative mildly 
increased uptake when compared with the normal left hip. The uptake curve is 
gradually rising and therefore suggestive of aseptic loosening which 






6.4.6 CT Periprosthetic Lucency Analysis 
 
Periprosthetic lucency as seen on the CT density map images (Figure 45) were 
positive in 12 of 12 patients with aseptic loosening (Table 21) and positive in 3 
of 3 patients with infection/inflammation. CT periprosthetic lucency and CT 
density maps did not distinguish aseptic loosening from septic loosening 
(Tables 18 and 21). Hence, CT periprosthetic lucency is a poor discriminator 
between aseptic loosening and infection/inflammation (Table 21). The CT 
lucency was assessed by applying the final prosthetic joint diagnosis using two-
tailed Fisher’s exact test, p = 1 (Table 21), indicating that null hypothesis can be 
accepted and the results show no significant effect of the final prosthetic joint 
diagnosis on the CT lucency, i.e., independence between final prosthetic joint 
diagnosis and the CT lucency (Table 21). Fisher’s exact test was used to 
determine the statistical significance of differences between variables. The CT 
density map demonstrated periprosthetic radiolucency in all patients regardless 
of the final diagnosis (Table 21) and (Figure 42). 
 
 
Table 19. Periprosthetic lucency on CT 
 
CT Lucency Aseptic Septic/inflamed 
Positive 12* 3* 
Negative 0* 0* 
 
  








Figure 45. Plain radiograph, NaF PET-CT, CT density map and bone scan  
Patient 9’s plain radiograph of right THR shows periprosthetic radiolucency 
(black arrows). The NaF PET-CT of the hip demonstrates increased 
periprosthetic activity (blue arrows). The CT density map of the right THR 
shows periprosthetic radiolucency (red arrows). The arterial phase bone scan 
and blood pool phase bone scan without increased uptake. The delayed phase 




In summary, the results were affected by the reduced number of scans due to 
data corruption and storage difficulties with some of the 
18
F-NaF PET images 
which were unavailable for analysis (Table 13) which ultimately contributed to 
the inconsistent results from the dynamic 
18
F-NaF PET-CT (Table 18) and 
(Figures 43 and 44). Similarly, reduced numbers contributed to inconsistent 
static 
18
F-NaF results (Tables 19 and 20). Thus results revealed no significant 
correlation between the 
18
F-NaF uptake patterns; dynamic NaF pattern; bone 
scan uptake pattern and periprosthetic lucency with the final diagnoses (Tables 
19, 20, 16 and 21 respectively). However, there was significant correlation 
between the R
2




The diagnosis of periprosthetic aseptic loosening or septic periprosthetic 
loosening can be challenging, and any new imaging technique to diagnose or 
exclude periprosthetic complications should attract attention. Distinguishing 
between periprosthetic joint infection and aseptic loosening by conventional 
radiology and nuclear medicine techniques can be difficult and prolonged (105). 
An accurate diagnosis of periprosthetic aseptic loosening or septic 
periprosthetic loosening can be made from a combination of clinical features, 
laboratory investigations including standard joint radiographs and joint 
aspirates. However, in some patients the diagnosis remains unclear prior to 
revision joint surgery (200).  Plain radiographs and conventional nuclear 
medicine often cannot distinguish between septic and aseptic periprosthetic 
loosening. Radionuclide imaging is currently not reliably specific enough for 
infection and is unable to distinguish infection from inflammation (201). 
Consequently, in the final diagnosis, patients with synovitis had similar results to 
septic loosening. One of the main limitations of this issue is that radionuclide 
imaging techniques would be unable to detect infection when prosthetic joint 
replacements are used in the management of rheumatoid arthritis. In addition, 




metal related artefacts can be reduced to an extent by using metal artefact 
reduction techniques (202). 





PET-CT with 3-phase bone scans in diagnosing prosthetic loosening and in 
distinguishing between aseptic or septic loosening. NaF PET-CT static 
periprosthetic uptake images were correctly interpreted as positive for aseptic 
loosening in 5 of the 5 patients. On the other hand, 3 out of the 3 patients with 
infection/inflammation were correctly identified but there were 2 false positive 
cases of infection/inflammation. One explanation for false positives in the 2 
patients diagnosed with sepsis could be the long femoral stems, heterotopic 
ossification as well as the presence of multiple periprosthetic wires and screws. 
In the limited number of successfully archived dynamic NaF pattern images; 
there was 1 false positive case of dynamic NaF pattern which was possibly 
related to the unusually long femoral and tibial stem components in the total 
knee replacement. Hence, neither the static NaF PET-CT nor the dynamic NaF 
PET-CT scans have shown improved accuracy over conventional bone scans.  
Analysis of periprosthetic uptake in 3-phase bone scan images showed 7 true 
positive aseptic loosening cases and 3 true positive cases of septic loosening. 
However, there were 5 false positive of aseptic loosening which were incorrectly 
identified as septic loosening cases. In the analysis of bone scan R
2
 trend lines, 
we found 12 cases of true positive aseptic loosening and 3 cases of true 
positive septic loosening. This R
2
 trend line method shows promise as there 
was no false positive or false negative case. 
CT periprosthetic lucency analysis was positive in all 12 cases of aseptic 
loosening as well as all 3 cases of infection/inflammation. Hence, CT 
periprosthetic lucency was not able to distinguish between aseptic loosening 
and infection/inflammation. 
The evidence purports that bone scan R
2
 trend line analysis can be useful in the 
evaluation of suspected periprosthetic sepsis and aseptic loosening. The 
addition of CT data from SPECT-CT could provide additional information that 




when periprosthetic fractures, pseudotumours and collections are suspected 
(106). 
Therefore, the accuracy of highly sensitive but poorly specific NaF PET-CT and 
conventional bone scans can be improved when bone scan data is combined 
with R
2
 trend line data to assist in the differentiation of infection from aseptic 
loosening. Additional information from CT images could reveal complications 
which are not related to aseptic or septic loosening (106). Results from the trial 









F-NaF) SUVmax levels. The small 
numbers in the infected category as well as the loss of NaF data in both 
dynamic 
18
F-NaF PET-CT and 
18
F-NaF most likely contributed to the 
inconsistent findings.  
In conclusion, both static and dynamic NaF PET-CT have not yet been proven 
to be useful as a single imaging technique in the evaluation of suspected of 
periprosthetic joint infection and aseptic loosening. Furthermore, dynamic NaF 
PET-CT is burdensome due to high data and long transfer times.  Conventional 
bone scans show better results when combined with R
2
 Trendline results from 
additional information that may influence the management of the disease. 
Lastly, CT periprosthetic lucency was found to be nonspecific and is thought to 
be a poor discriminator of aseptic loosening and septic loosening.  
 
6.5.2 Discussion of Trial Problems Encountered and Critical Analysis 
General problems encountered in the study include the identification of eligible 
trial patients; patient recruitment and retention; prolonged period between scan 
dates and surgery dates and patient frailty. 
Patient recruitment was a significant obstacle in performing the trial and we 
managed to recruit and scan 15 patients from a potential pool of 190 patients 
(Figure 46). Difficulty in patient recruitment would need to be considered when 
planning future larger trials. Clinical trial recruitment is often slower and more 




sample size within the allocated timescale (203). Our trial recruitment process 
was radiology led and the processes were inefficient as we had no prior 
relationship with the patients. This was unexpectedly more time-consuming than 
usual and there was not enough face-to-face contact with trial participants. The 
recruitment would have been better led by orthopaedic surgeons, nurses or 
physiotherapists. The longwinded process involved the initial identification of 
patients via hospital waiting lists for joint revision surgery. The surgical waiting 
list was based on a first-come-first served basis as opposed to severity of 
symptoms.  Thereafter, there was a time lag between patient recruitment, 
prosthetic joint imaging and revision surgery or joint aspiration. 
There was a risk of selection bias in this recruitment process because only 
patients that were contactable by telephone during working hours were enrolled. 
Further selection bias resulted from nonresponse bias (204) due to the fact that 
only patients on the waiting list for revision surgery were recruited and patients 
considered well enough for non-surgical treatment would have been excluded. 
The targeting and enlistment of participants from the waiting list was performed 
by a radiologist and not a clinician or nurse. However, patient recruitment is well 
known to be improved through favourable long-standing patient-physician 
relationships (205) and nurse-led patient recruitment is just as effective as and 
more cost-effective than doctor-led recruitment (206). Nurses and 
physiotherapists that are directly involved in orthopaedic patient care are more 
likely than radiologists to develop rapport with patients making them more likely 
to be successful at recruiting patients on to clinical trials than radiologists who 
have not had prior dealings with the patient. In addition, allied clinical personnel 
such as nurses and physiotherapists that are familiar with the clinical trial can 
establish how well patients understand and are satisfied with being recruited on 
a one-to-one basis (207, 208). Furthermore, the referral of patients for imaging 
tests is not normally under the control of radiologists and therefore the process 
of patient identification and enrolment for imaging-centred clinical trials is 
therefore more likely to occur optimally when performed by the caring clinical  




Other requirements for successful patient recruitment include a supportive 
departmental leadership, dedicated experienced administrative trial personnel 
and available trial infrastructure (209). Furthermore, opt-out methodology in 
medical trial recruitment can be more efficient and more successful than opt-in 
methods (210, 211), but opt-out methods of recruitment are more appropriate to 
survey-type studies only (212). Opt-in methods are essential for satisfactory 
informed consent and medical ethical standards (211). 
Following the identification of eligible patients, the prolonged pre-surgery 
waiting list occasionally resulted in a time lag between imaging and surgery 
dates which resulted in reduced patients' enthusiasm with the clinical trial 
recruitment process. Some other factors which resulted in reduced patients' 
willingness to enrol in the clinical trial included the lack of opportunities to 
improve their chances of a cure, no actual alteration in their received treatment 
or specialist care, but this perceived lack of additional care was offset by the 
altruistic chance to contribute towards medical research (205). Expedient 
factors that were used in our study included the altruistic motives, the promise 
to cover travel costs as well as the potential of undergoing a better test. 
Although we adequately explained the study over the telephone and in the 
multipage letter, we found that the later involvement of family members led to 
patient withdrawal (2). Other helpful factors that can lead to improved 
recruitment rates include the use of optimistic language in patient letters and 
leaflets as well as the provision of practical or psychological assistance (205). 
Other important steps in the successful recruitment process include enrolling a 
sufficient representative selection of the population and receiving informed 
consent by direct recruitment from outpatient clinics and initial face to face trial 
discussions by orthopaedic nurses, surgeons and physiotherapists (213) 
followed up by trial literature. This method is likely to avoid any ethical issues 












Figure 46. Patient recruitment  
Note: The patients were recruited to the trial from the prosthetic joint revision 
surgical waiting list. Those retained following recruitment were scanned 
according to the trial protocol. 
 
Analyses of randomised controlled trials in elderly patients demonstrate 
approximately 50% median rates for recruitment and 15% attrition rate (214) 
which matches our high dropout rate of 50%. These group of patients are 
generally are elderly with reduced mobility and despite the ongoing complaints 
of joint pain and relatively lengthy scan times we did not have any patient 
terminate the scan procedure. The use of blankets, pillows and knee rests 
improved patient comfort.  
One specific problem encountered was a false positive case resulting from 
rheumatoid arthritis. Therefore any patient with inflammatory arthropathy 
may need to be screened out and excluded from any future potential clinical 
study. The incidence of claustrophobia in Positron Emission Tomography is 
significantly lower than in Magnetic Resonance Imaging (215). The non-
completion rate was 0%, because no test was discontinued due to anxiety, 
discomfort, fear or claustrophobia. There was no requirement for the use of 
anxiolytic and sedative medication, noise-reduction techniques, special 
psychological support, anxiety reduction protocols, or cognitive behavioural 

















therapy (216). Patients were scanned supine and no complication was 
observed in any of the patients. Patients should be kept comfortable due to 
relatively longer scan acquisition timing over one bed position which occurs 
during the dynamic PET technique immediately following the inline CT (217, 














F-NaF)  scan times would need to match the 
production timetables and delivery timetable of the preferred NaF supplier 





F-NaF)  is on the increase (221). Commonly 
used cyclotron-produced radiotracers are commercially available in the 
United Kingdom from Erigal Limited (Erigal), Siemens PET-CT, IBA 







F-NaF) production sites in the United 
Kingdom as at February 2018 are Erigal Limited with production sites at 
Keele, Preston and Sutton. Siemens PETNET has sites at Mount Vernon 
hospital as well as in Nottingham. General Electric (GE
®
) Healthcare does 
not directly manufacture and deliver radiotracers around the country but 
instead provides synthesizer cassettes to PET centres using the FASTlab™ 
system. IBA Molecular UK has sites at Dinnington and Guildford for the 







 is a high performance chemistry system which features a 
single-use cassette system that contains pre-measured quantities of all 
chemicals required for the synthesis of specific radiopharmaceuticals. This  
is thought to be flexible, economical and results in its high yield and high 
reproducibility (223). PET-CT requires a co-registered CT scan to correct 





F-NaF) is close to 5 times more than the dose 












F-NaF) PET-CT scan is usually completed in 30 minutes 
whilst it takes 3 to 4 hours to acquire the planar dynamic bone scan images. 
Despite, the relatively low PET-CT usage in England when compared with other 
parts of Europe, there is limited capacity on the available PET-CT scanners in 
many parts of the United Kingdom as PET-CT demand has grown by 14% per 
annum over the last decade (224). 
The PET-CT machine was changed from a GE Discovery ST with 16 slice CT 
(GE Healthcare
®
) to a GE Discovery 710 with 64 slice CT (GE Healthcare
®
) in 
2015 and some patients were scanned in my absence both resulting in partial 
data loss and data corruption of dynamic NaF images that had been stored in 
the hard drive of the GE Discovery ST. The large data set results in system 
overload once the bandwidth of the system is exceeded leading to image failure 
and losses. This was a major limitation of the study for which the following 
learning points will be emphasised. Four major causes of PACS image loss 
include (225)  
x Vendor Incompatibility – the lack of conformance between machinery 
and computer systems from different sellers.  
x Unsupported Options - when two DICOM devices do not match each 
other on advanced transfer options, system failure may arise and the 
computer systems stop communicating 
x System overload – occurs when the limits of the bandwidth are exceeded 
resulting in image failure and losses become inevitable 
x Collateral image loss – image loss occurs due to other unrelated 
problems such as blackouts and server failures 
To prevent these unpredicted events from happening, daily audits of PACS 
images need to be performed in a manner similar to daily quality assurance 
tests on machinery should be performed to ensure that there is no case of 
partial series loss or complete series missing (225). In order to ensure test 
uniformity between the multicentre trial participants, the set-up process will 
need to create standard operating procedures that would ensure consistent 
high-quality imaging data based on quality assurance, fixed imaging protocols 




standardised patient preparation instructions, matched scan statistics and 
standard activity prescription as well as standardised scanning protocols 
including bed position timing, bed overlap, the use of 2D or 3D, resolution as 
well as reconstruction protocols for each centre (227). The framework for image 
transfer and storage can be achieved via compact discs, or better still with the 
use of internet-based and cloud-based technologies (228). Phantoms should be 
used to harmonize both data acquisition and processing as well as analysis 
parameters (229). The criteria for radiology reporting should be sufficiently 
robust to allow for blinded radiology reporting (230). 
The important statistical issues that need to be considered in setting up a NaF 
trial include assessing numbers needed to allocate to the clinical trial size; the 
new imaging test that needs to be compared with a control group of patients 
receiving a standard imaging investigation; randomization of patients to different 
comparative groups to avoid bias; Stratification the randomization process will 
need to be stratified or restricted to make sure that different investigations are 
comparable (231). Although small pilot trials can be beneficial and may help in 
the planning of trial protocols and schedules to avoid unacceptable levels of 
patient harm before rolling it out to a larger patient group (232), but even pilot 
trials can be controlled by randomization (233) to avoid uncontrolled pilot 
studies can be as misleading due to their small sizes and also due to random 
differences between different groups (232). Most randomised clinical trials in the 
United Kingdom do not achieve their original recruitment target and about half 
the trials have their recruitment period extended (203, 213). Some of the 
strategies that were employed to improve recruitment included regular visits to 
the orthopaedic department, making amendments to trial inclusion criteria by 
increasing the patient age range and also removing restrictive exclusion criteria, 
as well as presentation to consultant orthopaedic groups, research team 





6.5.3. Single versus Multicentre Trial 
 
Single-centre trials are the preferred trial method because they are less 
expensive, easier to run and also because logical multi-centre trial planning 
may lead to an unequal distribution of patients across centres (234).  
Multicentre trials are often spread unevenly between sites. Some authors argue 
that this reflects inefficiency, poor planning and or poor control in execution 
(234). Patient recruitment often mirror attendance rates in clinics or other 
recruitment venues (234). Therefore, recruitment and coordination of multi-
centre trials must allow for disparity in the number of recruited patients per 
centre (234). In order to achieve statistical relevance by increasing sample size 
and complete recruitment within acceptable time period trials in a timely 
manner, multi-centre trials are able to provide a major advantage by recruiting 
patients simultaneously from a number of centres. The multicentre trial also 
produces more representative trial conclusions regarding the whole population.  
Multiple independent trials may also provide a summary of trial data from 
different sources and are beneficial for evaluating adverse events, but multiple 
independent trials have less statistical strength than single and multi-centre 
trials (235). Organisational and extra-organisational practises, structures and 
processes contribute towards the progress or obstruction of the patient 
recruitment process (236). Specifically, competition for research participants 
between different organisations, conflict between clinical and clinical research 
work, a perceived staff increased workload burden due to the trial patients as 
well as perceived vulnerability of older patients to excessive research exposure 
are considered detrimental (236, 237). Rigid ethical regulations as well as the 






6.5.4 Change in Practice and Future Research 
 




F-NaF) was thought to be more accurate than 
conventional imaging techniques for diagnosis of complicated joint prostheses. 





F-NaF) PET-CT leads to improved management of patients 
in routine clinical practice. 
This pilot study provides prior feasibility work before setting up to a single centre 
or multicentre randomized controlled trial. It demonstrates ideal recruitment 
methods and rates, obstacles to patient participation in clinical trials, as well as 





The information from this feasibility study will be of value to researchers and 
funders in the design and commissioning of future research in to prosthetic joint 
infection imaging (238). The ideal trial would be a multicentre trial to improve 
trial recruitment numbers and patients could be entered in the two arms of 




F-NaF) PET-CT versus isotope 
bone scans. 
Before treatment or revision, patients from multiple centres will be randomly 





F-NaF) PET-CT group (DNPG). Patients will be followed up 
with surgery, microbiology, biochemistry and clinically for 2 years. The primary 
outcome measure will be speed and accuracy of true positive and true negative 
diagnoses.  A balance between patient safety, access to innovative 
technologies and improved patient care should be maintained when introducing 
new uses for radiopharmaceuticals or new radiopharmaceuticals for clinical use 
(239). International standards of quality assurance, good manufacturing practice 
and risk assessment studies should be adhered to and it is important to 
collaborate with both clinical and nonclinical professionals as well as industry 
and academia (239). 




F-NaF) PET-CT will also 




cost-savings when used to investigate painful joint prostheses. The role of 
SPECT-CT bone (
99m
Tc-HDP) scans will be assessed at the same time. The 
potential cost saving would be obtained chiefly from the reduced clinic visits, 
reduced imaging and non-imaging investigations (240), reduced use of 
pharmaceuticals as well as avoidance of unnecessary surgery such as 
examination under anaesthesia. The economic benefits can be obtained by 
examining Patient Reported Outcome Measures (PROMs) to calculate the 
quality-adjusted life years (QALYs) (241) and the improvement in health-related 
quality of life (HRQoL) (241). The analysis will provide a cost–utility ratio using 




F-NaF) PET-CT and SPECT-CT 
bone (
99m
Tc--HDP) scans, yielding a cost per QALY gained (241). 
Quantification and graphical presentation of test results are potential ways of 
solving some of the difficulties in assessing nuclear medicine images. The 
importance and relative ease of interpretation as well as improved accuracy of 
graphical presentation of cardiac imaging tests results has been demonstrated 
in radionuclide imaging (242) with significant superior results when compared 
with visual interpretation (242). Furthermore, quantitative radionuclide 
angiographic data from dynamic brain imaging using 
99m
Tc-HMPAO can be 
presented graphically resulting in an effortless non-invasive way of 
demonstrating cerebral perfusion without any blood sampling (243). Graphical 
time activity curves can also be applied to the in vitro studies such as in the 
measurements of radionuclide concentration in the marine environment where 
there are non-detect values (244).  
 
6.5.5 Lessons Learnt and How to Address Trial Problems 
 
The planned study should ideally be a multicentre trial to improve patient 
recruitment numbers via the orthopaedic department’s nurses, physiotherapists 
or surgeons. Data from 
99m




F-NaF) PET-CT will be analysed and presented with 








are data-heavy and both image transfer and storage process will require close 










F-NaF) PET-CT may be reduced by batching patients and 
scanning in bulk. In addressing some of the queries that we received from the 
research ethics committee, although there is a higher patient radiation dose 
which mainly comes from the CT component (245), this should be partially 
offset by the reduced requirement for repeated imaging. The life cycle of the 
scanner should be taken into consideration before the start of the trial to avoid 
scanner replacements during trial period. There should be a more robust trial 






F-NaF PET-CT is feasible but it produces large data files which can 
be corrupted resulting in data loss.  Dynamic
 18
F-NaF PET-CT as a single 
imaging investigation is not a reliable method of diagnosing infection or 
loosening of joint prostheses. Dynamic
 18
F-NaF PET-CT has not been proven to 
be a reliable method of differentiating loosening from infection of joint 
prostheses. Dynamic
 18
F- NaF PET-CT on its own has not been proven to be 
more cost-effective and accurate in the detection of infection/loosening of joint 
prostheses.  





F-NaF) PET-CT imaging and data storage, this trial has demonstrated that 
image acquisition is possible and may provide additional data. This trial has 
conclusively demonstrated that it is possible to extract new graphical 
mathematical data such as m and R² (Equation 1) from the commonly used 
99m
Tc-MDP dynamic bone scan. Further research is required to replicate this 
level of accuracy in using R
2
 values greater than 0.2 in larger studies whether to 
distinguish septic loosening or inflammation from aseptic loosening. Combining 




accuracy even further. In addition, 
99m
Tc-MDP dynamic bone scans are cheaper 










F-NaF) PET-CT scans is required before firm conclusions can be drawn from 




F-NaF) PET-CT to distinguish 




x Useful graphical mathematical data can be extracted from the commonly 
used 
99m
Tc-MDP dynamic bone scan which may distinguish septic 
loosening or inflammation from aseptic loosening.  
x This is important because 99mTc-MDP dynamic bone scans are cheaper 




F-NaF) PET-CT.  
x R2 values greater than 0.2 may indicate septic loosening or inflammation  
x CT periprosthetic lucency from SPECT-CT may improve the accuracy 
even further.  





Chapter 7  Research Proposal.  Labelling Study - A Potential Role 
for Lymphoseek
®
 In the Assessment of Patients with Painful Hip and 




Background: This experiment was designed and planned but was not carried 
out. The study was designed to analyse how Lymphoseek
®
, a new 
radiopharmaceutical that binds to the mannose receptor on the cell surface of 
macrophages can assist in the radiological assessment of patients with painful 
hip and knee joint prostheses from wear particle induced loosening. This 
imaging test is based on the innovative demonstration of the accumulation of 
activated macrophages in aseptically loose periprosthetic membranes. It is 
expected that our outcomes will show the need for more medical imaging 
research in this area and that the imaging of periprosthetic membranes in the 
future should involve a combination of anatomical and functional imaging.  
Methods: Two groups of experiments will be performed – in vivo intravenously 
injections in pre-surgery joint revision patients and ex vivo examination of 
surgically extracted periprosthetic membranes in patients with painful joint 
prostheses using 
99m
Tc-Tilmanocept. Lastly, ex vivo confirmatory 
immunohistochemistry experiments will be performed on the fresh periprosthetic 
membranes from these same 10 patients after joint revision surgery on the 
painful failed knee and hip arthroplasties by using CD68 or CD206. The ex vivo 
fixed tissue specimens will also be labelled using haematoxylin-eosin for the 
histological examination  The purpose of the histological examination is to rule-
out infection based on the degree polymorphonuclear leukocytic infiltration 
and/or confirm the presence of foreign body particles; macrophages and 





Results:  This experiment was designed but not performed and no result is 
available. However, it is hoped that the results will demonstrate that 
Lymphoseek
®
 binds to the mannose receptor on the cell surface of 
macrophages in aseptic wear particle induced loosening in prosthetic joints. 
Conclusion: This experiment was designed but not performed. It is expected 
that it will assist in the radiological assessment of patients with painful hip and 
knee joint prostheses using the novel technique of a macrophage mannose 
receptor imaging in humans to demonstrate periprosthetic membrane aseptic 
loosening.  It is also hoped that radionuclide scintigraphy with 
99m
Tc-
Tilmanocept SPECT-CT scan will be a useful imaging investigation in the 
assessment of the painful knee arthroplasty and that a negative 
99m
Tc-
Tilmanocept scan would reassuring make a diagnosis of aseptic loosening 
unlikely.  
 
7.2 Background and Introduction 
Due to the disabling nature of arthritis, surgical attempts have been made for 
well over a century to treat diseased joints (9). At least 40,000 hip and knee 
replacements are carried out every year in the UK (2). Approximately 0.4 to 4% 
of these are complicated by deep infection but the true figure is probably less 
than 1% (2). Complications of joint prostheses include aseptic loosening with an 
incidence of 2-18% and 23% respectively in the knees and hips (4), but 
infection has much more devastating consequences (5). The mean time from 
surgery to diagnosis is just under 14 months with the majority of patients 
presenting after 3 months (2). The diagnosis of prosthetic aseptic loosening and 
infection is very important both to patient well-being and mobility as well as the 
health economy. Management of these cases could be conservative or surgical.  
The clinical features of aseptic loosening consist mainly of joint pain in the 
absence of clinical features of infection (247) such as sinus formation or 
discharge and also an absence of leucocytosis, elevated erythrocyte 
sedimentation rate (ESR) and/or C-reactive protein (CRP) (2, 7, 247). Current 




contrast arthrography, ultrasound, MRI, CT and conventional Nuclear Medicine 
studies. The sensitivity, specificity and accuracy for the plain radiographs are 
approximately 43%, 86% and 64%, respectively (170). Although serial 
radiographs are insensitive, non-specific and generally unhelpful (248), they 
often are sufficient and are also able to detect periprosthetic factures (45). CT 
and MRI are particularly useful for periprosthetic collections, but they produce 
significant artefact in the region of the prostheses which can render them 
uninterpretable. Ultrasound has no role to play in diagnosing loosening with 
accuracy (45) and contrast arthrography is invasive and requires skilled staff. 
Nuclear medicine techniques are generally very sensitive for aseptic loosening 
and prosthetic infection but due to low specificity there is often a requirement to 
combine with different imaging tests (249, 250). Conventional nuclear medicine 
studies employed in the investigation of painful joint prostheses include dynamic 
3-phase radionuclide bone scans as well as radionuclide infection/inflammatory 
scans which include labelled white cell scans and 
67
Gallium imaging. Until 
recently, labelled monoclonal immunoglobulin fragments such as sulesomab 
(LeukoScan
©
) were used to distinguish aseptic loosening from periprosthetic 
infection (128) with an accuracy of over 80% (249) but immunoglobulins were 
beset with problems such as human anti-mouse antibody (HAMA) response due 
to the production of endogenous antibodies (128) as well as anaphylactic and 
other hypersensitivity reactions (128). The use of monoclonal antibodies was 
permanently discontinued in 2018 by Immunomedics™ GmbH and the 
European Union for commercial reasons (187). 
99m
Tc-HDP 
(hydroxydiphosphonate) /MDP (methylene diphosphonate) planar bone scans 
have a sensitivity of 66.7%, specificity of 94.5% and accuracy of 87.5% for 
detecting infection and aseptic loosening (72) but differentiating one from the 
other can be difficult. With bone scans, infection usually demonstrates diffusely 
increased uptake on both the blood pool and delayed phases, whilst aseptic 
loosening bone scans tend to feature focal uptake at the prosthetic tip usually 
on the delayed phase only. Hence, combination imaging remains the gold 
standard in radionuclide diagnosis of prosthetic infections (47). Consequently, a 
combination of indium-labelled white cell Imaging using SPECT-CT with bone or 




Tc sulphur colloid respectively is 




loosening from prosthetic joint infections. Other combinations which have been 
tried with varying results include 
67
Gallium imaging and labelled Immunoglobulin 
imaging (178) but monsoonal antibodies have since been discontinued (187). 
The accuracy of imaging techniques is improved when combined with ESR and 
CRP measurements (251). Positron Emission Tomography (PET) in conjunction 
with CT (PET-CT) is a relative new Nuclear Medicine imaging technique. It is 
well established as a powerful diagnostic tool in oncology but has rapidly 
broadening applications as new radiopharmaceuticals and methodologies 
become available. The radionuclides used in PET imaging typically decay by 
positron emission with short half-lives (less than 120 minutes) and PET 
scanners benefit from improved sensitivity and spatial resolution compared to 
conventional gamma cameras due to the coincidence detection of the two 
annihilation photons, arising from a positron/electron interaction which permits 
an imaging modality that is not burdened with a collimator (252). PET imaging is 
intrinsically tomographic and tomographic imaging, as opposed to planar 
imaging offers clear advantages in terms of localisation of pathology and image 
contrast allowing differentiation between bony cortex and marrow as well as the 
acquisition of images in a considerably shorter periods of time than with single 
photon emission computerised tomography (SPECT). PET-CT scanners 
incorporate high quality CT devices and, although the primary purpose of this 
transmission device is to assist with attenuation correction of the PET emission 
data, diagnostic quality CT images are available for localising functional 
information and the radiological assessment of any structural changes (252). 
Two readily available PET radiopharmaceuticals which have been investigated 
in the differentiation of aseptic loosening from prosthetic joint infection are 
18
F-
Fluorodeoxyglucose (FDG) and 
18
F-NaF (253) with widely variable accuracy 
(49, 254) but negative results are more informative than positive ones (255). In 
general, than Leukocyte imaging has a greater role to play than FDG PET-CT in 
distinguishing aseptic loosening from prosthetic joint infection (256). In essence, 
there is currently no effective single imaging test capable of both diagnosing 
and distinguishing between aseptic loosening and infection of joint prostheses. 
Plain radiographs and dynamic planar bone imaging are accepted first line 
techniques to evaluate symptomatic hip and knee prostheses. Technical 




additional nuclear medicine investigations such as radiolabelled white cell scans 
or in the recent past - LeukoScan
©
 investigations. These additional 
investigations are costly and time consuming for both patients and staff and 
may still not offer a definitive diagnosis. 
18
F-NaF PET-CT is very sensitive to 
change in bone metabolism but lacks specificity in distinguishing between 
simple loosening or loosening with underlying infection (41, 78).  
Histopathological studies of the periprosthetic membranes performed 
demonstrate 4 types of periprosthetic membranes (246) and surgical sampling 
of the prosthetic interface membrane yields better specimens for more accurate 
histopathological diagnosis of prosthetic joint infections than from 
pseudocapsule specimens (257). The 4 types are: 
 
1. Type I - Wear particle induced type (detection of foreign body particles; 
macrophages and multinucleated giant cells occupy at least 20% of the 
area (246). 
 
2. Type II - Infectious type (granulation tissue with neutrophilic 
granulocytes, plasma cells and few, if any, wear particles (246). 
 
3. Type III - Combined type (aspects of type I and type II occur 
simultaneously (246). 
 
4. Type IV - Indeterminate type (neither criteria for type I nor type II are 
fulfilled (246).  
 
The incidence of histopathological membrane types was: type I (54.3%), type II 
(19.7%), type III (5.4%) and type IV (15.4%) with 5.1% of cases not being 
assessable (246). The results showed a high correlation between 
histopathological and microbiological results (246). 
Activated macrophages heavily infiltrate periprosthetic membranes with aseptic 
loosening and express CD206 (cluster of differentiation) receptors. This 









) scintigraphy which is marketed by Norgine B.V  for sentinel 
lymph node mapping by binding to activated macrophages in lymph nodes 





), accumulates in the periprosthetic membrane to different 
degrees in the 4 histological types based on the classification by Morawietz 










) is a radiopharmaceutical macromolecule with a 
molecular weight of 28-kilodalton, a diameter of 0.007 µm and a surface area of 
7.1nm
2 
(259, 260). It is comprised of a dextran backbone (10-kilodalton) to 
which multiple units of mannose and DTPA (diethylenetriaminepentaacetic acid) 
are attached (259). It is the mannose backbone that binds to the CD206 (cluster 





 is licenced for intradermal, subcutaneous, subareolar and 
peritumoral injection routes for lymphatic mapping in the localization of sentinel 
lymph nodes draining a primary tumours in a variety of cancers. Theoretically, 
Lymphoseek
®
 binding in high concentration will provide evidence of high 
numbers of macrophages (259, 261). The intravenous route of 
99m
Tc-
Tilmanocept injection into patients has been assessed in a single centre phase 
1/2 clinical study to evaluate with Kaposi sarcoma as an open-label, non-
randomized trial (262). Preclinical studies imply that subcutaneous radiolabelled 
Tilmanocept is excreted from plasma by means of glomerular filtration, passive 
secretion into the Bowman’s capsule and also by binding to the CD206 








This study addressed the following hypotheses: 




 can accurately 
demonstrate high levels of activated macrophage cells in periprosthetic tissue.  




 SPECT-CT can 
accurately demonstrate the distribution of activated macrophages in 
periprosthetic tissue.  




 SPECT-CT can 
accurately diagnose aseptic loosening in periprosthetic tissue.  




 distribution in 
periprosthetic tissue does not accurately match the distribution of neutrophils 
and 
99m
Tc labelled Lymphoseek will therefore distinguish aseptic loosening from 










as a viable in vivo agent to accurately demonstrate activated macrophage cell 
distribution in periprosthetic tissue sections. The aim is to validate high-levels of 
99m
Tc-Tilmanocept Lymphoseek activity in aseptically loosened periprosthetic 
membrane in vivo following intravenously administered 
99m
Tc-Tilmanocept (264, 
265) and at the same time demonstrate low uptake in asymptomatic as well as 
septic periprosthetic membranes.  In addition, ex vivo studies will be performed 
to reveal co-localization between 
99m
Tc-Tilmanocept) and CD206 positive 
macrophages on periprosthetic membranes. Ex vivo experiments will be 




against CD206 and CD68 (b) Immunofluorescence with dual-labelled 
Tilmanocept with CD68 and CD206  antibodies detected using fluorescent 
markers such as Alexa 488 (266).  These will quantify activated macrophages in 
periprosthetic membrane tissues and assess the concentration of periprosthetic 





The studies will be performed following approval by local research ethics 
committee and the University Coventry and Warwickshire Research & 
Development department. Informed patient consent will be obtained. Two 
groups of experiments will be performed – in vivo intravenously injections in 
pre-surgery joint revision patients and ex vivo examination of surgically 
extracted periprosthetic membranes in patients with painful joint prostheses. 
In vivo experiments will be performed on 10 patients with painful prosthetic 
joints prior to joint revision surgery. This imaging technique was developed to 
diagnose aseptic loosening using single photon emission computer tomography 
(SPECT) by analysing the presence of activated macrophages in symptomatic 
knee and hip periprosthetic membranes using mannose receptors (CD206) 
present in the macrophage cell membranes. This assumes that following the 
intravenous administration of 
99m
Tc-Tilmanocept, periprosthetic membrane 
uptake would be proportional to the presence of activated macrophages present 
in the periprosthetic membrane (264) and that SPECT-CT-based quantification 
of 
99m
Tc-Tilmanocept uptake would be feasible based on prior studies which 
measured 
99m
Tc-Tilmanocept  uptake in joints and the aorta (264, 266). Recent 
research studies refer to physiological accumulation of increased background 
activity in the kidneys and liver (266) and planar images of the abdomen will 





Patients will receive intravenous injections 400µg Tilmanocept radiolabelled 
with 370 MBq of 
99m
Tc. Planar images of the affected joints and the abdomen 
will be acquired at 60 minutes and 180 minutes post-injection. SPECT-CT 
images of the prosthetic joints will also be performed at 180 minutes post-
injection (264, 266). Similar injection doses of 400µg Tilmanocept radiolabelled 
with 370 MBq of 
99m
Tc will be administered to patients with bilateral lower limb 
prostheses followed by the acquisition of planar images of both joints and the 
abdomen at both 60 minutes and 180 minutes post-injection. Thereafter, 
SPECT-CT images of both prosthetic joints will be performed at 180 minutes 
post-injection (264, 266). Imaging will be performed with a Discovery NM/CT 
670 gamma camera from GE™ Healthcare. Thereafter, SPECT-CT images of 
the symptomatic joint will be acquired with the dual head gamma camera and 
16-slice CT scanner. Image projections will be acquired using the 140 KeV 
energy window and ordered subsets expectation maximization algorithm 
(OSEM) iterative reconstruction will be used to reconstruct the SPECT images. 
Corrections will be made for motion and misregistration. The acquired CT 
images will be used for attenuation correction. Target to background ratios will 
be calculated using fused SPECT-CT guided voxels (volumes of interest) in the 
reconstructed images by comparing pathological Tilmanocept uptake which will 
be normalized to a reference region in unaffected skeletal muscle because of 
the propensity of muscle to display consistent low levels of activity (266). The 
scan duration will be 15 to 30 minutes (depending on the metallic stem length). 
Three hours was chosen as the most ideal acquisition time point after 
intravenous administration because research and pharmacokinetics have 
shown this to be optimal (266). In patients with more than one knee or hip joint 
prosthesis, the 
99m
Tc-Tilmanocept percentage uptake in the symptomatic joint 
prosthesis will be compared with the percentage uptake in non-symptomatic 
joints. Images will be analysed and reviewed on GE Xeleris
TM
 version 4 
workstations. Identical in vivo imaging techniques can also be performed using 
a Discovery 710 PET-CT scanner with 64 slice CT capability instead of SPECT-








Ex vivo experiments on fresh periprosthetic membranes from these same 10 
patients will be performed subsequent to the surgical removal of periprosthetic 
membranes after joint revision surgery on painful failed knee and hip 
arthroplasties. The tissue specimens will be formalin-fixed, paraffin-embedded 
and then frozen immediately after removal (268) to prevent dehydration. 4 µm 
thick sections of the formalin-fixed, paraffin-embedded (FFPE) tissue blocks will 
be created from the resected surgical samples and then stored at ultralow 
temperatures (−80°C). The FFPE tissue sections will then be de-paraffinised 
and rehydrated in xylene and graded ethanol followed afterwards by antigen 
retrieval using high heat for 20 minutes as described by MV Zanni et al (266). 
The de-paraffinised sections will be incubated with peroxidase and washed in 
Tris Buffered Saline (TBS) followed by a 30 minute protein block (266).   
Single label immunohistochemistry on tissue sections will be performed at 4°C 
by overnight incubation with mouse anti–CD68 antibody (1/50, DAKO 
Corporation, Trappes, France) to identify both M1 and M2 macrophage 
subtypes (269). Whilst the goat anti-mannose receptor (MR) antibody (1/50, 
Santa Cruz Biotechnology, Heidelberg, Germany) will be used to distinguish 
between the CD68 positive mannose receptor (M1) and CD68 positive 
mannose receptor positive (M2) subtypes (269). Immunostaining will be 
performed for visualization using biotinylated secondary antibodies (1/200, 
Vector laboratories, Burlingam, CA), streptavidin–horseradish peroxidase 
(Vectastain ABC kit, Vector laboratories), and the 3-amino-9-ethylcarbazole 
substrate–chromogen system (Sigma-Aldrich) (269). Alternately, single label 
immunohistochemistry will be performed with antibodies against CD206 (R&D 
Systems) (Serotec) (266) and then visualized using 3, 3’-diaminobenzidine 
tetrahydrochloride (DAB, Dako) (266). Afterwards, the relative numbers of CD68 
positive mannose receptor (M1) and CD68 positive mannose receptor (M2) 
macrophages in the periprosthetic membrane tissue will be quantified to 
determine the M1/M2 ratio (269). Immunofluorescence will be performed with 
dual-labelled Tilmanocept with CD68 and CD206 antibodies and detected using 
fluorescent markers such as Alexa 488 (266). Alexa Fluor 488 is a fluorescent 
dye (266, 270) with emission/excitation spectra wavelength maximum of 488 




membrane tissues samples. The average number of immune positive 
macrophages will be counted in 20 high power fields of view using a 
microscope (269).  
The formalin-fixed, paraffin-embedded (FFPE) tissue blocks of periprosthetic 
membrane specimens will also be cut and stained with haematoxylin-eosin to 
rule-out infection  based of the degree polymorphonuclear leukocytic infiltration 
(137) as stipulated in the proceedings from the 2013 International Consensus 
Meeting on Periprosthetic Joint Infection held in Philadelphia (272). Samples 
would have to demonstrate less than 5 neutrophils per high-power field with 
negative cultures on periprosthetic cultures extended to 2 weeks to exclude 
periprosthetic sepsis as a cause of symptoms (137, 272). Alternately, aseptic 
loosening consists of a dense mass like infiltrate of particle-laden macrophages 
with resultant central necrosis, increased osteoclastic activity and surrounding 
bone resorption and the histological samples would be examined for the 






This is the first-in-human study to identify activated macrophages in aseptic 
loosening of periprosthetic membrane in joints using 
99m
Tc-Tilmanocept 
SPECT-CT to detect the presence of CD206 positive macrophages in vivo. The 
ex vivo experiment will also confirm the presence of macrophages in the 
surgically excised periprosthetic membranes. Therefore, following the 
intravenous injection of 
99m
Tc-Tilmanocept and the subsequent periprosthetic 
membrane 
99m
Tc-Tilmanocept uptake quantified by SPECT-CT can be inferred 
to reflect CD206 positive macrophage concentration in periprosthetic 
membranes. From prior research studies, we expect that there will be an 
increased background activity in the kidneys as well as the liver and planar 




There is significant heterogeneity in the macrophage categories and an in vivo 
overlap exists between M1 and M2 subsets of macrophages due to in vivo 
plasticity that is not clearly witnessed in in vitro and ex vivo environments (266, 
273). This is thought to result from phenotypical alteration in response to signals 
in the local environment (266, 273, 274). This study will reveal the important 
role of CD206 positive macrophages in aseptic loosening of periprosthetic 
membranes as well as demonstrate a connection between aseptic loosening in 
periprosthetic membranes and elevated levels of periprosthetic membrane 
99m
Tc-Tilmanocept uptake. Additional research is required to determine optimal 
intravenous doses in human periprosthetic joint imaging and also to determine 
whether false positive cases occur in the asymptomatic early post joint 
replacement period. The likelihood of 
99m
Tc-Tilmanocept becoming a mannose 
receptor imaging in CD206 positive macrophages in inflamed human joints has 
recently been proposed (128, 264, 275) but the potential role for Lymphoseek
®
 
in the imaging assessment of painful joint prostheses requires further research 
before it becomes an established imaging technique.   
There are other MRC1 antibodies (Mannose Receptor, C Type 1) which are 
expressed by the Human MRC1 gene and also demonstrate cytoplasmic 
positivity in macrophages. Some of these exist as 3 clones of the MRC1 
antibodies - HPA004114, HPA045134 and AMAb90746 which are all produced 
from rabbit host species. Alternately, the polyclonal antibodies - HPA004114 
and HPA045134 or the monoclonal antibody - AMAb90746 may also be used 
(276). These antibodies are supplied by Sigma-Aldrich Company Ltd. The Old 
Brickyard, New Road, Gillingham, Dorset, SP8 4XT United Kingdom and Atlas 
Antibodies AB, Voltavägen 13A, SE-168 69 Bromma, Sweden (276).  
PET scanners  possess inherently better contrast and spatial resolutions than 
SPECT scanners (277).Therefore, significant improvement in imaging quality 
over 
99m




Ga) labelled Tilmanocept (128, 267). 
68
Ga-Tilmanocept is produced 
by chelating radioactive 
68
Ga to the diethylenetriaminepentaacetic acid (DTPA) 
moiety of the Tilmanocept molecule. 
68







Ga generators that serve as a stable source of 
68




year (128) and has a half-life of 68 minutes and decays by emitting positrons 
(128, 267). 
Critical analysis of the research methodology in this prospective uncontrolled in 
vivo and ex vivo trial to test whether a Lymphoseek
®
 can detect wear particle 
induced loosening in hip and knee joint prostheses reveals advantages and 
disadvantages. The advantage of the in vivo study includes the relatively lower 
cost and also the fact that the prosthetic membranes would be studied in their 
‘native’ environment. The downside of the in vivo study is that it would require 
an intravenous 
99m
Tc-Tilmanocept which is a new radiopharmaceutical that 
binds to the mannose receptor on the cell surface of macrophages and is only 
licenced for subcutaneous use. The in vivo study assumes favourable 
pharmacokinetics of intravenous 
99m
Tc-Tilmanocept and also that periprosthetic 
membrane uptake following the intravenous administration of 
99m
Tc-Tilmanocept 
would be proportional to the activated macrophage numbers present in the 
periprosthetic membranes. The ex vivo material would also require technically 
challenging steps of tissue fixing and preservation as well as 
immunohistochemistry staining. Potential sources of error include the small 
number of in vivo and ex vivo experiments. Further limitations of the study 
include selection bias because only symptomatic joint prostheses would be 
included. The absence of control group potentially reduces the statistical power 
of the study. However, there will be 2 blinded readers to reduce intra-observer 
variability. New knowledge that will be identified includes the co-localisation 
between 
99m
Tc-Tilmanocept and CD206+ macrophages in ex vivo aseptically 
loosened periprosthetic membranes and in vivo demonstration of high levels of 
99m
Tc-Tilmanocept uptake in aseptically loosened periprosthetic membranes. 
There are limitations to this proof-of concept study. One of the most important 
limitations is the small non-blinded sample size. In addition, the ex vivo studies 
performed on periprosthetic membrane tissue specimens will have to be taken 
from all patients that undergo the in vivo 
99m
Tc-Tilmanocept SPECT-CT scan. 
From past experience, this is not always achievable due to patients dropping 
out of trials and also because intended revision surgeries do not always 
proceed as planned in every single case. The study strengths include the first 




technique which targets CD206 positive activated macrophages in prosthetic 
joint aseptic loosening. The experiment methodology may be extrapolated to 
larger multicentre studies to provide a clearer perspective into the non-invasive 
investigation and diagnosis of painful joint prostheses. It also is not clear if 
99m
Tc-Tilmanocept SPECT-CT scan will result in false-positive studies in the 
early post-surgical period.  
The products contain material of animal origin and human tissue and risk 
assessment for biohazards and safety will need to be performed. As with all 
human tissue samples, patient specimens will all be handled as potential 
biohazards. As with all biological material, direct handling will be reduced to a 
minimum and appropriate protective clothing will be worn. Chemical hazards will 
also be avoided when preservative products are added. Radiation hazards will 
also be avoided during the patient imaging process. For biosafety reasons, if 
samples need to be transported from the University Hospital across town to the 
chemistry laboratories at the University of Warwick then they may require 
screening for blood borne infections such as Human Immunodeficiency Virus 
(HIV) and hepatitis. Locked storage of biological samples and secure 
transportation between surgical theatres, laboratories and the imaging 
department.  
We hope that the results will provide a new isotope for joint imaging by 
demonstrating co-localisation between 
99m
Tc-Tilmanocept and CD206+ 
macrophages in ex vivo aseptically loosened periprosthetic membranes. The in 
vivo application of 
99m
Tc-Tilmanocept single-photon emission computed 
tomography/computed tomography should demonstrate high levels of 
99m
Tc-
Tilmanocept uptake in aseptically loosened periprosthetic membranes assessed 
using regions of interest (246) and validated using immunohistochemistry by 




7.7 Further Areas of Future Research  
 
7.7.1 The Development of New Molecular Imaging Probes 
 
Radiopharmaceuticals labelled with positron emitting isotopes provide more 
favourable physical characteristics in radionuclide imaging than single photon 
isotopes (278). On the other hand, radionuclides for single photon labelled 
compounds do provide a wider variety than PET agents and single photon 
labelled molecules also offer an important complimentary array of new 
possibilities in the development of new agents used in the process of drug 
development (278). Other advantages of PET agents over SPECT agents are 
the higher sensitivity and more accurate quantification features (278), but PET 
agents are disadvantaged by their shorter half-lives and they are also less 
abundant as well as more expensive (278). Single photon emission 
radionuclides on the other hand are foreign to the human physiology and 
biochemistry (279). Exploratory studies for investigational new drugs (IND) are 
also known as phase 0 studies (280) and improve or understanding of toxicity 
and efficacy thus reducing clinical trial time, costs  as well as the high failure 
rate of new drugs that occur during the traditional phases I to IV clinical trial 
stage. Phase 0 studies follow on from preclinical pharmacology and toxicology 
tests and occur before the typical Phase I clinical trial. Phase 0 studies involve 
restricted human exposure to non-therapeutic quantities of the IND (280). 
Radionuclide imaging with positron emission tomography (PET) and single-
photon emission computed tomography (SPECT) enables speedier proof-of-
concept testing and allows non-invasive visualization, characterization and 
quantification of biochemical processes that occur at cellular and subcellular 
levels in both humans and animals whilst only using nanomolar to picomolar 
concentrations of the IND (278).  
Radionuclide imaging plays a big role in target identification and validation. The 
drug target can be a membrane, nuclear receptor, ion channel, enzyme, 




Radionuclide imaging does not play a significant role in lead finding and 
optimization. This stage usually relies on in vitro drug target analysis with 
biochemical and cellular assays, e.g., for compound purity, integrity, solubility, 
lipophilicity, safety, dissociation constant, permeability and target affinity (278).  
Radionuclide imaging is used in compound profiling in animal models at the 
preclinical stage. In this, the investigative drug itself is labelled with an imaging 
probe for in vivo imaging using animal models of disease to provide valuable 
information concerning drug absorption, distribution, metabolism, elimination 
and efficacy (ADME). The images provide pharmacodynamics and 
biodistribution properties of a candidate drug  (278). 
Safety evaluation can involve imaging with animal studies for toxicology and 
determining the proper dose to be tested in the clinical trials. Many 
pharmaceutical companies have established their own imaging laboratories to 
do carry out these processes (278). 
Clinical evaluation with SPECT involves clinical studies in 4 sequential phases 
(I–IV) after authorization by regulatory agencies (278). 
 
 
7.7.2 Regulatory Bodies 
 
Worldwide, nuclear Medicine guidelines are developed by a number 
international, continental, national as well as local regulatory organisations 
(281) and the introduction of new isotopes or the institution of new usages of old 
isotopes would have to navigate these guidelines and regulations. In Europe, 
the European Association of Nuclear Medicine (EANM) coordinates the 
development of guidelines, but also recognises the need for national guidelines. 
Likewise, In the United Kingdom, there are national regulations on the 
administration of radioactive substances but differences in clinical practice and 
service delivery mean that guidelines do not readily apply across regional and 




Some examples of the various statutory nuclear medicine guidelines and 
regulatory bodies in England include: Medicines and Healthcare products 
Regulatory Agency (MHRA) which regulates the use of new and established 
medicines and devices; the Carriage of Dangerous Goods and Use of 
Transportable Pressure Equipment Regulations 2009 regulates the 
transportation of radioactive substances; the Administration of Radioactive 
Substances Advisory Committee (ARSAC); the Radioactive Substances Act 
1993 (RSA93) in Scotland, or the Environmental Permitting Regulations 2010 
(EPR2010) in England and Wales which oversees the management of 
radioactive wastes and is policed by the Environment Agency; the Medical and 
Dental Guidance Notes which covers Ionising Radiation Regulations (IRR99) 
and is policed by the Health and Safety Executive (HSE). Lastly, there is the 
Ionising Radiation (Medical Exposure) Regulations (IRMER) 2000 with 





) was first postulated by Solanki (284). Its 
physiological distribution does not include the normal bone marrow and this 
allows for evaluation of the spine and proximal limbs unlike radiolabelled white 
cell and Gallium-67 scans which demonstrate background bone marrow uptake 
(285). Although initial reports for the use of 
99m
 Tc-labelled Ciprofloxacin in 
infection were promising (284). More recent accounts of the use of 
99m
Tc-
labelled Ciprofloxacin show a reduced specificity for detecting of bacterial 
infections. Also the radioisotope physically disappeared from sites of infection 
and inflammation with equal rapidity (286). Therefore, 
99m
Tc-labelled 






7.7.3 Future Research with Folate Imaging 
 
The beta folate receptor (FR-β isoform) is overexpressed on activated 
macrophages which accumulate at sites of inflammation and infection. Folate 
receptor avid isotopes have been shown to accumulate at sites of inflammation 
and could act as markers for inflammatory processes such as rheumatoid 
arthritis (287). In addition, to the beta folate receptor (FR-β isoform), there are 3 
other separate types of receptor polypeptides located in cell membranes (α, γ 
and δ) which also bind and endocytose folates and folate conjugates. The alpha 
folate receptor (FR-α isoform) demonstrates limited expression in normal tissue, 
mainly kidneys, choroid plexus, lungs, and placenta (288), but is upregulated in 
ovarian, uterine, brain, lung, kidney, breast as well as colorectal tumours (287). 
PET and SPECT folate imaging can be performed with 
18
F-Fluorodeoxyglucose 
folate PET (288) and 
99m
Tc-EC20 SPECT (288, 289) imaging respectively. 
 
 
7.7.4 Future Research with 3-Phase 99mTechnetium Labelled Bone Scans with 
SPECT-CT 
 
More data can be gleaned from current well established imaging methods of 
imaging PJI and loosening. A follow up retrospective research study into PJI 
and loosening with Time-Activity Curves and CT density maps obtained from 3-
phase 
99m
Technetium labelled bone scans with SPECT-CT is already in 






7.8 Summary and proposed imaging algorithms 
 
Multiple different proposed imaging algorithms are being proposed to cover 
different imaging scenarios as well as the availability or unavailability of SPECT-
CT and PET-CT scanners. The initial imaging of painful joint prostheses with 3-
phase 
99m
Tc bone scans SPECT-CT or 
18
F-NaF PET-CT should be able to 
detect mechanical complications on the CT component as well as infection and 
aseptic loosening on the radionuclide images (Figures 47 and 48).  
Infectious type (Type II) periprosthetic membranes which consist of granulation 
tissue with neutrophilic granulocytes, plasma cells and few, if any, wear particle 
are usually obvious on 3-phase 
99m
Tc bone scans SPECT-CT and 
18
F-NaF 
PET-CT (Figures 47 and 48), but these patients may be assessed further using 
labelled white cells (Figure 49) with SPECT-CT if required. In patients with no 
clear evidence of mechanical complications or infection on initial imaging with 
predominantly late-phase positive isotope planar or SPECT bone scans or late 
phase positive 
18
F-NaF PET (41, 78), the periprosthetic membranes may be 
assessed for the presence of activated macrophages with Tilmanocept receptor 
imaging using either SPECT or PET imaging (Figures 50 and 51) depending on 
the availability of scanning equipment and local expertise. The presence of a 
high concentration of macrophages would suggest particulate-induced wear 
(Type-I) or the combined type (Type III).   
The cost and availability of scans as well as the radiation dose to the patient 
should be factored in when considering the choice of imaging algorithms for 



















































Computed Tomography (CT) 




Magnetic Resonance Imaging (MRI) 






























































Note: including COR = including cost of reporting 
Typical cost and radiation dose of commonly performed examinations. Source 
NHS National tariff payment system Annex A: The national tariff workbook 
(Unbundled service prices 2019/20) (290) 
Some variances: 1 vial of Lymphoseek
®
 costs circa £1,175 (because this is a 
new patented radiopharmaceutical agent). 
A new PET-CT machine with service contract in place will cost approximately 
£1.6 million. 
A modern SPECT-CT gamma camera machine with diagnostic CT capability 















Figure 47. Proposed radionuclide imaging algorithm using SPECT-CT 
 
Note: Imaging algorithm for dynamic SPECT-CT initial imaging of painful joint 
prostheses – yielding results compatible with normal, aseptic loosening or 















Septic loosening  
(high R2) 






Figure 48. Proposed radionuclide imaging algorithm using PET-CT 
 
Note: Imaging algorithm for dynamic PET-CT initial imaging of painful joint 



























Figure 49. Proposed radionuclide imaging algorithm for suspected infection 
with SPECT-CT 
 
Note: Imaging algorithm for SPECT-CT labelled white cell imaging of suspected 
infected joint prostheses – yielding results compatible with no infection or 
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Figure 50. Proposed Radionuclide imaging algorithm for suspected aseptic 
loosening with SPECT-CT 
 
 
Note: Imaging algorithm for SPECT-CT Tilmanocept imaging of suspected 
aseptic loosening in joint prostheses – yielding results compatible with a high 
























Figure 51. Proposed radionuclide imaging algorithm for suspected aseptic 
loosening with PET-CT 
 
Note: Imaging algorithm for PET-CT Tilmanocept imaging of suspected aseptic 
loosening in joint prostheses – yielding results compatible with a high 
macrophage burden or no macrophages. 
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This is a novel technique and the first in-vivo use of a macrophage mannose 
receptor imaging in humans to demonstrate periprosthetic membrane aseptic 
loosening.  Radionuclide scintigraphy with 
99m
Tc-Tilmanocept SPECT-CT scan 
will be a useful imaging investigation in the assessment of the painful knee 
arthroplasty. A negative 
99m
Tc-Tilmanocept scan should be reassuring and 











x Lymphoseek® is a relatively new radiopharmaceutical that binds to the 
mannose receptor on the cell surface of macrophages. 










Ga) labelled Tilmanocept PET-CT.  
x A negative Tilmanocept scan should be reassuring and make a diagnosis 
of wear particle induced aseptic loosening unlikely. 









Chapter 8   Conclusion 
 
 
This dissertation aimed to show that dynamic 
18
F-Fluoride PET-CT may have a 
role in the investigation of painful hip and knee prosthetic joint replacements as 
well as analyse the relationship between 
18
F-Fluoride PET-CT and 
99m
Tc-MDP 
dynamic bone scans. 
There is a rising incidence of joint replacement surgery and a growing need for 
prosthetic joint imaging. Chapter 1 provided an overview of the background and 
history of joint prostheses with theoretical framework and context information. 
Because of the importance and expanding role of hybrid imaging the 
contribution of CT to prosthetic joint imaging was outlined along with a CT 
spectrum of pathological complications of prosthetic joints. The concept of 
prosthetic joint imaging with dynamic 
18
F-NaF PET-CT as well as radionuclide 
imaging of activated macrophages in periprosthetic tissue were introduced as 
possible means of increasing diagnostic accuracy and efficiency. 
Chapter 2 was a small retrospective investigation of the use of dynamic bone 
scans in painful hip and knee prosthetic joint replacements which demonstrated 
delays in diagnosing painful joint prostheses. The use of multiple tests was 
identified as possibly contributing to diagnostic delay and a streamlined reduced 
number of imaging tests may contribute to an improve the speed of diagnosing 
painful joint prostheses. Fused functional anatomical imaging may also reduce 
the number of imaging tests required. 
Chapter 3 was a systematic review of 
18
F-NaF PET in diagnosing and 
distinguishing between septic and aseptic loosening in hip and knee 
prostheses. Sodium fluoride positron emission tomography (
18
F-NaF-PET) is an 
old isotope which is making a comeback as a promising tool with high sensitivity 
and specificity in bone imaging. The small series was a limiting factor of the 
series. 
18
F-NaF PET is also of limited use before the ninth post-surgical month, 




month intervals for the detection of abnormal rates of decline in periprosthetic 
NaF uptake. 
Chapter 4 introduced research on the promising role of dynamic 
18
F NaF PET-
CT in diagnosing symptomatic joint prostheses. The preliminary data validated 
early proof of principle that dynamic 
18
F-NaF PET-CT can detect aseptic 
loosening of lower limb prostheses with anatomical correlation provided by the 
CT component. More research is required to establish a role for dynamic 
18
F-
NaF PET-CT for detecting aseptic loosening and septic loosening. Further 
comparative studies of dynamic 
18
F-NaF PET-CT versus technetium-based 3-
phase bone scans are needed with larger patient populations in the assessment 
of painful hip and knee prostheses before routine clinical use. 
Beam hardening artefacts from prostheses have a significant deleterious effect 
on hybrid images. Hence, chapter 5 compared the use of pre-filtering with 
Aluminium; dual-energy CT and mathematical algorithms with MATLAB
®
 filtered 
back projection to evaluate and correct beam hardening artefact from 
prostheses on Dynamic NaF PET-CT. Although pre-filtering with Aluminium; 
dual-energy CT and mathematical algorithms with MATLAB
®
 filtered back 
projection can reduce beam hardening artefact, there was no significant 
difference and the use of these techniques introduced other artefacts with 
subsequent reduction in image quality. 
Chapter 6 was a prospective study comparing dynamic 
18
F-NaF PET-CT and 3-
phase bone scans of hip and knee joint prostheses. The limitations and 
problems encountered in this clinical trial were recounted. Graphical and 
mathematical data was extracted from 
99m
Tc-MDP dynamic bone scans to 
improve diagnostic accuracy but the trial population was small. Further research 
is required with a larger study to distinguish septic loosening or inflammation 
from aseptic loosening. Combining this method with CT periprosthetic lucency 





F-NaF) study was partly corrupted and could not be retrieved 
resulting in inconsistent outcomes from the small numbers. Hence, no strong 
conclusion could be drawn especially in the infected category. 
99m
Tc-MDP 





F-NaF PET-CT. Therefore, the use of graphical and mathematical data from 
99m





F- NaF) PET-CT. but more research is needed. While the 
corrupted 
18
F-NaF data limits the accuracy of the 
18
F-NaF results, this study 
provides new insight into how graphical and mathematical data extracted from 
99m
Tc-MDP dynamic bone scans can improve diagnostic accuracy. 
Chapter 7 provided new insights into future research and the use of 
Tilmanocept
®
 and further future areas of research as well as the regulatory 
hurdles of radiopharmaceutical licencing. Tilmanocept
®
 is a novel technique 
involves the first in-vivo use of an isotope-labelled macrophage mannose 
receptor imaging study in humans to demonstrate periprosthetic membrane 
aseptic loosening.  This research will clearly illustrate that radionuclide 
scintigraphy with 
99m
Tc-Tilmanocept SPECT-CT scan will be a useful imaging 
investigation in the assessment of the painful knee arthroplasty but it also raises 
the question of how early in the post-surgical period Tilmanocept
®
 imaging can 
be used. It is likely that a negative 
99m
Tc-Tilmanocept scan would be rule-out a 




Ga) labelled Tilmanocept 
PET-CT imaging is an alternative to
 99m
Tc-Tilmanocept SPECT imaging. 
This study had several limitations. First, the study had selection bias because 
the dynamic 
18
F-NaF PET-CT trial included only patients who were on the 
surgical waiting list for revision surgery. This may overestimate the sensitivity of 
the test because patients who did not undergo revision surgery could be more 
likely to have a negative or equivocal 
18
F-NaF PET-CT results. The exclusion of 
patients not being considered for revision surgery could also affect the 
sensitivity because lesions in nonsurgical patient may be smaller and difficult to 
visualise on imaging. Secondly, the 3 month bone scan study was a 
retrospective study and images from the metal-artefact study were read by a 
single radiologist and a blinded review by more than one radiologist would have 
been more ideal. Lastly, the small population in the samples studied as well as 
the lack of dynamic NaF images for positive septic prostheses.  
Future studies of dynamic 
18
F-NaF PET-CT, 3-phase bone scans with graphical 
presentation as well as Tilmanocept
®




patterns, combined with morphologic features of CT would be valuable in 
formulating a new imaging pathway. 
This dissertation provides new knowledge into the optimising isotope bone 
SPECT-CT scans by extracting graphical and mathematical data whilst 
minimising prosthetic induced artefacts may be more cost effective. 
The improved specificity provided by Tilmanocept
® 
imaging is a novel approach 
to the assessment of prosthetic joint complications by directly demonstrating 
particle-laden macrophage infiltrates in the zone of bone resorption. Hence, 
combining mathematical data from 
99m
Tc labelled bone scans and Tilmanocept
® 
imaging into an algorithm (Figure 52) is likely to ultimately improve diagnostic 
























Figure 52. Proposed combined radionuclide imaging algorithm for painful joint 
prostheses accounting for diverse equipment availability and local expertise 
Note: Proposed exhaustive radionuclide imaging algorithm for painful joint 
prostheses (including PET-CT and SPECT-CT options for 
68
Ga) 















3-phase bone scan or  
















x There is a rising incidence of joint replacement surgery and a growing 
need for prosthetic joint imaging  
x Dynamic 18F-Fluoride PET-CT may have a role in the investigation of 
painful hip and knee prosthetic joint replacements. 
x There is an important contribution of CT to prosthetic joint hybrid imaging 
and may also reduce the number of imaging tests required. 
x 18F-NaF PET is also of limited use before the ninth post-surgical month 
x Dynamic 18F-NaF PET-CT can detect aseptic loosening of lower limb 
prostheses but beam hardening artefacts from prostheses have a 
significant deleterious effect on hybrid images. Pre-filtering with 
Aluminium; dual-energy CT and mathematical algorithms with MATLAB
®
 
filtered back projection can reduce beam hardening artefact to the same 
extent. 
x Dynamic 18F-NaF PET-CT was not proven to be more accurate than 3-
phase bone scans in the diagnosis of aseptic loosening and infection of 
hip and knee joint prostheses partly due to limitations and problems 
encountered in the clinical trial.  
x Graphical and mathematical data extracted from 99mTc-MDP dynamic 
bone scans may add further diagnostic information in distinguishing 
septic loosening or inflammation from aseptic loosening. 
x Tilmanocept® is a novel technique with the potential for identifying 
macrophages in aseptic loosening in prosthetic joints.  
x Algorithmic combinations of mathematical data from 99mTc labelled bone 
scans and Tilmanocept
®







Some trial documents and selected pages from the preclinical trial agreement 
with Norgine Limited.  
 
 
CONSENT FORM  
A Direct Comparison of 
18
F-Fluoride PET-CT and Conventional Radionuclide 
Bone Scans in the follow-up of patients with Prosthetic Joint Replacements in 
the Hips and Knees.  
Trial Number:  
Part 1 (please read carefully):  
Please initial to agree  
I confirm that I have read and understand the Patient Information Sheet dated 
............................ (version1.1) for the above study and have had the opportunity 
to ask questions.  
I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 




I understand that sections of any of my medical notes may be looked at by 
responsible individuals involved in the running of the trial, or authorised 
personnel from the NHS Trust R & D for audit or other regulatory authorities 
where it is relevant to my taking part in research, and that I may followed up 
through usual NHS mechanisms (e.g. Office for National Statistics). All access 
to my data must be compliant with the Data Protection Act 1998.  
I give permission for these individuals to have access to my records.  
I understand that copies of my scans will be sent for radiological review for 
confirmation of diagnosis.  
I understand that my General Practitioner will be informed of my treatment and 
may be contacted to supply details of my progress  
I agree to take part in the above study.  
 
Name of patient                             Date                                    Signature  
Name of person taking consent      Date                                   Signature 
(if different from researcher)  
Researcher                                    Date                                     Signature  








University Hospital  
Clifford Bridge Road Walsgrave Coventry CV2 2DX  
Tel: 024 7694000 Fax: 024 7696 6056 www.uhcw.nhs.uk  
PATIENT INFORMATION SHEET – PART 1  
Version 1.5 Date 23.10.2012  
Study title: A Direct Comparison of F-18-Fluoride PET-CT and 
Conventional Radionuclide Bone Scans in the follow-up of patients with 
Prosthetic Joint Replacements in the Hips and Knees.  
Study acronym: F-18-Fluoride PET-CT in Prosthetic Joint Replacements 
(F18 Prosthetic Joint). 
Introduction  
This study has been reviewed by the Coventry and Warwickshire Research 
Ethics Committee and will count towards the attainment of a PhD by Dr Olu 
Adesanya at the University of Warwick. We have invited you to take part in a 
research study. Before you decide if you would like to take part, it is important 
that you understand why the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with 
friends, relatives and your GP, if you wish. If you decide to enter the study your 
GP will be made aware of this. Please ask us if there is anything that is not 
clear or if you would like more information.  
What is the purpose of the study?  
This study is designed to test whether we can use a new type of scanning to tell 




replacement and this occurs at some point in time for 4 in every 100 persons 
who have had this type of surgery. Treatment for the pain depends on its cause 
and but in some cases, for example when the replacement has become 
infected, the only effective treatment is further surgery. Currently, the only way 
of determining the presence or absence of infection involves inserting needles 
into the joint to draw off fluid and/or undergoing more than one imaging test. 
These tests include x-rays, bone scans and white cell imaging studies. With the 
introduction of PET-CT scanning in 2001– a type of scan which can tell the 
difference between active and inactive cells in the body –it has been made 
possible to detect small amounts of disease and infection in the body. We know 
that this type of scan is much more accurate than bone scans for all other 
common uses. It is our hope that we will be able to design an imaging study 
using this type of scan so that someone like you will receive a prompt and 
timely diagnosis involving only a single hospital visit.  
What is PET scanning?  
Unlike ordinary X-rays or computed tomography (CT) scans, PET scans are 
able to provide information regarding increased bone turnover around joint 
prostheses. We already know that PET scanning can be used to detect areas of 
infection and tumours, and we also know that if the scan is clear 12 months 
after surgery, it is very likely that there is no infection and that the prosthesis is 
normal or at worst simply loose. We also know that if the scan is not clear 
particularly in the early phase of the scan, there is a high chance of infection, so 
we think that people with a positive PET scan might benefit from targeted 
antibiotic treatment.  
Why have I been chosen?  
You have been diagnosed with a replaced joint which is causing discomfort pain 
or difficulty and will be re-treated surgically. Therefore you are suitable for this 
study and we are asking whether you would like to take part. 
Initial Assessment 




be undertaken. This will involve blood tests, as well as weight/height 
measurement. Some of these tests may have already been carried out as they 
are routinely performed prior to starting treatment whether or not you take part 
in a study. As part of the study you will also be required to have a PET-CT scan. 
This type of scan is becoming part of the standard process for other diseases in 
the UK, although because it is quite new, not all centres are yet carrying it out 
routinely. It will therefore be necessary for you to travel to University Hospital 
Coventry to have your scan. The scan itself involves a simple intravenous 
injection of a mildly radioactive substance (
18
F-NaF) followed immediately by a 
scanning procedure for about 30-45 minutes. You will not need to fast and may 
take all your usual medications. If travelling by car you should be free to go or 
drive yourself home afterwards. 
What exactly would the study involve? This is a prospective uncontrolled 
longitudinal (case series) study. This means that all persons will undergo PET-
CT imaging as well as a standard bone scan (if this has not already been 
performed recently). You will know what test you are undergoing at each point 
in time. The bone scan and PET-CT scan will occur over two separate days 
(possibly with a month), therefore, involve two injections given over a 1 month 
period. Imaging usually occurs between (9 am and 5pm between Monday and 
Friday as an outpatient (unless you need to stay in hospital for any other 
reason). After both the bone scan and the PET-CT scan have been performed, 
the treatment you receive will be the same regardless of the results of the PET-
CT scan or bone scan. This treatment will have been decided by your doctor 
and will yield useful data for the trial. We hope that by demonstrating this novel 
use of PET-CT, this may improve the speed and accuracy of diagnosing people 
with prosthetic problems. For quality control purposes we plan to review the 
bone scans and PET-CT scans of everyone taking part in the trial and, if you 
agree, your images will be anonymized and also sent to a Radiology 
department in Birmingham. As part of the study, you will be required to provide 
blood samples as is the usual practice. What will happen to any samples I 
give? 




other blood samples taken from you or any other patient in your hospital. These 
will be destroyed after analysis. 
All joint prostheses and tissue samples in this study will be collected and 
processed in exactly the same way as for a patient not in the study. All samples 
will be destroyed after analysis. 
Assessment 
You will be asked a few questions about how you have been since the last time 
you had surgery on your joint. People participating in this study would also be 
asked other questions as part of a questionnaire. 
Follow up When you have completed your study treatment you will be seen as 
often as is deemed necessary by your clinical team. Finally, routine blood tests 
and x-rays may be taken during follow up. 
Payment 
You will not receive payment/reimbursement for participating in this study, but 
will have your travel expenses reimbursed up to a reasonable amount. 
What are the possible risks of taking part? 
The dose of the injected tracer for PET-CT is very low and there are no known 
side effects from it. If you do develop troublesome side effects, your doctor may 
need to adjust your treatment to try and avoid further problems. The more 
common side effects of HDP bone scans: 
Allergic Reaction – this is very rare and if at all it occurs is limited to flushing or 
redness of skin. 
Nausea and vomiting – this is also rare due to the very small amounts of 
injected tracer. It can usually be managed with anti-sickness (anti-emetic) 
drugs.  
We have listed the most common side effects of these tracers, but it is unlikely 




if you suffer from any of these side effects, or if you have experienced any new 
symptoms since your last visit. Your doctor can help you by giving you 
medication or advice, to reduce or stop these side effects from occurring in the 
future. PET-CT scans also involve exposure to radiation. However the doses 
are very small and we have kept the number of scans required to a minimum. In 
fact, you will only receive one more scan by taking part in the study than is 
currently received as part of normal clinical routine.  
In total you will be receiving one bone scan and one PET-CT scan. Each CT 
scan is equivalent to about 4 years of natural background radiation exposure. 
Each PET-CT scan is equivalent to about 8 years of natural background 
radiation exposure. The radiation exposure you will be receiving will 
approximate from about 30 times that of natural background radiation over the 
same period of time, with an equivalent to a lifetime additional risk of 
approximately 1 in 280, of getting a fatal cancer from these examinations. 
These exposures are very unlikely to put you at significant health risk. A leaflet 
is available entitled “X-rays – How safe are they?” that provides further 
information on radiation exposure and which you may find useful. 
What do I have to do? 
It is important that you attend for all scheduled visits for blood tests, scans, 
clinic appointments and surgical treatment to ensure that the treatment can be 
delivered and you can be monitored for any complications. 
What are the benefits of taking part? Although most people can expect to be 
cured with antibiotics and revision surgery, the standard treatment for infected 
prostheses, it is clear that separating aseptic loosening from infected 
prostheses will allow infected people receive the required more intensive 
treatment and also less intensive treatment in aseptic loosening. Before the 
advent of PET scanning the presence of infection around the prosthesis could 
be assessed with bone scans but these results are thought not to be very 
accurate. PET scanning is able to assess infection accurately, and by using this 
information we hope to tailor treatment more closely to your needs. Taking part 




information gained from this study will help us to improve the future treatment of 
people like you with painful joint prostheses.  
What are the potential disadvantages of taking part?  
Having a bone and PET scan would involve the inconvenience of travelling to 
the hospital on 2 different days and in some cases 2 whole days off work may 





Tc-HDP into an arm vein will cause slight discomfort 
(like having a blood test) and sometimes minor bruising.  
Do I have to take part?  
No. It is up to you to decide whether or not to take part. If you decide to take 
part you will be given this information sheet to keep and be asked to sign a trial 
consent form. You may still decide to withdraw at any time without having to 
give a reason. 
What if I decide not to enter the trial? 
If you decide not to take part, or if you withdraw, this will not affect the standard 
of care you receive. Agreeing or refusing to take part will not affect your legal 
rights as an individual receiving treatment under the National Health Service. 
Your relationship with the doctors and nurses looking after you will not be 
affected. If you decide not to take part, your surgical treatment will proceed as 
planned. 
What happens if the research study stops? 
If the research study stops early your doctor will inform you and discuss the 
treatment options with you. If the research study is completed you will be 
followed up in clinic as is normal practice. 
What if there is a problem? 
If you wish to complain or have any concerns about any aspect of the way you 
have been approached or treated during the course of this trial, the normal 




are harmed by taking part in this trial, there are no special compensation 
arrangements but if this is due to someone’s negligence then you may have 
grounds for a legal action. 
Contact for further information 
If you have any concerns or questions about this study, please contact the 
Nuclear Medicine department on 02476 962812 who will be happy to give you 
further information. General information for joint prostheses is also available 
from the Prosthetic and Orthotic department on 0800 252060. If you have any 
further queries please contact our Patient Advice and Liaison Service (PALS) in 
the first instance in any of the following ways: By phone 0800 028 4203 (calls 
are free from a BT landline but mobile phone charges may vary); By 
email:feedback@uhcw.nhs.uk; In writing to: Patient Advice and Liaison Service 
(PALS), University Hospitals Coventry and Warwickshire NHS Trust, University 
Hospital, Clifford Bridge Road, Coventry, CV2 2DX. They will ensure that your 
query is directed promptly to the most appropriate person. 
Contact details for concerns or complaints about the Research, Staff, 
Conduct etc: Please write to Ms Nicola Owen, Deputy Registrar, University of 
Warwick, Research Support Services, University House, Kirby Corner Road, 
Coventry CV4 8UW; or e-mail:  
Nicola.Owen@warwick.ac.uk. Alternately, you may telephone: 024 7652 2785 
or fax: 024 7652 4751  
This completes Part 1 of the Information Sheet. If the information in Part 1 
has interested you and you are considering participation, please continue 





GP LETTER  
A Direct Comparison of F-18-Fluoride PET-CT and Conventional Radionuclide 
Bone Scans in the follow-up of patients with Prosthetic Joint Replacements in 
the Hips and Knees.  
Trial Number:  
Dear Dr ____________  
Version 1.0 Date 24.07.12  
Your patient, ________________ (date of birth dd/mm/yyyy), has a 
symptomatic joint prosthesis and has consented to participate in a study 
evaluating joint prostheses with F18 -NaF-PET-CT scans.  
Please find enclosed a copy of the patient information sheet for this trial.  
You will be kept up to date with your patient’s progress but if you have any 
concerns or questions regarding this study please contact the responsible 
doctor:  
Dr___Olu Adesanya_______at (University Hospitals Coventry & Warwickshire)  
Tel: __________________________  




adesanya@doctors.org.uk Message 19/07/2012 21:59  
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From: Subject: RE: SCOPE: Protocol Review - F-18-Fluoride PET-CT in 
Prosthetic Joint Replacements (F18 Prosthetic Joint) Date: Fri, 29 Jun 2012 
13:12:49 +0000 To: Oludolapo Adesanya <adesanya@doctors.org.uk>  
Notification that a Clinical Trial Authorisation (CTA) is not required  
Dear Ms O Adesanya,  
Thank you for your email dated 17th June 2012.  
I can confirm that your proposal is not a Clinical Trial of an Investigational 
Medicinal Product (IMP) as defined by the EU Directive 2001/20/EC and no 
submission to the Clinical Trials Unit at the MHRA is required.  
Kind regards  
Clinical Trial Helpline MHRA  
-----Original Message-----From: Oludolapo Adesanya 
[mailto:adesanya@doctors.org.uk] Sent: 17 June 2012 00:53 To: 
clintrialhelpline@mhra.gsi.gov.uk. Subject: SCOPE: Protocol Review - F-18-
Fluoride PET-CT in Prosthetic Joint Replacements (F18 Prosthetic Joint)  
Would you please advise me as to whether comparison of 
18
F-NaF PET-CT vs 
99m
Tc-hydroxydi- phosphonate (HDP) isotope bone scans to diagnose infection 
of joint prostheses constitutes the clinical trial of an investigational medicinal 
product?  
Regards  









Research agreement between Norgine Limited and University 










1. Rabin DN, Smith C, Kubicka RA, Rabin S, Ali A, Charters J, et al. Problem 
prostheses: the radiologic evaluation of total joint replacement. Radiographics. 
1987;7(6):1107-27. 
2. Phillips J, Crane T, Noy M, Elliott T, Grimer R. The incidence of deep 
prosthetic infections in a specialist orthopaedic hospital: a 15-year prospective 
survey. Journal of Bone and Joint Surgery-British Volume. 2006;88-B(7):943-8. 
3. Mumme T, Reinartz P, Alfer J, Muller-Rath R, Buell U, Wirtz DC. Diagnostic 
values of positron emission tomography versus triple-phase bone scan in hip 
arthroplasty loosening. Arch Orthop Trauma Surg. 2005;125(5):322-9. 
4. Berquist TH. Musculoskeletal imaging companion: Lippincott Williams & 
Wilkins; 2006. 
5. Trampuz A, Zimmerli W. Prosthetic joint infections: update in diagnosis and 
treatment. Swiss Med Wkly. 2005;135(17-18):243–251. 
6. Lidwell O, Lowbury E, Whyte W, Blowers R, Stanley S, Lowe D. Effect of 
ultraclean air in operating rooms on deep sepsis in the joint after total hip or 
knee replacement: a randomised study. British medical journal (Clinical 
research ed). 1982;285(6334):10-4. 
7. Berbari E, Mabry T, Tsaras G, Spangehl M, Erwin PJ, Murad MH, et al. 
Inflammatory blood laboratory levels as markers of prosthetic joint infection: a 
systematic review and meta-analysis. The Journal of Bone and Joint Surgery 
(American). 2010;92(11):2102-9. 
8. Zimmerli W. Infection and musculoskeletal conditions: Prosthetic-joint-
associated infections. Best practice & research Clinical rheumatology. 
2006;20(6):1045-1063. 
9. Gomez PF, Morcuende JA. Early attempts at hip arthroplasty: 1700s to 
1950s. The Iowa Orthopaedic Journal. 2005;25:25-29. 
10. Boston City Hospital. Medical And Surgical Report of the Boston City 
Hospital. Boston, [Mass.]: Little, Brown, and Co., 1870. 
11. Pramanik S, Agarwal AK, Rai KN. Chronology of total hip joint replacement 
and materials development. Trends in Biomaterials & Artificial Organs. 
2005;19(1):15-26. 
12. Folz BJ, Silver CE, Rinaldo A, Ferlito A. Themistocles Gluck: biographic 
remarks emphasising his contributions to laryngectomy. Eur Arch 
Otorhinolaryngol. 2011;268(8):1175-9. 
13. Alvarez KE. Total Hip Replacement. New Materials and Technologies for 
Healthcare. 2011:179-191. 
14. Emery R. Surgery to the shoulder—shoulder replacement. Rheumatology. 
1995;34(7):653-62. 
15. Foruria AM, Antuña S, Rodríguez-Merchán EC. Shoulder hemiarthroplasty: 
review of basic concepts. Revista Española de Cirugía Ortopédica y 
Traumatología. 2008;52(6):392-406. 
16. Brand RA, Bigliani LU. Biographical Sketch: Charles S. Neer, II, MD (1917–
2011). Clinical Orthopaedics and Related Research
®
. 2011;469(9):2407-8. 
17. Smith-Petersen MN. Arthroplasty of the hip: a new method. The Journal of 
Bone & Joint Surgery. 1939;21(2):269-88. 
18. Emery R, Bankes M. Shoulder replacement: historical perspectives. 





19. Torrisi L, Visco AM, & Valenza A. Ion Implantation on Ultra High Molecular 
Weight Polyethylene (UHMWPE) for Medical Prosthesis, Radiation Effects and 
Defects in Solids. 2003; 158:(9): 621-633 
20. Reingold N, Park J, Rice J. Materials research chronology, 1917-1957. 
Library of Congress Washington DC science and technology division. 1962 
21. Venable CS, Stuck WG. Clinical uses of vitallium. Annals of Surgery. 
1943;117(5):772-82.  
22. Wang KK, Gustavson LJ, Dumbleton JH. Prosthesis formed from dispersion 
strengthened cobalt-chromium-molybdenum alloy produced by gas atomization. 
Google Patents; 1987. 
23. Grigoris P, Roberts P, Panousis K, Jin Z. Hip resurfacing arthroplasty: the 
evolution of contemporary designs. Proceedings of the Institution of Mechanical 
Engineers, Part H: Journal of Engineering in Medicine. 2006;220(2):95-105. 
24. MacAusland WR. The classic: Total replacement of the knee joint by a 
prosthesis. 1957. Clin Orthop Relat Res. 2011;469(1):5-9. 
25. Fischer LP, Planchamp W, Fischer B, Chauvin F. [The first total hip 
prostheses in man (1890 - 1960)]. Hist Sci Med. 2000;34(1):57-70. 
26. Wilson FC. Total Replacement of the Knee in Rheumatoid Arthritis A 
prospective study of the results of treatment with the Walldius prosthesis. The 
Journal of Bone and Joint Surgery (American). 1972;54(7):1429-43. 
27. Jackson J. Father of the modern hip replacement: Professor Sir John 
Charnley (1911–82). Journal of Medical Biography. 2011;19(4):151-6. 
28. Wroblewski BM. Professor Sir John Charnley (1911–1982). Rheumatology. 
2002;41(7):824-5. 
29. Burgers PT, van Gijn J. Sir John Charnley en de totale heupartroplastiek. 
Ned Tijdschr Geneeskd. 2011;155(A3564):1-2. 
30. Gomez PF, Morcuende JA. A Historical and Economic Perspective on Sir 
John Charnley, Chas F. Thackray Limited, and the Early Arthroplasty Industry. 
The Iowa orthopaedic journal. 2005; 25:30-37 
31. Jackson DW. The Century in Orthopedics. A Year by Year Review of the 
Advance, Events and Accomplishments of the Specialty. Orthopaedics Today. 
2000 January issue:73-82. 
32. Temmerman OPP, Raijmakers PGHM, Berkhof J, Hoekstra OS, Teule GJJ, 
Heyligers IC. Accuracy of diagnostic imaging techniques in the diagnosis of 
aseptic loosening of the femoral component of a hip prosthesis. Journal of Bone 
& Joint Surgery, British Volume. 2005;87(6):781-5. 
33. Adams D, Quigley S. Hip resurfacing: past, present and future. Journal of 
Orthopaedic Nursing. 2005;9(2):87-94. 
34. NCD Risk Factor Collaboration. Trends in adult body-mass index in 200 
countries from 1975 to 2014: a pooled analysis of 1698 population-based 
measurement studies with 19·2 million participants. The Lancet. 
2016;387(10026):1377-96. 
35. Losina E, Thornhill TS, Rome BN, Wright J, Katz JN. The dramatic increase 
in total knee replacement utilization rates in the United States cannot be fully 
explained by growth in population size and the obesity epidemic. J Bone Joint 
Surg Am. 2012;94(3):201-7. 
36. Lindahl H, Malchau H, Oden A, Garellick G. Risk factors for failure after 





37. Peel T. Introduction to Prosthetic Joint Infection.  Prosthetic Joint Infections: 
Springer; 2018. p. 1-4. 
38. Kurtz SM, Ong KL, Schmier J, Mowat F, Saleh K, Dybvik E, et al. Future 
clinical and economic impact of revision total hip and knee arthroplasty. The 
Journal of Bone & Joint Surgery. 2007;89(suppl 3):144-51. 
39. Manthey N, Reinhard P, Moog F, Knesewitsch P, Hahn K, Tatsch K. The 
use of [18F] fluorodeoxyglucose positron emission tomography to differentiate 
between synovitis, loosening and infection of hip and knee prostheses. Nuclear 
medicine communications. 2002;23(7):645-653. 
40. Marmery H, Ostlere S. Imaging of prosthetic joints. Imaging. 
2007;19(3):299-309. 
41. Adesanya O, Sprowson A, Masters J, Hutchinson C. Review of the role of 
dynamic 18F-NaF PET in diagnosing and distinguishing between septic and 
aseptic loosening in hip prosthesis. J Orthop Surg Res. 2015;10(5):1-5.  
42. Sterner T, Pink R, Freudenberg L, Jentzen T, Quitmann H, Bockisch A, et 
al. The role of [18F] Fluoride positron emission tomography in the early 
detection of aseptic loosening of total knee arthroplasty. International Journal of 
Surgery. 2007;5(2):99-104. 
43. Palestro CJ. Nuclear medicine and the failed joint replacement: Past, 
present, and future. World J Radiol. 2014;6(7):446-58. 
44. Swan JS, Braunstein EM, Wellman HN, Capello W. Contrast and nuclear 
arthrography in loosening of the uncemented hip prosthesis. Skeletal radiology. 
1991;20(1):15-9. 
45. Ostlere S, Soin S. Imaging of prosthetic joints. Imaging. 2003;15(4):270-85. 
46. Gemmel F, Van den Wyngaert H, Love C, Welling MM, Gemmel P, Palestro 
CJ. Prosthetic joint infections: radionuclide state-of-the-art imaging. Eur J Nucl 
Med Mol Imaging. 2012;39(5):892-909. 
47. Strobel K, Stumpe KDM. PET/CT in musculoskeletal infection. Semin 
Musculoskelet Radiol 2007; 11(4): 353-364. 
48. Love C, Marwin SE, Tomas MB, Krauss ES, Tronco GG, Bhargava KK, et 
al. Diagnosing infection in the failed joint replacement: a comparison of 
coincidence detection 18F-FDG and 111In-labeled leukocyte/99mTc-sulfur 
colloid marrow imaging. J Nucl Med. 2004;45(11): 1864-71. 
49. Kwee TC, Kwee RM, Alavi A. FDG-PET for diagnosing prosthetic joint 
infection: systematic review and metaanalysis. European journal of nuclear 
medicine and molecular imaging. 2008;35(11):2122-32. 
50. Temmerman OP, Raijmakers PG, David EF, Pijpers R, Molenaar MA, 
Hoekstra OS, et al. A comparison of radiographic and scintigraphic techniques 
to assess aseptic loosening of the acetabular component in a total hip 
replacement. JBJS. 2004;86(11):2456-63. 
51. Oyen WJ, Lemmens JA, Claessens RA, van Horn JR, Slooff TJ, Corstens 
FH. Nuclear arthrography: combined scintigraphic and radiographic procedure 
for diagnosis of total hip prosthesis loosening. Journal of nuclear medicine: 
official publication, Society of Nuclear Medicine. 1996;37(1):62-70. 
52. Temmerman OPP, Raijmakers PGHM, Berkhof J, David EFL, Pijpers R, 
Molenaar MA, et al. Diagnostic accuracy and interobserver variability of plain 
radiography, subtraction arthrography, nuclear arthrography, and bone 
scintigraphy in the assessment of aseptic femoral component loosening. 




53. Love C, Tomas MB, Marwin SE, Pugliese PV, Palestro CJ. Role of Nuclear 
Medicine in Diagnosis of the Infected Joint Replacement1. Radiographics. 
2001;21(5):1229-38. 
54. Sousa R, Massada M, Pereira A, Fontes F, Amorim I, Oliveira A. Diagnostic 
accuracy of combined 99mTc-sulesomab and 99mTc-nanocolloid bone marrow 
imaging in detecting prosthetic joint infection. Nucl Med Commun. 
2011;32(9):834-9. 
55. Love C, Palestro CJ. Radionuclide imaging of infection. Journal of nuclear 
medicine technology. 2004;32(2):47-57. 
56. Pulled N, Market FU. Radiologists Weigh Challenges of Obesity. Radiol 
Technol 2006 77(3):238M-238M. 
57. Pakos EE, Trikalinos TA, Fotopoulos AD, Ioannidis JPA. Prosthesis 
Infection: Diagnosis after Total Joint Arthroplasty with Antigranulocyte 
Scintigraphy with 99mTc-labeled Monoclonal Antibodies—A Meta-Analysis1. 
Radiology. 2007;242(1):101-8. 
58. Palestro CJ, Love C, Miller TT. Diagnostic imaging tests and microbial 
infections. Cell Microbiol. 2007;9(10):2323-33. 
59. Tsopelas C. Radiotracers used for the scintigraphic detection of infection 
and inflammation. The Scientific World Journal. 2015 Feb;1-33. 
doi:10.1155/2015/676719. 
60. Wooley PH, Nasser S, Fitzgerald Jr RH. The immune response to implant 
materials in humans. Clinical orthopaedics and related research. 1996;326:63-
70. 
61. Palestro C. Radionuclide imaging of the painful joint replacement: past, 
present and future. Brazilian Archives of Biology and Technology. 
2002;45(SPE):9-14. 
62. Dollé F, Roeda D, Kuhnast B, Lasne MC, Tressaud A, Haufe G. Fluorine-18 
chemistry for molecular imaging with Positron Emission Tomography: Elsevier, 
Amsterdam; 2008. 
63. Coenen HH. Fluorine-18 labeling methods: Features and possibilities of 
basic reactions. PET Chemistry. 2007:15-50. 
64. Anbar M, Guttmann S, Lewitus Z. Effect of monofluorosulphonate, 
difluorophosphate and fluoroborate ions on the iodine uptake of the thyroid 
gland. Nature. 1959;183(4674):1517-8. 
65. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone 
scanning. J Nucl Med. 1962 Jul;3:332-4. 
66. Blau M, Ganatra R, Bender MA, F-fluoride for bone imaging. Semin Nucl 
Med. 1972 Jan;2(1):31-7. 
67. Li J, Miller MA, Hutchins GD, Burr DB. Imaging bone microdamage in vivo 
with positron emission tomography. Bone. 2005;37(6):819-24. 
68. Czernin J, Satyamurthy N, Schiepers C. Molecular mechanisms of bone 
18F-NaF deposition. J Nucl Med. 2010;51(12):1826-9. 
69. Schnockel U, Reuter S, Stegger L, Schlatter E, Schafers KP, Hermann S, et 
al. Dynamic 18F-fluoride small animal PET to noninvasively assess renal 
function in rats. Eur J Nucl Med Mol Imaging. 2008;35(12):2267-74. 
70. Even-Sapir E. Imaging of malignant bone involvement by morphologic, 
scintigraphic, and hybrid modalities. J Nucl Med. 2005;46(8):1356-1367 
71. Stumpe KDM, Nötzli HP, Zanetti M, Kamel EM, Hany TF, Görres GW, von 
Schulthess GK, Hodler J. FDG PET for Differentiation of Infection and Aseptic 




Radiography and Three-Phase Bone Scintigraphy. Radiology. 2004;231(2):333-
41. 
72. Kumar R, Kumar R, Malhotra R, Sharma P, Bal C, Malhotra A. Role of F18-
Fluoride PET-CT and F18-FDG PET-CT in differentiating septic from aseptic 
loosening in patients with painful hip prosthesis. Journal of Nuclear Medicine 
2009, 50 (supplement 2): 89-89. 
73. Mawlawi O, Townsend DW. Multimodality imaging: an update on PET/CT 
technology. European journal of nuclear medicine and molecular imaging. 
2009;36(1):15-29. 
74. Goerres GW, Ziegler SI, Burger C, Berthold T, von Schulthess GK, Buck A. 
Artifacts at PET and PET/CT Caused by Metallic Hip Prosthetic Material. 
Radiology. 2003;226(2):577-84. 
75. Heiba SI, Luo JQ, Sadek S, Macalental E, Cacavio A, Rosen G, et al. 
Attenuation-correction induced artifact in F-18 FDG PET imaging following total 
knee replacement. Clinical Positron Imaging. 2000;3(6):237-9. 
76. Li Y, Schiepers C, Lake R, Dadparvar S, Berenji GR. Clinical utility of (18)F-
fluoride PET/CT in benign and malignant bone diseases. Bone. 2012;50(1):128-
39. 
77. Lim R, Fahey FH, Drubach LA, Connolly LP, Treves ST. Early experience 
with fluorine-18 sodium fluoride bone PET in young patients with back pain. J 
Pediatr Orthop. 2007;27(3):277-82 
78. Adesanya O, Foguet P, Hutchinson C. The Promising Role of Dynamic 18F-
NaF PET-CT in Diagnosing Symptomatic Joint Prosthesis. Integrative 
Biomedical Sciences. 2015;1(2):64-70. 
79. Dixon T, Shaw M, Ebrahim S, Dieppe P. Trends in hip and knee joint 
replacement: socioeconomic inequalities and projections of need. Annals of the 
rheumatic diseases. 2004;63(7):825-30. 
80. Mahomed NN, Barrett JA, Katz JN, Phillips CB, Losina E, Lew RA, et al. 
Rates and outcomes of primary and revision total hip replacement in the United 
States Medicare population. J Bone Joint Surg Am. 2003;85(1):27-32. 
81. Brammen L, Palestro C, Sinzinger H. Radionuclide imaging: Past, present 
and future outlook in the diagnosis of infected prosthetic joints. Hellenic journal 
of nuclear medicine. 2015;18(3):95-102. 
82. Sofka CM. Optimizing techniques for musculoskeletal imaging of the 
postoperative patient. Radiologic Clinics of North America. 2006;44(3):323. 
83. Seynaeve PC, Broos JI. [The history of tomography]. J Belge Radiol. 
1995;78(5):284-8. 
84. Maizlin ZV, Vos PM. Do we really need to thank the Beatles for the 
financing of the development of the computed tomography scanner? J Comput 
Assist Tomogr. 2012;36(2):161-4. 
85. Beckmann EC. CT scanning the early days. Br J Radiol. 2006;79(937):5-8. 
86. Cahir J, Toms A, Marshall T, Wimhurst J, Nolan J. CT and MRI of hip 
arthroplasty. Clinical radiology. 2007;62(12):1163-71. 
87. Hayter CL, Potter HG, Su EP. Imaging of metal-on-metal hip resurfacing. 
Orthopedic Clinics of North America. 2011;42(2):195-205. 
88. Dai K-R, Yan M-N, Zhu Z-A, Sun Y-H. Computer-aided custom-made 





89. Hafez M, Chelule K, Seedhom B, Sherman K. Computer-assisted total knee 
arthroplasty using patient-specific templating. Clinical orthopaedics and related 
research. 2006;444:184-92. 
90. Zhang Z, Liao W, Hou C, Wu P, Kang Y, Zhao X. [Selectively upward 
placement of acetabular implants in patients with anatomically abnormal 
acetabulum during total hip arthroplasty]. Zhongguo Xiu Fu Chong Jian Wai Ke 
Za Zhi. 2014;28(5):566-70. 
91. Renkawitz T, Haimerl M, Dohmen L, Gneiting S, Wegner M, Ehret N, et al. 
Minimally invasive computer-navigated total hip arthroplasty, following the 
concept of femur first and combined anteversion: design of a blinded 
randomized controlled trial. BMC Musculoskelet Disord. 2011;12:192-7. 
92. Parratte S, Argenson JN, Flecher X, Aubaniac JM. [Computer-assisted 
surgery for acetabular cup positioning in total hip arthroplasty: comparative 
prospective randomized study]. Rev Chir Orthop Reparatrice Appar Mot. 
2007;93(3):238-46. 
93. Hsu AR, Davis WH, Cohen BE, Jones CP, Ellington JK, Anderson RB. 
Radiographic outcomes of preoperative CT scan–derived patient-specific total 
ankle arthroplasty. Foot & ankle international. 2015;36(10):1163-9. 
94. Siebert W, Mai S, Kober R, Heeckt PF. Technique and first clinical results of 
robot-assisted total knee replacement. Knee. 2002;9(3):173-80. 
95. Barrack RL, Ruh EL, Williams BM, Ford AD, Foreman K, Nunley RM. 
Patient specific cutting blocks are currently of no proven value. J Bone Joint 
Surg Br. 2012;94(11 Suppl A):95-9. 
96. Ensini A, Timoncini A, Cenni F, Belvedere C, Fusai F, Leardini A, et al. 
Intra- and post-operative accuracy assessments of two different patient-specific 
instrumentation systems for total knee replacement. Knee Surg Sports 
Traumatol Arthrosc. 2014;22(3):621-9. 
97. Wines AP, McNicol D. Computed Tomography Measurement of the 
Accuracy of Component Version in Total Hip Arthroplasty. The Journal of 
Arthroplasty. 2006;21(5):696-701. 
98. National Joint Registry. www.njrcentre.org.uk. [Last updated 14 Jan 2021. 
Last accessed 16
th
 January 2021]. Available from: 
http://www.njrcentre.org.uk/njrcentre/Healthcareproviders/Accessingthedata/Sta
tsOnline/NJRStatsOnline 
99. Day JS, Lau E, Ong KL, Williams GR, Ramsey ML, Kurtz SM. Prevalence 
and projections of total shoulder and elbow arthroplasty in the United States to 
2015. Journal of shoulder and elbow surgery. 2010;19(8):1115-20. 
100. Tomas X, Bori G, Garcia S, Garcia-Diez AI, Pomes J, Soriano A, et al. 
Accuracy of CT-guided joint aspiration in patients with suspected infection 
status post-total hip arthroplasty. Skeletal Radiol. 2011;40(1):57-64. 
101. Mizu-uchi H, Matsuda S, Miura H, Okazaki K, Akasaki Y, Iwamoto Y. The 
evaluation of post-operative alignment in total knee replacement using a CT-
based navigation system. J Bone Joint Surg Br. 2008;90(8):1025-31. 
102. Parvizi J, Della Valle CJ. AAOS Clinical Practice Guideline: diagnosis and 
treatment of periprosthetic joint infections of the hip and knee. Journal of the 
American Academy of Orthopaedic Surgeons. 2010;18(12):771-2. 
103. Lentino JR. Prosthetic joint infections: bane of orthopedists, challenge for 
infectious disease specialists. Clinical Infectious Diseases. 2003;36(9):1157-61. 




105. Beall DP, Martin HD, Ly JQ, Campbell SE, Anderson S, Tannast M. 
Postoperative imaging of the hip. The Radiologic clinics of North America. 
2006;44(3): 343-365. 
106. Roth TD, Maertz NA, Parr JA, Buckwalter KA, Choplin RH. CT of the hip 
prosthesis: appearance of components, fixation, and complications. 
Radiographics. 2012;32(4):1089-107. 
107. DeSmet A, Kramer D, Martel W. The metal-cement interface in total hip 
prostheses. American Journal of Roentgenology. 1977;129(2):279-82. 
108. McGee MA, Howie DW, Neale SD, Haynes DR, Pearcy MJ. The role of 
polyethylene wear in joint replacement failure. Proceedings of the Institution of 
Mechanical Engineers, Part H: Journal of Engineering in Medicine. 
1997;211(1):65-72. 
109. Hozack W, Parvizi J, Bender B. Surgical Treatment of Hip Arthritis: 
Reconstruction, Replacement, and Revision E-Book: Expert Consult-Online and 
Print: Elsevier Health Sciences; 2009. 
110. Singh C, Kaplan A, Pambuccian SE. Necrotic granulomatous pseudotumor 
following metal-on-metal hip arthroplasty: a potential mimic of sarcoma on fine 
needle aspiration cytology. Diagn Cytopathol. 2012;40(Suppl 2):E104-8. 
111. Frick MA, Collins MS, Adkins MC. Postoperative imaging of the knee. 
Radiologic Clinics of North America. 2006;44(3):367-89. 
112. Miller TT. Imaging of knee arthroplasty. European journal of radiology. 
2005;54(2):164-77. 
113. Long M, Rack H. Titanium alloys in total joint replacement—a materials 
science perspective. Biomaterials. 1998;19(18):1621-39. 
114. Pakos EE, Ntzani EE, Trikalinos TA. Patellar resurfacing in total knee 
arthroplasty; a meta-analysis. The Journal of Bone & Joint Surgery. 
2005;87(7):1438-45. 
115. Rodríguez-Merchán EC, Liddle AD. Microbiological concepts of the 
infected total knee arthroplasty. InThe Infected Total Knee Arthroplasty 2018 
(pp. 11-17). Springer, Cham. 
116. Bauer TW, Schils J. The pathology of total joint arthroplasty. Skeletal 
radiology. 1999;28(9):483-97. 
117. Monti C, Molinari M, Bianco T, Sudanese A, Busanelli L, Toni A. 
Indications and limits of CT scan in prosthetic loosening. Chir Organi Mov. 
1994;79(4):269-77. 
118. Kiernan S, Hermann KL, Wagner P, Ryd L, Flivik G. The importance of 
adequate stem anteversion for rotational stability in cemented total hip 
replacement: a radiostereometric study with ten-year follow-up. Bone Joint J. 
2013;95-b(1):23-30. 
119. Adolphson P. Endosteal femoral bone loss after hip rearthroplasty. A 
controlled computed tomography study of 12 patients. Arch Orthop Trauma 
Surg. 1995;114(2):103-5. 
120. Peterson JJ. Postoperative infection. Radiol Clin North Am. 
2006;44(3):439-50. 
121. Thornton-Bott P, Fung S, Walter W, Zicat B. Computerised tomography 
reports of osteolysis in ceramic-on-ceramic total hip arthroplasty; true lysis, 
stress-shield or cysts? Bone Joint J. 2016;98(Supp 10):124-124. 
122. Bozic KJ, Kurtz SM, Lau E, Ong K, Chiu V, Vail TP, et al. The 
Epidemiology of Revision Total Knee Arthroplasty in the United States. Clinical 






123. White LM, Buckwalter KA. Technical considerations: CT and MR imaging 
in the postoperative orthopedic patient. In Seminars in musculoskeletal 
radiology 2002;6(1):pp 5-18. Copyright
©
 2002 by Thieme Medical Publishers, 
Inc., 333 Seventh Avenue, New York, NY 10001, USA.  
124. Xin CH, Chang-sheng ZH, Jun ZH, Hai-feng GU, SONG L, Ling ZH. 
Preliminary Experience of Joint Replacement-Knee by Spiral CT. Chinese 
Medical Equipment Journal. 2011(6):28-28. 
125. Weber M-A, Egermann M, Thierjung H, Kloth J, editors. Modern 
radiological postoperative diagnostics of the hip joint in children and adults. 
Modern Radiological Postoperative Diagnostics. 2015; 187: 525–542. 
126. Sudanese A, Toni A, Busanelli L, Furno A, Montina PP, Marraro MD, et al. 
Diagnostic protocol in prosthetic loosening. Chir Organi Mov. 1994;79(4):257-
67. 
127. Kaisidis A, Megas P, Apostolopoulos D, Spiridonidis T, Koumoundourou D, 
Zouboulis P, et al. [Diagnosis of septic loosening of hip prosthesis with 
LeukoScan. SPECT scan with 99mTc-labeled monoclonal antibodies]. 
Orthopade. 2005;34(5):462-9. 
128. Adesanya O, Hutchinson C. Designing a New Molecular Probe: The 
Potential Role for Tilmanocept (Lymphoseek
®)
 in the Assessment of Patients 
with Painful Hip and Knee Joint Prostheses. The open orthopaedics journal. 
2017;11:212–224. 
129. Choe H, Inaba Y, Kobayashi N, Ike H, Aoki C, Shizukuishi K, et al. Use of 
18
F-fluoride PET to determine the appropriate tissue sampling region for 
improved sensitivity of tissue examinations in cases of suspected periprosthetic 
infection after total hip arthroplasty. Acta Orthop. 2011;82(4):427-32. 
130. Siebelt M, Agricola R, Weinans H, Kim YJ. The role of imaging in early hip 
OA. Osteoarthritis and Cartilage. 2014;22(10):1470-80. 
131. Kwon H, Kim KS, Chun YM, Wu HG, Carlson JN, Park JM, et al. 
Evaluation of a commercial orthopedic metal artifact reduction tool in radiation 
therapy of head and neck patients. Br J Radiol 2015;88(1052):20140536: 
132. Huang JY, Kerns JR, Nute JL, Liu X, Balter PA, Stingo FC, et al. An 
evaluation of three commercially available metal artifact reduction methods for 
CT imaging. Phys Med Biol. 2015;60(3):1047-67. 
133. Pessis E, Campagna R, Sverzut J-M, Bach F, Rodallec M, Guerini H, et al. 
Virtual monochromatic spectral imaging with fast kilovoltage switching: 
reduction of metal artifacts at CT. Radiographics. 2013;33(2):573-83. 
134. Watzke O, Kalender WA. A pragmatic approach to metal artifact reduction 
in CT: merging of metal artifact reduced images. Eur Radiol. 2004;14(5):849-56 
135. Cooper HJ, Della Valle CJ. Advances in the diagnosis of periprosthetic 
joint infection. Expert opinion on medical diagnostics. 2013;7(3):257-63. 
136. Lavernia CJ, Drakeford MK, Tsao AK, Gittelsohn A, Krackow KA, 
Hungerford DS. Revision and Primary Hip and Knee Arthroplasty: A Cost 
Analysis. Clinical orthopaedics and related research. 1995;311:136-41. 
137. Atkins BL, Athanasou N, Deeks JJ, Crook DW, Simpson H, Peto TE, et al. 
Prospective evaluation of criteria for microbiological diagnosis of prosthetic-joint 
infection at revision arthroplasty. Journal of clinical microbiology. 
1998;36(10):2932-9. 
138. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, 




infection: clinical practice guidelines by the Infectious Diseases Society of 
America. Clinical Infectious Diseases, 2013;56(1):1–25. 
139. Bancroft LW. Postoperative musculoskeletal imaging: Radiologic Cllinics of 
North America 2006; 44(3): page 323-472. 
140. Barberán J, Aguilar L, Carroquino G, Giménez M-J, Sánchez B, Martínez 
D, et al. Conservative treatment of staphylococcal prosthetic joint infections in 
elderly patients. The American journal of medicine. 2006;119(11):993. e7-. e10. 
141. Esposito S, Leone S. Prosthetic joint infections: microbiology, diagnosis, 
management and prevention. International journal of antimicrobial agents. 
2008;32(4):287-93. 
142. Lewis SS, Dicks KV, Chen LF, Bolognesi MP, Anderson DJ, Sexton DJ, et 
al. Delay in diagnosis of invasive surgical site infections following knee 
arthroplasty versus hip arthroplasty. Clinical Infectious Diseases. 
2015;60(7):990-6. 
143. Lonner JH, Siliski JM, Scott RD. Prodromes of failure in total knee 
arthroplasty. The Journal of arthroplasty. 1999;14(4):488-92. 
144. Mikulin T, Hardcastle J. Gastric cancer—delay in diagnosis and its causes. 
European Journal of Cancer and Clinical Oncology. 1987;23(11):1683-90. 
145. Geraghty O, Korompoki E, Filippidis FT, Rudd A, Veltkamp R. Cardiac 
diagnostic work-up for atrial fibrillation after transient ischaemic attacks in 
England and Wales: results from a cross-sectional survey. BMJ open. 
2016;6(11):e012714. 
146. Lidwell O, Lowbury E, Whyte W, Blowers R, Stanley S, Lowe D. Infection 
and sepsis after operations for total hip or knee-joint replacement: influence of 
ultraclean air, prophylactic antibiotics and other factors. Epidemiology & 
Infection. 1984;93(3):505-29. 
147. Arndt V, Stürmer T, Stegmaier C, Ziegler H, Dhom G, Brenner H. Patient 
delay and stage of diagnosis among breast cancer patients in Germany–a 
population based study. British journal of cancer. 2002;86(7):1034–1040. 
148. Santaguida PL, Hawker GA, Hudak PL, Glazier R, Mahomed NN, Kreder 
HJ, et al. Patient characteristics affecting the prognosis of total hip and knee 
joint arthroplasty: a systematic review. Canadian Journal of Surgery. 
2008;51(6):428–436. 
149. Werner Z. Prosthetic-joint-associated infections. Best Practice & Research 
Clinical Rheumatology. 2006;20(6):1045–63. 
150. Moran E, Byren I, Atkins BL. The diagnosis and management of prosthetic 
joint infections. Journal of antimicrobial chemotherapy. 2010;65(suppl_3):iii45-
54. 
151. Hyman JL, Salvati EA, Laurencin CT, Rogers DE, Maynard M, Brause BD. 
The arthroscopic drainage, irrigation, and debridement of late, acute total hip 
arthroplasty infections: average 6-year follow-up. The Journal of arthroplasty. 
1999;14(8):903-10. 
152. Goodman LR, Lipchik RJ. Diagnosis of acute pulmonary embolism: time 
for a new approach. Radiology. 1996;199(1):25-7. 
153. Attarian DE, Vail TP. Medicolegal aspects of hip and knee arthroplasty. 
Clinical orthopaedics and related research. 2005;433:72-6. 
154. Thienpont E, Bellemans J, Delport H, Van Overschelde P, Stuyts B, 
Brabants K, et al. Patient-specific instruments: industry’s innovation with a 





155. Leung AN, Bull TM, Jaeschke R, Lockwood CJ, Boiselle PM, Hurwitz LM, 
et al. American Thoracic Society Documents: an official American Thoracic 
Society/Society of Thoracic Radiology clinical practice guideline—evaluation of 
suspected pulmonary embolism in pregnancy. Radiology. 2012;262(2):635-46. 
156. Ruggeri J, Mariani L-L, Aix S, Bonnet A-M, Cormier F, Corvol J-C, et al. 
“De-novo” consultation: Evaluation of an outpatient's clinic dedicated to early 
diagnosis of parkinsonian syndromes. Revue Neurologique. 2017;173(1):55-61. 
157. Fischer JE, Bachmann LM, Jaeschke R. A readers' guide to the 
interpretation of diagnostic test properties: clinical example of sepsis. Intensive 
Care Medicine. 2003;29(7):1043-51. 
158. Purohit MR, Sharma M, Rosales-Klintz S, Lundborg CS. ‘Multiple-
test’approach to the laboratory diagnosis of tuberculosis-perception of medical 
doctors from Ujjain, India. BMC infectious diseases. 2015;15(1):1-9. 
159. Fleischer AE, Didyk AA, Woods JB, Burns SE, Wrobel JS, Armstrong DG. 
Combined clinical and laboratory testing improves diagnostic accuracy for 
osteomyelitis in the diabetic foot. The Journal of Foot and Ankle Surgery. 
2009;48(1):39-46. 
160. Mazurek A, Dziuk M, Witkowska-Patena E, Piszczek S, Gizewska A. The 
Utility of Hybrid SPECT/CT Lung Perfusion Scintigraphy in Pulmonary 
Embolism Diagnosis. Respiration. 2015;90(5):393-401 
161. Ponzio DY, Lonner JH. Preoperative Mapping in Unicompartmental Knee 
Arthroplasty Using Computed Tomography Scans Is Associated with Radiation 
Exposure and Carries High Cost. J Arthroplasty. 2015;30(6):964-7. 
162. Matthews PC, Berendt AR, McNally MA, Byren I. Diagnosis and 
management of prosthetic joint infection. BMJ (Clinical research ed.) 
2009;338:b1773. 
163. Zimmerli W. Bone and joint infections: from microbiology to diagnostics 
and treatment: Wiley Blackwell; 2014.p.113-46. ISBN 1118581709, 
9781118581704 
164. Vandenbroucke JP. Prospective or retrospective: what's in a name?. BMJ: 
British Medical Journal. 1991;302(6771):249. 
165. Strobel K, Steurer-Dober I, Huellner MW, Veit-Haibach P, Allgayer B. 
[Importance of SPECT/CT for knee and hip joint prostheses]. Radiologe. 
2012;52(7):629-35. 
166. Cook GJR, Fogelman I.. PET Imaging of the Skeleton: Springer London; 
2013. 317-35. 
167. Kawaguchi M, Tateishi U, Shizukuishi K, Suzuki A, Inoue T. 18F-fluoride 
uptake in bone metastasis: morphologic and metabolic analysis on integrated 
PET/CT. Annals of Nuclear Medicine. 2010;24(4):241-7 
168. Creutzig H. [A comparison of osteotropic radiopharmaceuticals. II. Plasma 
clearance of 18F and 99mTc-EHDP (author's transl)]. RoFo. 1975;123(4):313-8. 
169. Kobayashi N, Inaba Y, Choe H, Ike H, Fujimaki H, Tezuka T, et al. Use of 
F-18 Fluoride PET to Differentiate Septic From Aseptic Loosening in Total Hip 
Arthroplasty Patients. Clinical Nuclear Medicine. 2011;36(11):E156-E61. 
170. Sterner T, Pink R, Freudenberg L, Jentzen T, Quitmann H, Bockisch A, 
Löer F. The role of [18F]fluoride positron emission tomography in the early 





171. Creutzig H. Bone imaging after total replacement arthroplasty of the hip 
joint. A follow-up with different radiopharmaceuticals. Eur J Nucl Med. 
1976;1(3):177-80. 
172. Levy PY, Fenollar F. The role of molecular diagnostics in implant-
associated bone and joint infection. Clin Microbiol Infect. 2012;18(12):1168-75. 
173. Bauer TW, Parvizi J, Kobayashi N, Krebs V. Diagnosis of periprosthetic 
infection. The Journal of Bone & Joint Surgery. 2006;88(4):869-82. 
174. Zhuang H, Duarte PS, Pourdehnad M, Maes A, Acker FV, Shnier D, et al. 
The Promising Role of 18F-FDG PET in Detecting Infected Lower Limb 
Prosthesis Implants. J Nucl Med 2001;42(1):44–48 
175. Park S-J, Ionascu D, Killoran J, Mamede M, Gerbaudo VH, Chin L, et al. 
Evaluation of the combined effects of target size, respiratory motion and 
background activity on 3D and 4D PET/CT images. Phys Med Biol. 2008 
7;53(13):3661-79. 
176. Wong KK, Piert M. Dynamic Bone Imaging with 99mTc-Labeled 
Diphosphonates and 18F-NaF: Mechanisms and Applications. Journal of 
Nuclear Medicine 2013, 54 (4) 590-599. 
177. Tande AJ, Patel R. Prosthetic joint infection. Clinical microbiology reviews. 
2014;27(2):302-45. 
178. Love C, Marwin SE, Palestro CJ. Nuclear medicine and the infected joint 
replacement.  Semin Nucl Med. 2009;39(1):66-78 
179. Ryan P, Fogelman I, editors. Bone scintigraphy in metabolic bone disease. 
Seminars in nuclear medicine; 1997: Elsevier. 
180. Segall, G., D. Delbeke, M. Stabin, E. Even-Sapir, J. Fair, R. Sajdak and G. 
Smith. SNM Practice Guideline for Sodium 18F-Fluoride PET/CT Bone Scans 
1.0. The Journal of Nuclear Medicine 2010, 51(11):1813-1820. 
181. Cyteval C, Bourdon A. Imaging orthopedic implant infections. Diagn Interv 
Imaging. 2012;93(6):547-57. 
182. Palestro CJ, Love C, Schneider R. The evolution of nuclear medicine and 
the musculoskeletal system. Radiologic Clinics of North America. 
2009;47(3):505-32. 
183. Athwal KK, Hunt NC, Davies AJ, Deehan DJ, Amis AA. Clinical 
biomechanics of instability related to total knee arthroplasty. Clin Biomech 
(Bristol, Avon). 2014;29(2):119-28. 
184. Love C, Tomas MB, Marwin SE, Pugliese PV, Palestro CJ. Role of Nuclear 
Medicine in Diagnosis of the Infected Joint Replacement. Radiographics 
2001;21(5):1229-38. 
185. Iyengar KP, Vinjamuri S. Role of 99mTc Sulesomab in the diagnosis of 
prosthetic joint infections. Nuclear medicine communications. 2005;26(6):489-
96. 
186. Smith BT. Introduction to Diagnostic and Therapeutic Monoclonal 
Antibodies Univ New Mex Heal Sci Cent 2012;17(0039):1–34. 
187. European Medicines Agency. LeukoScan: Withdrawal of the marketing 
authorisation in the European Union 2018 . [Last accessed 15
th
 February 2021] 
Available from: 
https://www.ema.europa.eu/en/medicines/human/EPAR/leukoscan. 
188. Glaudemans AW, Signore A. FDG-PET/CT in infections: the imaging 





189. Bauer P, Brannath W. The advantages and disadvantages of adaptive 
designs for clinical trials. Drug discovery today. 2004;9(8):351-7. 
190. Yoon HJ, Jeong YJ, Son HJ, Kang D-Y, Hyun K-Y, Lee M-K. Optimization 
of the spatial resolution for the GE discovery PET/CT 710 by using NEMA NU 
2-2007 standards. Journal of the Korean Physical Society. 2015;66(2):287-94. 
191. Boas FE, Fleischmann D. CT artifacts: causes and reduction techniques. 
Imaging in Medicine. 2012;4(2):229-40. 
192. Boas FE. Iterative reduction of artifacts in computed tomography images 
using forward projection and an edge-preserving blur filter. Google Patents; 
2012. 
193. Razifar P, Lubberink M, Schneider H, Långström B, Bengtsson E, 
Bergström M. Non-isotropic noise correlation in PET data reconstructed by FBP 
but not by OSEM demonstrated using auto-correlation function. BMC Medical 
Imaging. 2005;5(1):1-18. 
194. Oliveira, E.F.; Dantas, C.C.; Vasconcelos, D.A.A.; Cadiz, F. Comparison 
Among Tomographic Reconstruction Algorithms With a Limited Data. In 
Proceedings of the International Nuclear Atlantic Conference-INAC 
2011, Belo Horizonte, Brazil, 24–28 October 2011. 
195. Gianni Schena. Mathworks
®
. Direct Fourier Reconstruction of a 
Tomographic Slice Experiments of reconstruction using Fourier Slice Theorem 
(rather than filtered back projection). Matlabcentral; 2018. [Last accessed 15
th
 
February 2021] . Available from: 
https://www.mathworks.com/matlabcentral/fileexchange/60257-direct-fourier-
reconstruction-of-a-tomographic-slice. 
196. Valeri G, Mazza FA, Maggi S, Aramini D, La Riccia L, Mazzoni G, et al. 
Open source software in a practical approach for post processing of radiologic 
images. La radiologia medica. 2015;120(3):309-23 
197. Ratib O, Rosset A. Open-source software in medical imaging: 
development of OsiriX. International Journal of Computer Assisted Radiology 
and Surgery. 2006;1(4):187-96. 
198. Yusoff S, Zakaria A. Determination of the optimum filter for qualitative and 
quantitative 99mTc myocardial SPECT imaging. Iranian Journal of Radiation 
Research. 2009;6(4):173-82. 
199. Barrett JF, Keat N. Artifacts in CT: recognition and avoidance. 
Radiographics. 2004;24(6):1679-91. 
200. Tohtz SW, Müller M, Morawietz L, Winkler T, Perka C. Validity of frozen 
sections for analysis of periprosthetic loosening membranes. Clinical 
Orthopaedics and Related Research®. 2010;468(3):762-8. 
201. Pickhardt PJ, Shapiro B. Three-phase skeletal scintigraphy in gouty 
arthritis: an example of potential diagnostic pitfalls in radiopharmaceutical 
imaging of the extremities for infection. Clinical nuclear medicine. 
1996;21(1):33-9. 
202. Do TD, Sutter R, Skornitzke S, Weber MA. CT and MRI techniques for 
imaging around orthopedic hardware. InRöFo-Fortschritte auf dem Gebiet der 
Röntgenstrahlen und der bildgebenden Verfahren 2018;39(1);31-41 © Georg 
Thieme Verlag KG. 
203. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook 
JA, et al. What influences recruitment to randomised controlled trials? A review 




204. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to 
selection bias. Epidemiology. 2004:615-25. 
205. Maida S, Dalla Costa G, Rodegher M, Falautano M, Comi G, Martinelli V. 
Overcoming recruitment challenges in patients with multiple sclerosis: Results 
from an Italian survey. Clin Trials. 2014;11(6):667-72.. 
206. Donovan JL, Peters TJ, Noble S, Powell P, Gillatt D, Oliver SE, et al. Who 
can best recruit to randomized trials?: Randomized trial comparing surgeons 
and nurses recruiting patients to a trial of treatments for localized prostate 
cancer (the ProtecT study). Journal of clinical epidemiology. 2003;56(7):605-9. 
207. Featherstone K, Donovan JLJSs, medicine. “Why don’t they just tell me 
straight, why allocate it?” The struggle to make sense of participating in a 
randomised controlled trial. 2002;55(5):709-19. 
208. Cohn E, Larson E. Improving participant comprehension in the informed 
consent process. Journal of nursing scholarship. 2007 Sep;39(3):273-80. 
209. Seltzer SE, Sullivan DC, Hillman BJ, Staab EV. Factors Affecting Patient 
Enrollment in Radiology Clinical Trials: A Case Study of the American College 
of Radiology Imaging Network. Academic Radiology. 2002;9(7):862-9. 
210. Vellinga A, Cormican M, Hanahoe B, Bennett K, Murphy AW. Opt-out as 
an acceptable method of obtaining consent in medical research: a short report. 
BMC medical research methodology. 2011;11(1):40. 
211. Junghans C, Feder G, Hemingway H, Timmis A, Jones M. Recruiting 
patients to medical research: double blind randomised trial of “opt-in” versus 
“opt-out” strategies. BMJ. 2005;331(7522):940. 
212. Hunt KJ, Shlomo N, Addington-Hall J. Participant recruitment in sensitive 
surveys: a comparative trial of ‘opt in’versus ‘opt out’approaches. BMC Medical 
Research Methodology. 2013;13(1):3. 
213. Blanton S, Morris DM, Prettyman MG, McCulloch K, Redmond S, Light KE, 
et al. Lessons learned in participant recruitment and retention: the EXCITE trial. 
Physical therapy. 2006;86(11):1520-33. 
214. Nyman SR, Victor CR. Older people's recruitment, sustained participation, 
and adherence to falls prevention interventions in institutional settings: a 
supplement to the Cochrane systematic review. Age and ageing. 
2011;40(4):430-6. 
215. Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJ. Imaging of 
inflammation by PET, conventional scintigraphy, and other imaging techniques. 
Journal of nuclear medicine technology. 2013;41(3):157-69. 
216. Munn Z, Jordan Z. The effectiveness of interventions to reduce anxiety, 
claustrophobia, sedation and non-completion rates of patients undergoing high 
technology medical imaging. JBI Libr Syst Rev. 2012;10(19):1122-85. 
217. Vogel WV, Oyen WJ, Barentsz JO, Kaanders JH, Corstens FH. PET/CT: 
panacea, redundancy, or something in between? The Journal of Nuclear 
Medicine. 2004;45(1):15S-24S. 
218. Steinert HC, von Schulthess GK. Initial clinical experience using a new 
integrated in-line PET/CT system. The British Journal of Radiology. 2002 
Nov;75(suppl_9):S36-8. 
219. Cohade C, Osman M, Marshall LT, Wahl RL. PET-CT: accuracy of PET 
and CT spatial registration of lung lesions. European journal of nuclear 




220. Even-Sapir E, Mishani E, Flusser G, Metser U. 18F-Fluoride positron 
emission tomography and positron emission tomography/computed 
tomography. Seminars in nuclear medicine 2007; 37(6):462-469..WB Saunders. 
221. Silveira MB, Soares MA, Valente ES, Waquil SS, Ferreira AV, Santos 
RGd, et al. Synthesis, quality control and dosimetry of the radiopharmaceutical 
18F-sodium fluoride produced at the Center for Development of Nuclear 
Technology-CDTN. Brazilian Journal of Pharmaceutical Sciences. 
2010;46(3):563-9. 
222. Competition and Markets Authority. A report on the completed acquisition 
by Alliance Medical Group Limited of the assets of IBA Molecular UK Limited 
used to manufacture 18F-Fluorodeoxyglucose  2014. Published 15 August 
2014  [Last accessed 15
th





223. UK PET Core Lab. Quality Control for PET Clinical Trials 2018. [Last 
accessed 15
th
 February 2021] . Available from: http://www.ncri-
pet.org.uk/radiotracer_supply.php. 
224. Scarsbrook AF, Barrington SF. PET-CT in the UK: current status and 
future directions. Clinical radiology. 2016;71(7):673-90. 
225. Oglevee C, Pianykh O. Losing images in digital radiology: more than you 
think. Journal of Digital Imaging. 2015;28(3):264-71. 
226. Dickson JC, Tossici-Bolt L, Sera T, de Nijs R, Booij J, Bagnara MC, et al. 
Proposal for the standardisation of multi-centre trials in nuclear medicine 
imaging: prerequisites for a European 123 I-FP-CIT SPECT database. 
European journal of nuclear medicine and molecular imaging. 2012;39(1):188-
97. 
227. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen 
AT, et al. The Netherlands protocol for standardisation and quantification of 
FDG whole body PET studies in multi-centre trials. European journal of nuclear 
medicine and molecular imaging. 2008;35(12):2320-33. 
228. Mendelson DS, Erickson BJ, Choy G. Image sharing: evolving solutions in 
the age of interoperability. Journal of the American College of Radiology. 
2014;11(12):1260-9. 
229. Makris NE, Huisman MC, Kinahan PE, Lammertsma AA, Boellaard R. 
Evaluation of strategies towards harmonization of FDG PET/CT studies in 
multicentre trials: comparison of scanner validation phantoms and data analysis 
procedures. European journal of nuclear medicine and molecular imaging. 
2013;40(10):1507-15. 
230. Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, et 
al. Concordance between four European centres of PET reporting criteria 
designed for use in multicentre trials in Hodgkin lymphoma. European journal of 
nuclear medicine and molecular imaging. 2010;37(10):1824-33. 
231. Pocock SJ. Allocation of patients to treatment in clinical trials. Biometrics. 
1979:183-97. 
232. Peto R, Pike M, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, 
McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical 
trials requiring prolonged observation of each patient. II. analysis and examples. 




233. Chalmers TC. Randomization of the first patient. Med Clin North Am. 
1975;59(4):1035-8. 
234. Senn S. Some controversies in planning and analysing multi‐centre trials. 
Statistics in medicine. 1998;17(15‐16):1753-65. 
235. Hedman C, Andersen AR, Olesen J. Multi-centre versus single-centre trials 
in migraine. Neuroepidemiology. 1987;6(4):190-7. 
236. Adams M, Caffrey L, McKevitt C. Barriers and opportunities for enhancing 
patient recruitment and retention in clinical research: findings from an interview 
study in an NHS academic health science centre. Health research policy and 
systems. 2015;13(1):1-9. 
237. Chenok K, Teleki S, SooHoo NF, Huddleston III J, Bozic KJ. Collecting 
patient-reported outcomes: lessons from the California Joint Replacement 
Registry. eGEMs. 2015;3(1):1196 
238. Wylde V, Marques E, Artz N, Blom A, Gooberman-Hill R. Effectiveness 
and cost-effectiveness of a group-based pain self-management intervention for 
patients undergoing total hip replacement: feasibility study for a randomized 
controlled trial. Trials. 2014;15(1):1-10. 
239. European Association of Nuclear Medicine. Good practice for introducing 
radiopharmaceuticals for clinical use. International Atomic Energy Agency; 
2016. 
240. Neilly B, Allen S, Ballinger J, Buscombe J, Clarke R, Ellis B, Flux G, Fraser 
L, Hall A, Owen H, Paterson A. Future supply of medical radioisotopes for the 
UK report 2014. arXiv preprint arXiv:1501.03071. 2015 Jan 13. 
241. Jenkins P, Clement N, Hamilton D, Gaston P, Patton J, Howie C. 
Predicting the cost-effectiveness of total hip and knee replacement: a health 
economic analysis. The bone & joint journal. 2013;95(1):115-21. 
242. Meade RC, Bamrah VS, Horgan JD, Ruetz PP, Kronenwetter C, Yeh E-L. 
Quantitative methods in the evaluation of thallium-201 myocardial perfusion 
images. Journal of Nuclear Medicine. 1978;19(10):1175-8. 
243. Matsuda H, Tsuji S, Shuke N, Sumiya H, Tonami N, Hisada K. A 
quantitative approach to technetium-99m hexamethylpropylene amine oxime. 
European journal of nuclear medicine. 1992;19(3):195-200. 
244. Fiévet B, Della Vedova C. Dealing with non-detect values in time-series 
measurements of radionuclide concentration in the marine environment. Journal 
of environmental radioactivity. 2010;101(1):1-7. 
245. Mick CG, James T, Hill JD, Williams P, Perry M. Molecular imaging in 
oncology: 18F-sodium fluoride PET imaging of osseous metastatic disease. 
American Journal of Roentgenology. 2014;203(2):263-71. 
246. Morawietz L, Classen R, Schröder J, Dynybil C, Perka C, Skwara A, et al. 
Proposal for a histopathological consensus classification of the periprosthetic 
interface membrane. Journal of clinical pathology. 2006;59(6):591-7. 
247. Ribera A, Morata L, Moranas J, Agulló J, Martínez J, López Y, et al. 
Clinical and microbiological findings in prosthetic joint replacement due to 
aseptic loosening. Journal of Infection. 2014;69(3):235-43. 
248. Tigges S, Stiles RG, Roberson JR. Appearance of septic hip prostheses 
on plain radiographs. AJR American journal of roentgenology. 1994;163(2):377-
80. 
249. Kaya M, Nagoya S, Yamashita T, Niiro N, Fujita M. Peri-prosthetic 




tuberculosis. Journal of Bone & Joint Surgery, British Volume. 2006;88(3):394-
5. 
250. Chryssikos T, Parvizi J, Ghanem E, Newberg A, Zhuang H, Alavi A. FDG-
PET imaging can diagnose periprosthetic infection of the hip. Clin Orthop Relat 
Res. 2008;466(6):1338-42. 
251. Gollwitzer H, Diehl P, Gerdesmeyer L, Mittelmeier W. [Diagnostic 
strategies in cases of suspected periprosthetic infection of the knee. A review of 
the literature and current recommendations]. Der Orthopade. 2006;35(9):904, 
906-8 
252. Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal 
PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 
2008;49(1):68-78. 
253. Adesanya O, Sprowson A, Masters J, Hutchinson C. Review of the role of 
dynamic 18F-NaF PET in diagnosing and distinguishing between septic and 
aseptic loosening in hip prosthesis. Journal of orthopaedic surgery and 
research. 2015;10(1):1-5. 
254. van der Bruggen W, Bleeker-Rovers CP, Boerman OC, Gotthardt M, Oyen 
WJ. PET and SPECT in osteomyelitis and prosthetic bone and joint infections: a 
systematic review. Semin Nucl Med. 2010;40(1):3-15. 
255. Delank KS, Schmidt M, Michael JP, Dietlein M, Schicha H, Eysel P. The 
implications of 18F-FDG PET for the diagnosis of endoprosthetic loosening and 
infection in hip and knee arthroplasty: results from a prospective, blinded study. 
BMC musculoskeletal disorders. 2006;7(1):20. 
256. Palestro CJ. Nuclear medicine, the painful prosthetic joint, and orthopedic 
infection. Journal of Nuclear Medicine. 2003;44(6):927-9. 
257. Bori G, Muñoz-Mahamud E, Garcia S, Mallofre C, Gallart X, Bosch J, et al. 
Interface membrane is the best sample for histological study to diagnose 
prosthetic joint infection. Modern Pathology. 2011;24(4):579-84. 
258. Seifert S, Lapa C, Buck A, Kircher M. Tc-99 m-Tilmanocept 
lymphoscintigraphy after inconclusive Tc-99 m-Nanocolloid scan in breast 
cancer. Nuklearmedizin. 2019;58(02):TV7. 
259. Pal D, De T, Baral A. Lymphatic Mappinh with A New Drug Lymphoseek 
(Technetium TC 99m Tilmanocept): A Receptor-Targeted Radiopharmaceutical. 
260. Wallace AM, Hoh CK, Vera DR, Darrah DD, Schulteis G. Lymphoseek: a 
molecular radiopharmaceutical for sentinel node detection. Annals of surgical 
oncology. 2003;10(5):531-8. 
261. Jarjour W, Rosol T, Schlesinger L, Blue M, Cope F. Fluorescent CD206-
targeted Manocept-Cy3 (Mano-Cy3) specifically localizes on macrophages 
(MPs) derived from rheumatoid arthritis (RA) patients’ synovial fluid & is 
quantitatively greater than that from non-RA patients. Journal of Nuclear 
Medicine. 2014;55(supplement 1):1229-1229. 
262. Businesswire. Biopharmaceuticals N. Navidea Awarded $1.8M Fast Track 
NIH SBIR Grant for Evaluation of a Manocept™ Agent in Kaposi’s Sarcoma 
Published September 03, 2015. [Last accessed 15
th
 February 2021]. Available 
from: http://www.businesswire.com/news/home/20150903005639/en/ 
263. Qin Z, Hoh CK, Olson ES, Jahromi AH, Hall DJ, Barback CV, You YH, 
Yanagita M, Sharma K, Vera DR. Molecular imaging of the glomerulus via 
mesangial cell uptake of radiolabeled tilmanocept. Journal of Nuclear Medicine. 




264. Kardan A, Abbruzzese B, Kissling A, Haynam M, Ralph D, Hershey R, et 
al. Intravenous 99mTc-tilmanocept in Planar and Fused SPECT/CT Imaging of 
Activated Macrophage Infiltration in Subjects with Active Rheumatoid Arthritis. 
Journal of Nuclear Medicine. 2018;59(supplement 1):110-110. 
265. Cope F, Bhambhvani P, McConathy J, Paluri R, Kissling A, Haynam M, 
Ralph D, Hershey R, Ismail A, Blue M, Hartings C. Intravenous 99mTc-
tilmanocept in Planar and Fused SPECT/CT Imaging of Activated Macrophage 
Infiltration in Subjects with Metastatic Liver Colorectal Adenocarcinoma (ML-
CRC). Journal of Nuclear Medicine. 2018;59(supplement 1):56-56. 
266. Zanni MV, Toribio M, Wilks MQ, Lu MT, Burdo TH, Walker J, et al. 
Application of a novel CD206+ macrophage-specific arterial imaging strategy in 
HIV-infected individuals. The Journal of infectious diseases. 2017;215(8):1264-
9. 
267. Stroup SP, Kane CJ, Farchshchi-Heydari S, James CM, Davis CH, 
Wallace AM, et al. Preoperative sentinel lymph node mapping of the prostate 
using PET/CT fusion imaging and Ga-68-labeled tilmanocept in an animal 
model. Clinical & experimental metastasis. 2012;29(7):673-80. 
268. Reubi J, Kvols L, Waser B, Nagorney D, Heitz P, Charboneau J, et al. 
Detection of somatostatin receptors in surgical and percutaneous needle biopsy 
samples of carcinoids and islet cell carcinomas. Cancer research. 
1990;50(18):5969-77. 
269. Boytard L, Spear R, Chinetti-Gbaguidi G, Acosta-Martin AE, Vanhoutte J, 
Lamblin N, et al. Role of proinflammatory CD68+ mannose receptor− 
macrophages in peroxiredoxin-1 expression and in abdominal aortic aneurysms 
in humans. Arteriosclerosis, thrombosis, and vascular biology. 2013;33(2):431-
8. 
270. Grinspoon S. Novel mechanisms and anti-inflammatory strategies to 
reduce cardiovascular risk in human immunodeficiency virus. Transactions of 
the American Clinical and Climatological Association. 2018;129:140-154. 
271. Panchuk-Voloshina N, Haugland RP, Bishop-Stewart J, Bhalgat MK, 
Millard PJ, Mao F, et al. Alexa dyes, a series of new fluorescent dyes that yield 
exceptionally bright, photostable conjugates. Journal of Histochemistry & 
Cytochemistry. 1999;47(9):1179-88. 
272. Zmistowski B, Craig Della Valle MD, US TW, Malizos KN. Workgroup 7: 
diagnosis of periprosthetic joint infection. In Consensus Meeting on 
Periprosthetic Joint Infection 2014; (p. 202). 
273. Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of 
cells of innate immunity: macrophages, mast cells and neutrophils. Nature 
immunology. 2011;12(11):1035–1044. 
274. Davis MJ, Tsang TM, Qiu Y, Dayrit JK, Freij JB, Huffnagle GB, et al. 
Macrophage M1/M2 polarization dynamically adapts to changes in cytokine 
microenvironments in Cryptococcus neoformans infection. MBio. 
2013;4(3):e00264-13. 
275. Young N, Rosol T, Schlesinger L, et al. OP0154 Manocept, A Derivative of 
FDA-Approved 99MTC-Tilmanocept, Exhibits Diagnostic Potential by 
Specifically Identifying Macrophages in Rheumatoid Arthritis: A Novel 
Application of an Existing Drug. Annals of the Rheumatic Diseases 
2015;74:127-127. 
276. The Human Protein Atlas: Sigma-Aldrich; [updated on 13-Mar-2020 Last 
Last accessed 15
th






277. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and 
challenges. Nuclear medicine communications. 2008;29(3):193-207. 
278. Cunha L, Szigeti K, Mathé D, Metello LF. The role of molecular imaging in 
modern drug development. Drug discovery today. 2014;19(7):936-48. 
279. Wolf AP. Special characteristics and potential for radiopharmaceuticals for 
positron emission tomography. InSeminars in nuclear medicine 1981 Jan 1 (Vol. 
11, No. 1, pp. 2-12). WB Saunders. 
280. Gomes CM, Abrunhosa AJ, Ramos P, Pauwels EKJ. Molecular imaging 
with SPECT as a tool for drug development. Advanced Drug Delivery Reviews. 
2011;63(7):547-54. 
281. British Nuclear Medicine Society (BNMS). [Last updated 6
th
 January 2021; 
Accessed 16
th
 January 2021]. Available from: 
https://www.bnms.org.uk/page/guidelines. 
282. Sampson CB. Textbk radiopharmacy. CRC Press; 1994 Mar 1. 
283. Sharp PF. Practical Nuclear Medicine  3rd ed. Sharp PF, Gemmell HG, 
Murray AD, editors. London: Springer; 2005 Sep 30. 
284. Britton KE. The Nuclear Medicine Point of View in Orthopaedic Infections: 
Imaging with Tc-99m-Ciprofloxacin, Infecton. In: Signore A, Liberatore M, 
Scopinaro F, editors. Nuclear Medicine in the Management of Inflammatory and 
Infectious Diseases. Berlin, Heidelberg: Springer Berlin Heidelberg; 2003. p. 70-
8. 
285. De Winter F, Van de Wiele C, Dumont F, Van Durme J, Solanki K, Britton 
K, et al. Biodistribution and dosimetry of 99mTc-ciprofloxacin, a promising agent 
for the diagnosis of bacterial infection. European Journal of Nuclear Medicine. 
2001;28(5):570-4. 
286. Welling M, Stokkel M, Balter J, Sarda-Mantel L, Meulemans A, Le Guludec 
D. The many roads to infection imaging. European journal of nuclear medicine 
and molecular imaging. 2008;35(4):848-9. 
287. Müller C. Folate-based radiotracers for PET imaging—update and 
perspectives. Molecules. 2013;18(5):5005-31. 
288. Fischer CR, Müller C, Reber J, Müller A, Krämer SD, Ametamey SM, et al. 
[18F]Fluoro-Deoxy-Glucose Folate: A Novel PET Radiotracer with Improved in 
Vivo Properties for Folate Receptor Targeting. Bioconjugate Chemistry. 
2012;23(4):805-13. 
289. Henne WA, Rothenbuhler R, Ayala-Lopez W, Xia W, Varghese B, Low PS. 
Imaging Sites of Infection Using a 99mTc-Labeled Folate Conjugate Targeted to 
Folate Receptor Positive Macrophages. Molecular Pharmaceutics. 
2012;9(5):1435-40. 
290. NHS Improvement. England National NHS Tariff 2020/21 2019 [Last 
updated: 26 November 2020; Accessed 16th January 2021]. Available from: 
https://improvement.nhs.uk/resources/national-tariff/ 
 
 
 
